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Disturbances of the menstrual cycle are relatively
common in modern industrialised societies, and excessively
heavy menstrual bleeding is one of the most important of
these in terms of potential health disturbance and social
distress. In spite of the large literature on the topic
there are still major gaps in our understanding of the
underlying causes and mechanisms of abnormal bleeding and
of the ways in which they may be satisfactorily managed.
This thesis describes a series of investigations which
have been carried out over a period of 12 years. They have
been devised to characterise certain abnormalities of
pituitary, ovarian and uterine function in a particular type
of excessive menstrual bleeding termed 'dysfunctional uterine
bleeding'. In several cases studies of normal women have
been carried out in a parallel for comparison.
Dysfunctional uterine bleeding occurs most commonly in
women in the later reproductive years and may be seen in
women who are still ovulating or have become anovulatory.
The investigations described in this thesis have addressed
several aspects of the condition which have not previously
been studied and have resulted in a range of new findings.
Some of the studies have involved fairly complex methodology
and considerable inconvenience for the subjects, all of whom
participated entirely voluntarily after receiving detailed
information on the projects.
These studies have led to many new questions, and to
continuing investigations of the condition in the 3 centres
where the work described in this thesis was carried out.
ABSTRACT
This thesis describes a series of investigations of a
rather poorly defined group of menstrual disturbances known as
dysfunctional uterine bleeding (DUB). This condition is charact¬
erised by excessively heavy menstrual bleeding and, although
commoner at ages 30-50 years, may occur at any time during rep¬
roductive life. The large published literature has been thorough
ly reviewed and areas of ignorance highlighted.
The investigations described have been devised to elucidate
several aspects of pituitary, ovarian and uterine function in
women of different ages with ovulatory and anovulatory DUB and
compare these with normal women. All have raised questions req¬
uiring future study. The first section describes the use of a
combination of isotope dilution techniques and direct sampling
of ovarian venous blood and follicular fluid to study the ovar¬
ian blood flow and the ovarian secretion and metabolism of oestra
diol and oestrone in women with normal menstrual function or DUB.
In normal women 95% of circulating oestradiol was secreted by the
developing follicle or corpus luteum. In women with DUB oestro¬
gen metabolism was normal but the dynamics of oestrogen secretion
was sometimes disturbed. In some cases multiple follicle growth
and inappropriately high oestradiol secretion was observed. In
the follicular phase most large follicles were functionally
active and contained very high concentrations of oestradiol
(>1250 ng/ml).
Most adolescents with DUB are anovulatory and a very small
proportion develop the more extreme endometrial changes of cys¬
tic glandular hyperplasia (CGH). Follow up of the group of 17
of these adolescents over 10 years revealed a high incidence of
long term menstrual and reproductive disturbances. Detailed
endocrine assessment over 3 cycles in 4 young women with DUB &
CGH,and dynamic testing with oestrogen provocation and gonado-
trophin-releasing hormone stimulation in a further 9 young women
revealed a failure of positive oestrogen feedback as a cause
of the anovulation. All exhibited prolonged follicular activity
with, excessive oestradiol secretion.
A careful study of perception of menstrual bleeding indi¬
cated that many women perceived their menstrual blood loss to
be much heavier than objective measurements demonstrated. Only
38% of women with a convincing clinical history of menorrhagia
had a measured blood loss of greater than 80 mis. These women
also demonstrated some difficulty in assessing month to month
and even day to day changes in blood loss volume. In a differ¬
ent group of 28 women it was found that only 36% of the menstr¬
ual discharge (range 1.6-81.7%) consisted of blood, and the
remainder of the fluid is probably an endometrial transudate.
This may contribute to difficulties in perception.
The final section describes the development and application
of two inert gas clearance techniques (with Krypton-85 and
Kenon-J.33) for the measurement of endometrial blood flow (EBF)
in women. The techniques have been validated by comparison with
radioactive-labelled microspheres in sheep. Cyclical fluctua¬
tions in EBF were seen during the menstrual cycle with a pre¬
ovulatory peak, early luteal fall and gradual sustained rise up
to the onset of menses. The pattern was similar in ovulatory
DUB, while anovulatory women showed variable rates.
SECTION 1
GENERAL REVIEW OF THE LITERATURE
Chapter 1
DYSFUNCTIONAL UTERINE BLEEDING:
A CONCEPT REQUIRING CLEARER DEFINITION AND MORE
LOGICAL MANAGEMENT.
"THE VAPOURS FROM HER NATURAL DISEASE RISE
TO HER HEAD, SUFFOCATE HER SPIRITS WITH TOO
MUCH MOISTURE, OFFEND THE CHAMBER OF REASON




Dysfunctional Uterine Bleeding is a common but con¬
fusing condition which merits consideration from several
different viewpoints. The aim of this review is to place
present knowledge of the condition in perspective with
relevant aspects of normal menstrual function and other
menstrual disorders. The published literature on matters
relevant to this thesis is enormous and over 2,000 ref¬
erences have been consulted during its preparation. In
the thesis reference has only been made to publications of
direct relevance. More detailed discussion of certain aspects
appears in individual chapters in the thesis. This intro¬
ductory review also incorporates data which have been pub¬
lished as a result of work described in the thesis.
BACKGROUND:
In most present-day cultures women are conditioned
to expect a state of regular menstrual bleeding at approx¬
imately monthly intervals throughout the major part of their
reproductive lives, although Homo Sapiens has until very
recently existed in a state where late menarche, early first
pregnancy, prolonged lactation and early menopause ensured
that regular menstrual cycles were few and far between (Short
1976). Menstrual disorders have been a source of great con¬
cern to the medical profession and to women since earliest
recorded history. Remedies for menorrhagia are mentioned
in the Ebers and other ancient Egyptian papyri (Ghalioungui
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1963). The social problems which menorrhagia and other
disorders are likely to have caused in early societies can
be gauged from the taboos and constraints which have often
been placed on all menstruating women (Koetsawang 1980;
Crawford 1981; Snowden and Christian 1983).
Nowadays, any spontaneous or contraceptive-induced
deviation from the regular pattern may be interpreted as
undesirable (Snowden and Christian 1983) although individual
women will often tolerate major changes without undue alarm.
It follows that complaints of abnormal menstruation or men-
strually-related symptoms are highly subjective and greatly
influenced by the local social and cultural environment.
Dysfunctional uterine bleeding (DUB) is an example of
a condition which is subject to substantial psychological
influences although there is little doubt that it has a
biochemical or endocrine basis in many cases. This
menstrual symptom is generally mediated through dysfunction
of one or more structures within the uterus itself.
Somewhat surprisingly, present understanding of the
sequence of events which occurs during normal menstruation
is still relatively poor and a discussion of present know¬
ledge of this complex process is fundamental to a rational
consideration of dysfunctional uterine bleeding.
NORMAL MENSTRUATION AND THE NORMAL CYCLE:
In women, normal menstruation consists of the loss of
blood, endometrial tissue and tissue fluid through the cervix
and vagina following the withdrawal of trophic hormone
support from the corpus luteum. The volume of blood lost per
cycle appears to vary in different countries from a median of
20 mis in Egypt through 30-40 mis in Northern Europe to 50 mis
in China (Hallberg et al 1966; Cole et al 1971; Hefnawi et al
1980; Gao et al 1981). The proportion of the total volume of
menstrual flow contributed by tissue and tissue fluid is
uncertain (Hahn 1980), but work described in Chapter 10 of
this thesis indicates that the proportion contributed by blood
is generally less than 40% (Fraser et al 1984b).
Most authors seem to be in. agreement that an
arbitrary upper limit for normal menstrual blood loss
can be set at about 80 mis, since iron deficiency anaemia
appears to become much more common in European women
with repeated blood loss in this range (Hallberg et al 1966).
Women with menorrhagia will lose in excess of 40 mg of
elemental iron per period (Cohen and Gibor 1980). Blood loss
may sometimes vary considerably from cycle to cycle in
individuals but in most cases the variation is small
(Hallberg and Nilsson 1964b).
The proportion of endometrium lost at menstruation has
been a subject of much controversy over the years (Bohnen
1927; McLennan and Rydell 1965; Flowers and Willborn 1978;
Nogales-Ortiz et al 1978), and it seems likely that there is
wide individual variation. In some women there is relatively
little tissue loss but a major restructuring of the tissue
architecture, whereas in others there maybe a loss of most
of the functional layer of the endometrium.
Modern understanding of the morphological events in the
endometrium during menstruation is still based to a great
extent on the elegant and meticulously described observations
of Markee (1940) of intraocular endometrial transplants in
rhesus monkeys. These observations are now being increasingly
supplemented by corroborative morphological data and new
biochemical and endocrine data in women. Spiral arterioles
seem to be essential for the process of menstruation, and
excessive growth and coiling of these vessels occurs during
the secretory phase. The coiling is greatly accentuated
during a period of endometrial regression which occurs
immediately prior to endometrial breakdown (Markee 1940;
1950). The regression merges into a period of intense
arteriolar constriction which is most obvious at the
myometrial-endometrial junction and in the inner myometrium.
This usually precedes bleeding by a few hours. It persists
throughout menstruation but intermittent relaxation of
individual vessels occurs with consequent bleeding.
The exact causes of the endometrial regression,
intense vasoconstriction and vascular breakdown are
unknown. In recent years evidence has accumulated to
implicate the prostaglandins, especially PGE2 and PGF2a,
in the vasoconstriction and regulation of the volume of
blood that is lost (Abel 1979). It is possible that these
agents may also cause direct damage to the structure of
the vessel walls and help to initiate bleeding. Since
prostaglandins and related 'prostanoids' (cyclic
endoperoxides, prostacyclin-PGI2-and thromboxane A2-TXA2)
have varying actions on blood vessels and platelets it
seems likely that a balance between different prostaglandins
is important. Interesting new information is compatible
with the hypothesis that PGI2 synthesised in the
myometrium from endometrial precursors may have a role in
the control of endometrial blood flow (Kelly 1981). It is
possible that ischaemia increases free arachidonic acid
concentration and that stasis prevents transfer of
intermediates to the myometrium. This would lead to a
marked increase in endometrial PGF2a concentration and
vasoconstriction limiting blood loss.
The sequence of events which links luteolysis and
falling levels of oestradiol and progesterone with actual
tissue breakdown is also far from clear. There is
strongly suggestive evidence to implicate lysosomes in
the initiation of tissue breakdown (Henzl et al 1972) but
their role could be limited to remodelling of the tissue
during and after breakdown (Wilson 1980). The elegant
ultrastructural and histochemical study of Henzl et al
(1972) demonstrated that acid phosphatase is released
from lysosomes into the cytoplasm and intercellular spaces
immediately prior to tissue breakdown. This release appears
to be consequent upon a fall in plasma levels of oestradiol
and progesterone. In most tissues, lysosome membrane
stability is influenced by ambient steroid levels, but at
the present time little information is available on the
behaviour of lysosomes of endometrial origin. Additionally,
very little is known about the different hydrolase
enzymes which could be present in endometrial lysosomes.
Of particular interest is the observation that the
arachidonic acid mobilising enzyme, phospholipase A2, is
sometimes present in lysosomes. This could provide the link
between lysosome activity and prostaglandin release at the
onset of menstruation.
Haemostatic mechanisms play a central role in control
of the volume of blood lost (Aparicio et al 1979; Paton
et al 1980; Sixma et al 1980; Christiaens et al 1982) and
this role is complementary to arteriolar constriction. The
haemostatic response in the endometrium is defective
compared with other tissues such as skin. This defective
response is almost certainly due partly to the highly
active fibrinolytic system within the endometrium (Rybo
1966b) and possibly also to increased release of prosta¬
cyclin and heparin (Foley et al 1978; Paton et al 1980).
Morphological studies indicate that bleeding begins when
gaps appear in the blood vessel walls. Intravascular
haemostatic plugs containing platelets and later some
fibrin slowly lead to partial or complete occlusion of
vessels, but these platelet and fibrin plugs are not seen
around the outside of vessels as in other tissues. The
haemostatic response is so defective that in the premen¬
strual phase gaps in vessel walls with exposed collagen
may appear without any evidence of platelet plug
formation. Platelet plugs only form in the vessel lumina
during the first 12-24 hours of menstruation and fibrin
is only detectable in small amounts during the first 48
hours. Haemostatic plugs are shed with the superficial
tissue layers into menstrual fluid. Uterine contractility
increases markedly at the onset of menstruation and
encourages rapid drainage of the uterus. All these
features seem to be aimed at preventing the deposition of
significant amounts of fibrin and true blood clot within
the cavity. This aim is obviously desirable since
organisation of a true clot could result in the formation
of intrauterine adhesions with serious consequences for
future reproduction.
Since haemostatic plugs and fibrin, are only present
in endometrium during the early stages of menstruation,
the mechanism of haemostasis during the remainder of
menstruation remains unexplained. It is possible that
blood loss after the first 12 hours is limited mainly by
vasoconstriction and after 48 hours by surface regeneration
of the epithelium (Ferenczy 1976) . The major quantity of
blood loss occurs during the first two days and usually
then tails off rapidly within the next 2-3 days (Haynes
et al 1977).
The most 'normal' menstrual patterns appear to occur
following oestrogen priming of the endometrium for 1-2
weeks followed by oestrogen and progesterone together
for a further 2 weeks. Predictable menstruation then
occurs following simultaneous withdrawal of oestrogen and
progesterone. Any departure from this pattern may be
accompanied by abnormalities of menstruation, as is well
illustrated by the endocrine patterns with the progestogen-
only minipill (Landgren and Diczfalusy 1980). Conversely,
it should be recognised that disturbances of menstruation
may sometimes occur when circulating hormone patterns
are indistinguishable from normal.
The average menstrual period lasts 5 days with 90
per cent having a duration between 2 and 8 days. Cycle
length is also very variable with the mean around 29.4
days (Gray 1980) and only 80 per cent of women in the mid-
reproductive years exhibiting cycles between 25 and 35 days.
There is a skewed distribution towards longer cycles, and
irregular cycles are much more common in adolescence and the
perimenopause.
DYSFUNCTIONAL UTERINE BLEEDING:
Dysfunctional uterine bleeding is one of the most
poorly understood of common gynaecological conditions. This
is partly due to great confusion over definitions and
terminology, and few authorities can agree on consistent
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criteria to delineate the condition. The definition which
this author prefers is "excessively heavy, prolonged or
frequent bleeding of uterine origin which is not due to
recognisable pelvic or generalised medical disease, or to
pregnancy". Therefore this is a diagnosis of exclusion -
a useful "working diagnosis". The commonest complaint is
of excessively heavy bleeding (menorrhagia) and it is this
symptom which is mainly considered in the following review
and the subsequent investigations.
There is little doubt that whatever definition is
used the aetiology is multifactorial and currently only a
few categories can be defined clearly. Perception of symptoms
by the patient can be quite misleading but forms a crucial
part of the initial presentation and the clinical assessment.
It is convenient to group the women into those with acute
or chronic symptoms and ideally also into those who are
predominantly ovulatory or predominantly anovulatory. Few
patients with dysfunctional bleeding are exclusively
ovulatory or anovulatory (Fraser and Baird 1974).
INCIDENCE:
DUB is a common diagnosis, being made in up to 10%
of cases attending a gynaecological outpatients clinic
(Taylor 1965). It may occur at any time between menarche
and menopause, but is particularly common in the ten years
leading up to the menopause. It is said that a small
peak also occurs in adolescence but this is difficult
to demonstrate because most cases are treated without
any contact with hospital clinics. This is illustrated by
a very large pathological study of DUB where only 4% of
patients undergoing curettage were under 20 years (Sutherland
1949). By contrast 40% were 40-50 years and 50% in the
20-40 year age group. Anovulatory DUB is certainly commoner
in adolescence and perimenopause, whereas 80% of cases in
the mid-reproductive years are ovulatory. Cystic glandular
hyperplasia (CGH) of the endometrium, one extreme of the
spectrum of anovulatory DUB, is mainly seen in the 40-50
year age group although a very small peak occurs in
adolescence (Schroder 1954; Fraser and Baird 1972). It
used to be taught that almost all cases of DUB in young
girls were associated with endometrial hyperplasia
(Jeffcqate 1937) but this is erroneous and the true
incidence is probably between 5 and 15% (Sutherland 1953;
Fraser and Baird 1972). The population incidence of
adolescent CGH is very low and is probably about 5 new
cases per million per year (Fraser and Baird 1972).
Population studies of menstrual blood loss indicate
that menorrhagia with measured loss over 80 mis per
cycle is relatively infrequent (Hallberg et al 1966;
Cole et al 1971). These studies are subject to many biases
but give an indication that perhaps 5-10% of women in
the reproductive age group in a general population will
exhibit objective menorrhagia at any one time. This seems
to be different from the subjective complaint of "menorr¬
hagia" as made by the patient, which is probably much
commoner (Fraser et al 1981). It is calculated that
10-25% of women will complain of menorrhagia at some time
(Richards 1979; Wood et al 1979 ; NOP Survey 1980).
DIFFERENTIAL DIAGNOSIS;
Since dysfunctional uterine bleeding is a diagnosis
of exclusion, recognition of other potential causes of
excessive uterine bleeding is of central importance.
Pelvic disease causing excessive bleeding.
Leiomyomata (fibroids) are a common cause of
menorrhagia (Buttram and Reiter 1981). Submucous and
intramural lesions seem much more likely to cause
menorrhagia than subserous ones, although no objective
measurements of blood loss have been reported. The
mechanism appears to be gross distortion of the venous
architecture around the fibroid (Farrer-Brown et al 1970 b).
Endometriosis is a common clinical association with
menorrhagia although again no objective measurements of
blood loss have been reported (Sensky and Liu 198 0) . The
mechanism is unknown but may be due to a disturbance of
local prostaglandin secretion.
Adenomyosis is another relatively common association
with menorrhagia, although the diagnosis is usually not
made until the time of hysterectomy (Vora et al 1981).
Again prostaglandins are thought to be involved in the
mechanism of disturbed bleeding.
Chronic pelvic inflammatory disease may cause heavy
or irregular bleeding, presumably through uterine vascular
congestion and dilatation.
Endometrial polyps are somewhat mysterious lesions
of uncertain aetiology, which are found more frequently
in women with anovulation. Use of the hysteroscope
suggests that they are probably much commoner than is
generally appreciated from routine curettage, and they
are undoubtedly associated with a proportion of cases of
clinically diagnosed DUB (Peterson & Novak 1956).
Endometrial adenocarcinoma usually presents with post
menopausal bleeding but 30-40% present before the meno¬
pause with irregular, intermenstrual, post coital or
excessive bleeding. Menorrhagia is uncommon as the sole
presenting feature. Many of these cases give a preceding
history of anovulatory DUB (Chamlian and Taylor 1970). This
is undoubtedly the most serious of all the differential
diagnoses of DUB.
Polycystic ovarian disease is often associated with
infrequent episodes of menorrhagia due to anovulation with
elevated circulating oestrogen levels (Goldzieher 1981).
Pelvic congestion syndrome is a rather nebulous concept
which may or may not exist as a distinct entity capable of
causing menorrhagia.
Bicornuate uterus is said to be associated with
menorrhagia due to the increased endometrial surface area,
but objective evidence is not available.
Rarities which may be associated with menorrhagia
include functional ovarian tumours, endometrial
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haemangiomata, uterine lymphangiomata and pelvic arterio¬
venous malformations.
Surface lesions of the genital tract may cause
irregular or intermenstrual bleeding at any age, although
in these cases regular menstruation usually continues normally.
Complications of pregnancy must necessarily be excluded
in all cases of acute or subacute 'menorrhagia'.
Medical disease causing excessive bleeding.
Disorders of haemostasis may present as rare causes
of menorrhagia (Quick 1S66) but can occur in as many as
20 per cent of adolescents with menorrhagia in whom pelvic
pathology has been excluded (Claessens and Cowell 1981).
Any type of haemostatic disorder may cause excessive
bleeding in some individuals, but in many, especially those
on anticoagulants, menstruation may be completely normal.
The disorders most commonly associated with menorrhagia
are disturbances of platelet function including thrombo-
cytopoenia, various thrombocytopathies, Von Willebrand's
disease and possibly chronic excessive aspirin ingestion.
Hypothyroidism is classically said to cause anovulation
and menorrhagia, although many will develop amenorrhoea or
oligomenorrhoea instead (Scott and Mussey 1964).
Systemic lupus erythematosus may cause menorrhagia
either by damage to vascular function or through the action
of a circulating coagulation-inhibiting antibody.
Other medical causes of menorrhagia include
congestive cardiac failure, chronic hepatic disease
and chronic renal failure following adequate dialysis.
AETIOLOGY AND MECHANISMS:
It is convenient to divide these patients into those
who are anovulatory and those who are ovulatory although it
should be recognised that women with a history suggestive of
anovulation will not infrequently have some ovulatory cycles
(Fraser and Baird 1974).
u
Anovulatory cycles.
The classical studies of Brown, Kellar and Matthew
(1959) have thoroughly documented the urinary oestrogen
excretion in women with anovulatory cycles. They have
shown that oestrogen levels usually fluctuate substantially
but may occasionally be relatively constant for some weeks.
In their studies heavy menstrual bleeding usually occurred
when oestrogen levels were falling but occasionally would
occur when levels were steady or even when they were rising.
These authors investigated the oestrogen levels in terms
of the degree of endometrial proliferation and clearly
demonstrated that cystic glandular hyperplasia of the
endometrium was associated with high fluctuating levels
of oestrogen or with moderate and prolonged unopposed
levels of oestrogen (Brown and Matthew 1962). It is now
clear that the condition of 'metropathia haemorrhagica'
with multi cystic ovaries, cystic glandular hyperplasia of
the endometrium and erratic menorrhagia is merely the severe
end of the spectrum of anovulatory dysfunctional uterine
bleeding rather than a specific disease-entity (Schroder
1954; Brown, Kellar and Matthew 1959).
It appears that ovarian synthesis and subsequent
metabolism of oestrogens is within normal limits in peri-
menopausal women with anovulatory DUB but the cyclical
dynamics of oestrogen secretion are disturbed (Baird and
Fraser 1974; Fraser and Baird 1974). In anovulatory women
in the late reproductive years significant amounts of
oestradiol may be secreted by both ovaries. This may
come from large and sometimes multiple active follicles
suggesting a disturbance of intra ovarian follicular
control mechanisms and/or abnormalities in gonadotrophin
release (Baird and Fraser 1975).
Very little information is available on human ovarian
blood flow but it appears that ovarian blood flow is similar
in women with anovulatory DUB and normal cycles (Baird
1973; Baird and Fraser 1973).
27
Detailed studies of perimenopausal women with
anovulatory DUB have reported results consistent with
a variety of defects both in hypothalamic-pituitary and
intra ovarian mechanisms (Aksel and Jones 1974; Van Look
et al 1977). The perimenopausal findings are in striking
contrast to the mechanism of anovulatory DUB in adolescents.
Detailed investigation has demonstrated that the majority of
adolescents with anovulation have a defect in the positive
feedback response to oestrogen (Fraser et al 1973; Van Look
et al 1978). It is suggested that these girls may be
experiencing a delay in the maturation of hypothalamic
control (Aksel and Jones 1974), although many continue to
experience menstrual disturbance for many years (Fraser and
Baird 1972).
Hyperprolactinaemia is occasionally recorded in women
with anovulatory DUB. Since treatment with bromocriptine
often does not cure the condition, it may j.ust be a chance
association or more likely may be a consequence of the
elevated oestrogen levels.
The erratic, prolonged and excessively heavy bleeding
which is typical of anovulatory DUB is clearly associated
with prolonged unopposed stimulation of the endometrium by
fluctuating and sometimes excessively high levels of
oestradiol. However, the exact mechanism of abnormal break¬
down of endometrium has not been elucidated. The endomet¬
rium is rarely found to be atrophic and generally varies from
different degrees of proliferation to cystic glandular
hyperplasia. Atypical forms of hyperplasia are associated
with an increased risk of endometrial malignancy later
(Chamblian and Taylor 1970). Endometrial polyps are some¬
times found. The histological findings have been well
described by Sutherland (1949). Orderly development of the
endometrial vasculature does not occur and there is usually
poor spiral arteriole development with exaggerated venous
vascularity and the development of venous sinusoids (Beilby
et al 1971).
It is usually stated that bleeding follows a fall
in oestrogen levels but this is not necessarily so and
the relative importance of different biochemical mechanisms
has not been elucidated. There is increasing evidence to
implicate the prostaglandins and two groups of investigators
have demonstrated an increased endometrial concentration or
synthetic capacity for prostaglandin E2 in anovulatory DUB
(Willman et al 1976; Smith et al 1981b). There may also be
abnormal intrauterine haemostasis due to excessive fibrino¬
lysis (Rybo 1966) or to excessive heparin production by
endometrial mast cells (Foley et al 1978; Paton et al 1980).
It is not known whether there is any abnormality of endomet¬
rial lysosome function although it could be expected that
uterine lysosome membrane stability would be reduced in the
presence of unopposed oestrogen (Szego 1971) .
Unopposed oestrogen may also lead to an increased
rate of endometrial blood flow (Killam et al 1973) which
could be translated into excessive blood loss at the time
of endometrial breakdown. In normal women endometrial
blood flow may remain elevated until very shortly before
the onset of menses (Fraser and McCarron 1984), but inform¬
ation is lacking on the changes occurring in women with
anovulatory DUB.
Ovulatory cycles.
The great majority of women with DUB in the mid
reproductive years will experience regular ovulatory cycles.
Daily plasma measurements of LH, FSH, oestradiol and
progesterone have indicated that these cycles are indist¬
inguishable from normal women (Haynes et al 1980). This
suggests that the disorder is due to a local functional
abnormality within the uterus itself or to some unidentified
circulating factor.
The majority of these women have secretory endometrium
which is indistinguishable from normal (Nedoss 1971; Taw 1975).
The literature is replete with descriptions of irregular
^ unpublished data
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ripening, irregular shedding and secretory hyperplasia of
endometrium. These appearances are presumably due to an
abnormal stromal and/or glandular response to progesterone
and perhaps oestrogen. The underlying causes and relative
importance of these appearances are quite unknown. It has
also been suggested that increased uterine weight and
increased uterine surface area may be important although
a recent careful study has not confirmed this (Chimbira
et al 1980).
Increasing evidence again implicates abnormalities of
prostaglandin metabolism in the mechanism of bleeding. There
is reasonable evidence to implicate a decreased production
of prostaglandin F2C1 (Smith et al 1982). There is also
evidence to indicate that endometria from these patients
have an increased capacity to synthesise prostacylin (Smith
et al 1982). Prostacyclin is a potent vasodilator and
inhibitor of platelet aggregation and hence could substant¬
ially influence degree and duration of menstrual bleeding.
The factors responsible for the shift in endometrial
conversion of prostaglandin endoperoxides from PGF2C1 to
PGE2 and PGI2 are unknown. It will be of interest to look
for an abnormality of catechol oestrogen metabolism in these
patients, since 2 hydroxy oestradiol is a potent stimulator
of prostaglandin synthesis (Kelly 1981) . Receptor binding
for PGE may also be increased in women with abnormal menstrual
bleeding (Hoffman et al 1983). It must be remembered that
endometrium is a highly biochemically active tissue and
there may well be abnormalities of fibrinolysis, heparin
secretion, lysosome activity, prolactin secretion (Maslar
and Riddick 1979) or even relaxin (Dallenbach-Hellweg, Dawson
and Hisaw 1966; Yki-Janinen et al 1983) or renin production
(Johnson 1980).
One study has suggested that iron deficiency and
anaemia are causative or exacerbating factors for DUB
(Taymor et al 1964), whereas it seems much more probable
that the majority of patients who develop iron deficiency
anaemia trigger a compensatory mechanism which tends to
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reduce the menstrual blood loss. Jacobs and Butler (1965)
studied 15 women with iron deficiency anaemia and found
that in the great majority the blood loss per menstrual
period almost doubled following correction of anaemia. The
increase in blood loss was greatest in those women whose
initial blood loss was about average. Clearly the develop¬
ment of anaemia depends upon a number of factors including
iron intake, efficiency of iron transport and storage,
and the efficiency of the erythropoietic system as well
as upon the amount of menstrual blood loss. This is clearly
seen in women blood donors who can maintain a normal haemo¬
globin, and compensate for blood loss at a rate of up to
300 mis per month (Fowler and Barer 1942).
For some years it has been alleged that surgical tubal
sterilisation may cause dysfunctional uterine bleeding with
menorrhagia and the question is still unresolved. Some have
even reported that sterilisation may ultimately lead to a
high incidence of hysterectomy (Muldoon 1972). Most of the
investigations indicating a relationship between tubal int¬
erruption and subsequent menorrhagia have been retrospective
and based entirely on the woman's perception. However, some
of these studies have been adequately controlled and are
apparently convincing (Neil et al 1976; Lawson et al 1979).
On the other hand there are now numerous studies in the
literature which have found no evidence of an adverse
relationship (Edgerton 1977; Lieberman et al 1978; Sapire
and Davey 1980).
The only study which has attempted an objective and
prospective evaluation of menstrual blood loss in sterilised
women found no increase in measured menstrual loss up to
one year following operation (Kasonde and Bonnar 1976).
These investigators measured menstrual loss objectively
over two to three cycles before sterilisation and at
intervals up to twelve months in 25 women.
It has been suggested that ceasing oral contraceptive
use at the time of sterilisation may be responsible for a
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real increase in perceived menstrual bleeding in many of
these women. Clearly this effect may be particularly
disturbing for some women who have not experienced normal
menstruation for many years because of pregnancies, lactation
and prolonged pill use. However, this does not account
for all cases and it seems likely that in some the problem
is one of decreased tolerance of menstruation. For these
women recurring menstruation is no longer a reminder of
continuing fertility and in addition it may be associated
with undesirable features such as pain and premenstrual
tension. Nevertheless some women do develop genuine
menorrhagia some years following sterilisation and it is
impossible to say that this association is not causal in
some cases.
If there is a genuine causal association between
surgical sterilisation and menorrhagia in a small number
of women the mechanism is quite unknown. Decreased corpus
luteum secretion of progesterone has been reported in
several studies (Donney et al 1981) but this type of endocrine
disturbance is not noted as a cause of menorrhagia in other
situations. The most likely explanation would be interrup¬
tion of vascular transport of some unknown factor from the
ovary along the utero-tubal arcade. However, further
speculation awaits a convincing prospective demonstration
that the post tubal ligation menorrhagia syndrome really
exists. In the meantime it is reasonable to manage these
patients as cases of ovulatory dysfunctional uterine
bleeding, from which they are indistinguishable in other
ways at the present time (Fraser et al 1981; Fraser 19 85").
It is important to recognise that many cases diagnosed
on clinical grounds as DUB will ultimately be found to have
pelvic or systemic pathology of sufficient degree to cause
the symptoms. This is clearly shown in a retrospective
study from the Chelsea Hospital for Women, London where
40 per cent (105 out of 287) of women undergoing hysterectomy
for 'dysfunctional uterine haemorrhage1 were found to have
substantial pelvic pathology (Beazley 1970). Nowadays
there is even the suggestion that some of these cases may
be associated with minor degrees or even microscopic
deposits of endometriosis.
PSYCHOLOGICAL ASPECTS:
These are of the utmost importance in the assessment
of DUB, since the diagnosis is based almost entirely
on the history presented by the patient.
Perception of menstrual bleeding is inaccurate and
retrospective recall is unreliable (Gray 1980). Many
women have little idea how their menstrual loss compares
with the norm and their recorded perception may bear little
relation to measured loss (Hallberg et al 1966; Chimbira
et al 1980; Fraser et al 1981). Hallberg et al (1966) found
that 40% of women with menstrual loss exceeding 80 mis
considered their periods only moderate or scanty, while 14%
of those with a loss of less than 20 mis judged their periods
to be heavy. In a recent study of 69 women presenting with
good clinical histories of menorrhagia (Fraser et al 1981)
it was found that only 31% had a measured menstrual loss
of greater than 80 mis and 22% actually had a loss of less
than 35 mis - the mean for the normal population. A more
detailed assessment demonstrated that some of these women
had difficulty in perceiving major changes in volume from
cycle to cycle and even from one day to the next (Fraser et
al 1984a).
It is not generally appreciated that only a small
proportion of the total menstrual flow (on average 36%) is
made up of whole blood while the remainder appears to be
mainly endometrial tissue fluid (Fraser et al 1984b).
Abnormalities of this relationship may well influence
perception of menstrual blood loss volume in some indiv¬
iduals .
It seems likely that women under different types of
emotional strain may have decreased tolerance of disturbances
of menstruation and this may be particularly so in women who
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have been surgically sterilised. There is some evidence
to suggest that women with a complaint of menorrhagia are
more likely to exhibit features of depression (Greenberg
1983) .
From time to time anecdotal reports are mentioned of
women who have experienced sudden unheralded bleeding
in the face of unexpected emotional trauma. The extent
of this phenomenon and the possible mechanisms are
speculative.
PROGNOSIS:
Very little accurate information is available about
this aspect of DUB. None of this is based on objective
measurements of blood loss.
Single episodes of DUB in adolescence probably
have a good prognosis, whereas the adolescent with
several episodes of DUB has a poor prognosis in terms
of persistent menstrual disturbances (30-80%), repeated
need for curettage (40-55%), anaemia (30%) and even
endometrial carcinoma if inadequately treated (1-2%)
(Southam 1959; Southam and Richart 1966). This prognosis
is particularly bad when CGH is diagnosed (Fraser and Baird
1972), and is a good reason for diagnostic curettage in the
adolescent with repeated episodes of DUB.
It is said that prognosis in ovulatory DUB in the mid
reproductive years is good, but convincing evidence is not
available. In some communities many of these women undergo
hysterectomy and an accurate assessment of prognosis is no
longer possible. From older literature it appears that long
term prognosis for anovulatory DUB in the later reproductive
years is poor and recurrence is frequent (Israel 1967).
It is often said that curettage leads to long term
reduction in menstrual blood loss in many patients.
However, published data do not confirm this. Objective
measurements indicate a reduction in loss in the first
cycle following curettage but a return to pretreatment
levels thereafter (Nilsson and Rybo 1971; Haynes et al
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1977). The persisting subjective benefit which many women
experience is presumably related to reassurance about the
absence of pathology and a change in tolerance of symptoms.
ASSESSMENT OF MENSTRUAL BLOOD LOSS:
There is only one reliable means of assessing volume
of menstrual loss and that is direct measurement. This
has been recommended by several investigators, but there
is resistance by many doctors to asking patients to collect
their sanitary towels for laboratory assessment. This is
most unfortunate in view of the major errors which many
women make in perception of their menstrual loss. In
fact, menorrhagia must be one of the few common subjective
medical complaints upon which treatment decisions of far
reaching import are made without any attempt at objective
measurement.
Many clinical means have been recommended for
quantitating menstrual loss, but none of these are
generally helpful. Even recognition of blood "clots" in
the flow does not correlate well with volume. "Flooding"
is probably the most reliable single symptom although
women with measured loss between 60 and 80 mis per period
may sometimes report unequivocal "flooding" (Fraser et
al 1981). Tiredness and lassitude are unhelpful, whereas
a previous history of objectively confirmed anaemia is
strong supportive evidence. Some doctors still rely on
a sanitary towel count to give a measure of volume of loss
although several authors have demonstrated that this is
unreliable (Chimbira et al 1980; Fraser et al 1981). A recent
study of 276 menstrual periods in women complaining of
menorrhagia found no significant correlation between object¬
ively measured menstrual loss and number of pads or tampons
used (Fraser et al 1981).
Several methods have been proposed for measurement of
menstrual blood loss (Cohen and Gibor 1980) but the one
which has gained most popularity because of relative
simplicity and reproducibility is that of Hallberg and
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Nilsson (1964a). This method relies on careful collection
of all menstrual pads, tampons and "clots" followed by
extraction of haemoglobin and conversion to alkaline
haematin with 5% sodium hydroxide. Practical application
of the method has been greatly increased by the use of a
semi-automatic extractor (Newton et al 1977). More wide¬
spread clinical use of objective methods of assessment
such as this must occur if progress is to be made in
management of menorrhagia.
MANAGEMENT:
A more rational approach to correction of pituitary,
ovarian and uterine dysfunction should be a logical sequel
to recent pathophysiological research on DUB. Although
studies of management are not directly reported in this
thesis they are a critical end point of the clinical research
picture. The aim of basic studies is ultimately to improve
management and studies of therapy are therefore a logical
extension of this approach.
Management of DUB has always involved a choice between
medical and surgical measures, both of which have an
important place in modern therapy. Medical therapy is
usually preferred initially because it does not involve
the hazards of anaesthesia and will potentially preserve
fertility. However, it may need to be used for many years.
Over the past 20 years or so the mainstay of medical
therapy has been the use of synthetic hormones (March 1979).
These may be of great value, but increasing experience has
indicated the importance of tailoring regimens to the
requirement of each individual.
For anovulatory women oral progestogens alone are a
logical first choice to replace missing luteal phase
progesterone. They should usually be given for 7-10 days
from day 15 - 18 of the cycle, eg. norethisterone (NET)
5 mg bd or tds. This will usually permit good secretory
change in the endometrium and a predictable withdrawal
bleed. However, some women with excessive oestrogen
secretion from early in the cycle may need a longer
duration of progestogen exposure, for example from day 5
to 25 to reduce endometrial proliferation. This regimen
has the further advantage that it is contraceptive and
can be used in women who are ovulating. After 2-3 courses
the dosage can often be reduced as low as 5 mg NET or 10
mg MPA daily.
If taken continuously oral progestogens may also be
used to produce complete amenorrhoea, an acceptable
scientific solution to the problem but one which may be
psychologically unacceptable. There are many racial,
religious and individual concerns about hormonally-induced
amenorrhoea (Snowden and Christian 1983) and careful
counselling of the patient is required. Injectable
progestogens (eg. depot medroxyprogesterone acetate, DMPA)
have also been used to produce amenorrhoea by inducing
extreme degrees of endometrial suppression (Bonte 1978).
Unfortunately the response is unpredictable with many women
(30-40%) experiencing irregular scanty bleeding and 10-20%
having episodes of prolonged, frequent or rarely heavy
bleeding (Fraser 1981). A novel approach is the use of
a progesterone-releasing intrauterine device which has
proved valuable in a small number of women with menorrhagia
following haemodialysis for chronic renal failure (Newton
et al 1976). Although these patients obtain a substantial
reduction in total volume of blood loss this is often at
the expense of an increase in duration of scanty inter¬
menstrual bleeding.
Recently, the novel synthetic steroid, danazol, has
been used in varying doses to induce amenorrhoea in women
with DUB (Chimbira et al 1979). In lower doses of 200-
400 mg daily menstruation is not always abolished but
measured menstrual blood loss is still reduced. This
steroid probably also acts by reducing cyclical endometrial
growth through a combination of mechanisms at all levels
in the reproductive system (Fraser 1979; Reyniak & Lauerson
1982) .
Many women with ovulatory or anovulatory DUB will
benefit from a combined oestrogen-progestogen oral
contraceptive and theoretically this should have a
relatively high progestogenic balance- This acts by
suppressing both ovulation and endometrial proliferation.
Women using combined oral contraceptives are much less
likely to complain of menorrhagia, irregular bleeding or
intermenstrual bleeding (Royal College of General
Practitioners 1974). Combined oral contraceptives can
also be shown to reduce substantially the measured
menstrual blood loss in women complaining of menorrhagia
(Nilsson and Rybo 1971) . However, it appears that at
least 20% of patients will not respond.
It must also be accepted that many women have risk
factors which make them unsuitable for long-term hormonal
therapy. These factors are well-known and include smoking,
age over 40 years, strong family history of cardiovascular
disease, diabetes mellitus, hyperlipidaemia and many others.
In women with anovulatory DUB and infertility induction
of ovulation may treat both problems. The drug of first
choice is usually clomiphene, which is thought to act
mainly as an anti-oestrogen at the hypothalamic level.
Bromocriptine may be appropriate in the occasional patient
with mild to moderate hyperprolactinaemia. If these do
not work the second line of treatment involves injections
of FSH and LH with midcycle HCG or pulsatile infusion
of gonadotrophin-releasing hormone (GnRH). In general,
pregnancy rates with these treatments are lower in women
with anovulatory DUB than in similarly treated patients
who have amenorrhoea (Cox 1976). The reasons for this
are not yet clear.
Other approaches to medical therapy are intended
to correct biochemical abnormalities occurring within
the uterus itself. One of the most promising recent
developments has been the use of antiprostaglandin agents.
These include several groups of drugs which act mainly
by inhibiting the cyclo-oxygenase enzyme system which
converts arachidonic acid into cyclic endoperoxides. It
has recently been shown that some of these agents may induce
a dramatic reduction in menstrual blood loss in some women
with menorrhagia. The most extensively investigated
preparation is mefenamic acid administered as 500 mg
tds during the days of menstruation only (Anderson et al
1976; Guillebaud et al 1978; Fraser et al 1981). This results
in a mean reduction in blood loss of 28%, but is usually
proportionately more effective in those with more excessive
loss. The benefit is usually maintained with repeated
treatment over long periods of time (Fraser et al 1983),
and may also be seen in women with menorrhagia due to an
IUCD, fibroids, or even Von Willebrand's disease
(Guillebaud et al 1978; Fraser et al 1981). Very limited
published information suggests that flufenamic acid,
indomethacin and naproxen may have similar beneficial effects
(Anderson et al 1976; Damarawy and Toppozada 1976; Davies
et al 1981).
Since the antiprostaglandin agents inhibit synthesis
of PGE2, PGF2C6, PGI2 and TXA2 it has been suggested that
their beneficial effect on menorrhagia may be mediated by
a relative increase in synthesis of a vasoconstrictive
leukotriene. However, not all women will experience a
reduction in blood loss with PG inhibitors, and therefore
these drugs may act merely by altering the balance of
prostanoid synthesis within the uterus. The fenamates may
have an advantage because of a weak end-organ action inhib¬
iting prostaglandins that have already been synthesised
(Collier and Sweatman 1968; Smith et al 1975).
Fibrinolytic inhibitors administered orally also
have a rational basis in therapy. Epsilon amino caproic
acid (EACA) and tranexamic acid (AMCA) have been used by
several investigators with striking benefit in some women
with menorrhagia and intermenstrual bleeding (Kasonde and
Bonnar 1975a; Westrom and Bengtsson 1970). Unfortunately,
the widespread use of these drugs has been limited by side
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effects and concerns about long term safety. Intrauterine
application may avoid these risks and appears to produce
benefit for several cycles following one treatment (Tauber
et al 1977). Several diamidines and guanidines which are
potent inhibitors of fibrinolysis are under investigation
as potentially valuable therapeutic or preventive agents
for IUD-related bleeding problems (World Health Organization
1979) .
Ethamsylate is a rather mysterious drug which is said
to reduce menstrual blood loss by a reduction in capillary
fragility (Harrison and Campbell 1976) acting perhaps as
an antihyaluronidase and an antiprostaglandin agent. A
50% reduction in blood loss in women with spontaneous
menorrhagia and 19% reduction in IUD users has been reported
by one group (Harrison and Campbell 1976) and confirmed by
another (Kovacs and Annus 1978). However, this benefit
could not be demonstrated by Kasonde and Bonnar (1975b).
Other agents which may correct abnormalities of
uterine biochemistry include vasopressin analogues, such as
triglycyl lysine vasopressin (Pavlin et al 1978), antiheparin
agents, including the rather non-specific toluidine blue
and protamine sulphate (Rumbolz et al 1952) and antagonists
of histamine, kinins and complement (World Health Organisation
1979). Distant possibilities include the use of specific
thromboxane analogues or prostacyclin inhibitors delivered
locally into the uterus. It has been suggested that micro¬
capsules placed in the vagina might provide a convenient
route for the delivery of intrauterine medication. There is
little doubt that greater understanding of the multiple
mechanisms of DUB will assist in development of alternative
logical approaches to medical therapy.
In the meantime surgery remains a frequent necessity in
the therapy of menorrhagia, whether it be due to pelvic
disease, medical disorders or DUB. Conservative surgery may
include myomectomy for fibroids and bilateral ovarian wedge
resection for polycystic ovarian disease. However, the
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choices with DUB are virtually limited to therapeutic
curettage and hysterectomy, although endometrial cryo¬
surgery and laser ablation have been reported (Droegemuller
et al 1971; Goldrath et al 1981).
Therapeutic curettage has often been advocated for
DUB but the evidence for its efficacy is uncertain. Many
women will experience a decrease in measured menstrual loss
in the cycle following curettage (Haynes et al 1977) but this
is not usually maintained. However, the subjective benefit
may persist and is probably related to reassurance and
increased tolerance.
Hysterectomy is probably the most widely used treatment
for DUB and is undoubtedly curative. Unfortunately, it
involves major abdominal or vaginal surgery and may occasion¬
ally be associated with a wide range of short and long term
complications. It is clearly a highly satisfactory method
of treatment for severe or refractory DUB but is increasingly
used for less severe cases. A recent survey of health
insurance statistics concluded that approximately 40 per cent
of Australian women will undergo hysterectomy at some time in
their lives (Selwood and Wood 1978). Although some of these
cases would be for cancer or uterine prolapse it is obvious
that many must have been for menstrual disturbances and
particularly 'menorrhagia'. In which case it is highly
probable that many women with menstrual blood loss in the
normal range have undergone hysterectomy for a symptom
which is perceived rather than real. It seems likely that
the same situation pertains in many centres in North America
and perhaps also in Europe.
One of the major concerns about hysterectomy is the
occurrence of post-operative psychological disturbances
(Menzer et al 1957). However, there is increasing evidence
that full counselling and ample thinking time prior to
finalising the decision for hysterectomy almost eliminate
significant adverse reactions. Use of medical agents for
control of abnormal bleeding may be a valuable adjunct
during this decision-making period.
CONCLUSION:
In the past two decades numerous advances have been
made in understanding the group of conditions currently-
known as dysfunctional uterine bleeding. There is now
better agreement as to the conditions which this term
includes although controversy still exists. Patient
perception of menstrual disturbances, especially
menorrhagia, is often inaccurate and greatly complicates
management.
Mechanisms are still not clearly defined although
it seems certain that there may be functional abnormalities
of the hypothalamic-pituitary unit, the ovaries or the
uterus itself. The condition occurs most frequently in the
5-10 years preceding the menopause and may represent one
aspect of the ageing process in the reproductive system.
However, it may also occur at any other time during the
reproductive years.
Management now includes a range of therapies designed
to correct hormonal, prostaglandin or fibrinolytic abnorm¬
alities. However, medical therapy may need to be continued
for many years and there are still a substantial number of
treatment failures. Therefore, surgery including particulary
hysterectomy, is still a very important option in therapy.
Ongoing research is aimed at a much better understanding of
the many underlying pathophysiological mechanisms and, as
a consequence, more precise therapy.
SECTION 2
OESTROGEN DYNAMICS DURING THE MENSTRUAL CYCLE
OESTROGEN DYNAMICS DURING THE MENSTRUAL CYCLE:
An experimental technique involving a combination of
isotope dilution techniques and direct sampling of ovarian
venous blood and follicular fluid was used to study the
ovarian secretion and metabolism of oestradiol and oestrone
in 11 women with normal menstrual function and 10 with
dysfunctional uterine bleeding (DUB). The mean metabolic
clearance rate of oestradiol in women with DUB (1198 ±
97 SEM, I plasma/24 hours) was not different from that
recorded in women with normal cycles (1202 ± 55 £ plasma/
24 hours). Similarly, the conversion ratio of oestradiol
to oestrone was not significantly different (DUB: 0.089 ±
0.010 compared with controls: 0.105 ± 0.010). In normal
women the blood production rate of oestradiol (yg/24 hour)
increased from 63 during menstruation to reach peaks of
394 immediately prior to ovulation and 337 during the mid-
luteal phase. Women with DUB also demonstrated cyclical
changes in oestradiol blood production rate. The highest
production rate of 497 yg/24 hour was seen in a patient
with cystic glandular hyperplasia of the endometrium. Two
other women exhibited inappropriately high production rates
at an early stage of the cycle. All three patients with
DUB who ovulated in the cycle studied had a corpus luteum
on each ovary and one further patient had bilateral large
functional follicles. In the luteal phase oestrogen
secretion and metabolism was normal.
In normal women over 95% of oestradiol entering the
blood originated from either the pre-ovulatory follicle
or corpus luteum. In 6 out of 10 patients with DUB sign¬
ificant amounts of oestradiol were secreted by both ovaries.
The ovarian secretion of oestrone fluctuated in a similar
manner to that of the blood production rate of oestradiol
to reach a maximum of just over 100 yg/24 hour at mid-
cycle, and no differences were seen in women with DUB.
Ovarian blood flow was calculated in 10 women with a mean
of 18.9 ± 5.2 SEM, ml/min in 6 normal women and 22.3 ±
4.0 ml/min in 4 women with DUB. Absolute blood flow was
calculated at approximately 2.3 ml/g/min. The highest
rates of flow (36.4 and 33.1 ml/min) were recorded in the
luteal phase and the lowest flow (4.6 ml/min) during
luteolysis.
In follicular fluid the concentration of oestradiol
was very much higher than that of oestrone. The concent¬
rations of oestrogens were similar in fluid collected
from small follicles at all phases of the cycle. The con¬
centration of oestradiol in large follicles (>1 cm diameter)
was much higher in the mid-late follicular phase (1520 ±
375 ng/ml; mean ± SEM) than in large or small follicles at
other phases of the cycle. In the mid-late follicular
phase large follicles were invariably associated with high
concentrations of oestradiol in venous plasma draining the
corresponding ovary (13.8 ± 3.1 ng/ml). The mean ratio of
oestradiol to oestrone in fluid from large follicles in
which the concentration of oestradiol was greater than
400 ng/ml (18.0 ± 1.0, n = 10) was significantly higher
than the ratio in corresponding samples of ovarian venous
plasma (10.7 ± 1.4, n = 11). These findings suggest that
when the concentration of oestradiol in a Graafian follicle
exceeds 1250 ng/ml it is likely to be functionally active
(i.e. contributing to circulating oestradiol). In women
with DUB the concentrations of oestradiol and oestrone were
similar to the normal women, but sometimes several large
active follicles were present. It is suggested that in
women with DUB inappropriate oestrogen secretion may result
from multiple follicular development due to abnormalities
in gonadotrophin release and/or intra ovarian control
mechanisms.
Chapter 2
BLOOD PRODUCTION AND OVARIAN SECRETION RATES OF
OESTRADIOL-173 AND OESTRONE IN WOMEN WITH NORMAL
MENSTRUAL CYCLES:
INTRODUCTION:
Ovarian secretion of "oestrogen" is abnormal in women
with anovulatory dysfunctional uterine bleeding (Brown and
Matthew 1962) but little is known about the details of
direct secretion of different oestrogens and their sub¬
sequent metabolism in this condition. In addition details
about ovarian secretion of oestrogens in normal women and
women with anovulatory dysfunctional uterine bleeding were
far from clear at the time of execution of this study.
An indirect index of ovarian secretion of oestrogens
can be obtained by measurements of urinary excretion of
oestrogen conjugates (Brown and Matthew 1962) or by measure¬
ments of peripheral blood concentrations of oestrone and
oestradiol (Baird 1968). A more direct index can be
obtained by measurement of the production and secretion
rates of oestrogens in urine by isotope dilution techniques
which require the injection of at least 2 radioactive tracers
labelled with different isotopes (Barlow and Logan 1966).
However, the interpretation of the secretion rates of
oestradiol estimated by this method is complicated by the
fact that at least two other known precursors of oestradiol
conjugates (androstenedicne and oestrone) are secreted by
both ovary and adrenal glands (Vandewiele et al 1968).
The measurement of production and secretion rates of
steroid hormones using the constant infusion technique and
sampling in blood, overcomes many of the problems of the
urinary technique (Baird et al 1969). The metabolic clear¬
ance rates (MCR) and transfer constants of oestrone and
oestradiol have been measured in normal men and women
(Longcope et al 1968; Longcope and Tait 1971) although it
has been suggested that this technique is inapplicable to
the study of oestrogens because of difficulty in achieving
H-b
the steady state (Hembree et al 1969). In spite of
the possible sources of error in both methods estimates
of the production rate of oestrone and oestradiol obtained
from a knowledge of the mean MCR and plasma concentrations
are similar to those based on urinary isotope dilution
studies (Kirschner and Taylor 1972) .
To determine the relative importance of secretion by
the adrenals and each ovary to the total production rate
of a steroid, direct sampling of glandular venous blood is
necessary (Baird 1970). In the present study isotope
dilution techniques involving continuous infusion techniques
were combined for the first time with direct sampling of
ovarian venous blood and follicular fluid, to investigate
the site of secretion and production of oestrone and
oestradiol in 11 subjects throughout the menstrual cycle.
The investigations in this section were developed from
an idea of Dr. Baird's and were planned, executed and
analysed jointly by Dr. Baird and myself. Mr Alan Galbraith
measured most of the endogenous plasma oestrogen concen¬
trations. I carried out all the extractions, purifications
and estimations of radioactive oestrogens and on 2 occasions
assayed the endogenous plasma oestrogens. I was also
responsible for developing a celite chromatography separation
and radioimmunoassay for oestrone and oestradiol for
comparison with the double isotope derivative method and as
a basis for future studies.
METHODOLOGY:
Radioactively-labelled reagents -
3H-6,7-oestradiol (44 Ci/mmole), 1kC-4-oestrone (50
mCi/mmole) and 1 ItC-4-oestradiol (50 mCi mmole) were
obtained from the Radiochemical Centre, Amersham and
purified every 3 months by thin-layer chromatography in
System 1 (see below) followed by paper chromatography in a
Bush type system (stationary phase: methanol; water 3:1;
mobile phase: toluene). The amount of radioactivity in
samples was determined by adding 10 ml of scintillation
H-f
fluid (Baird 1968) and counting for at least 200 min.
The settings on the counter were adjusted so that the
efficiency for counting 3H was 34% and for 1!>C was 52%
in their respective channels. The background in the 3H
and llfC channels was 16 and 12 cpm respectively, and the
efficiency of lltC in the 3H channel was 14% and negligible
for 3H in the 14C channel.
Metabolic clearance rates -
Metabolic clearance rates were measured by the
constant infusion technique (Longcope et al 1968; fig 1) .
The experiments were started between 7 and 8 am with the
subjects fasting and supine for at least 10 hrs before and
throughout the experiment. A priming dose of 4 yCi 3H 6,7-
oestradiol was injected into an arm vein at 0 min after 50 ml
of blood had been withdrawn for estimation of the mass of
endogenous oestrone and oestradiol-176. At 30 min a constant
infusion of 3H-oestradiol was started at the rate of 2 yCi
per hour and continued throughout the rest of the experiment
(usually 260 min). The techniques of sampling the solution
used for the priming dose and the rate of infusion were as
described by Longcope, Layne and Tait (1968), a glass syringe
and teflon tubing being used to prevent absorption of the
steroid. Forty ml samples of blood were collected from a
cannula in a vein in the contralateral arm at 150, 165, and
180 min. The infusion was continued during induction of
anaesthesia with intravenous sodium thiopentone (0.5 g)
between 180 and 195 min. Anaesthesia was maintained by the
injection of 20-30 ml of bupivacaine into the epidural space
and supplemented by inhalation of nitrous oxide and oxygen.
Premedication was not given.


















2jjCi / hour J JiU









Figure 1. Layout of constant infusion technique for the
measurement of MCR of oestradiol (E2) and CR for oestraaiol
to oestrone (Ei). (DPM = disintegrations per minute)
Subjects -
Informed consent was obtained from all subjects who
were admitted to hospital for hysterectomy for preinvasive
(Stage 0) carcinoma of the cervix. They were otherwise
healthy and had a history of regular menstrual cycles
(24-31 days). Their mean age was 33 years (27-47) and all
were parous except patient no.4.
Urine was collected for at least 4 days prior to the
experiment for serial determination of total oestrogen
and pregnanediol excretion (Brown 1971). The endometrium
on the day of the experiment was examined histologically
and dated according to the criteria of Noyes, Hertig and
Rock (1950). The ovaries were examined by the naked eye at
operation for the presence of follicles and/or corpora
lutea, and biopsies were taken for microscopic examination
if there was doubt about the nature of any structure. This
information together with the day of the cycle was then used
to estimate the date of ovulation, and the subjects were
grouped around this estimated point (Table 1).
Sampling during surgery -
When the abdomen was opened the state of the ovaries
was noted, and clamps were placed on the ovarian ligaments
on both sides to occlude the ovarian branch of the uterine
vein and artery. Particular care was taken to ligate veins
that drain the lateral pelvic wall and the uterus, and that
run in the leaves of the broad ligament to join the ovarian
venous plexus. In some initial studies a main trunk of the
ovarian vein on each side of the pelvis was cannulated with
a portex catheter allowing repeated sampling; in most cases
blood was collected by needle aspiration of a vein in the
infundibulopelvic ligament 2-3 cm from the ovary. Three
samples of peripheral venous and sometimes brachial arterial
blood were collected at approximately 15-min intervals
between 210 and 275 min, together with samples of ovarian
venous blood and follicular fluid. The heparinized samples
were cooled on ice after collection, centrifuged at 2000 rpm
for 20 min at 4 C and the plasma stored at -15 C until analysis.
Measurement of oestrogen concentration -
The concentration of oestrone and oestradiol-173 in
peripheral and ovarian venous plasma and in follicular fluid
was measured using a complex, time consuming, moderately
sensitive, highly specific and precise double isotope deriv¬
ative method (Baird 1968). This method involved addition of
3H-oestrone or 3H-oestradiol 176 (42.4 curie/mmol) as indicator
to the biological sample before extraction to allow for the
calculation of losses. The phenolic extract of blood was
reacted with 3 5S p-iodobenzene sulphonyl chloride (pipsyl
chloride; 150-200 millicurie/mmol) and the derivatives
purified by 4 chromatography and 2 further derivative steps.
About 10% of both steroids was present in the final sample
used for counting.
Table1:
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The volumes of peripheral and ovarian venous plasma
extracted were approximately 20 and 5 ml, respectively.
For follicular fluid the volume (0.2 ml) was made up to
5 ml with water. The blank (ng±SD) for 20 ml samples
(oestronei 0.19 ± 0.11 n = 27; oestradiol: 0.12 ± 0.12 n
= 27) was subtracted from the value of the estimate before
it was expressed in pg/ml. The blank for a 5 ml sample
(oestrone and oestradiol <50 pg) was negligible in compar¬
ison to the mass of oestrogen in ovarian venous plasma or
follicular fluid and was not subtracted from the estimate.
The coefficient of variation of replicate estimates of a
pool of nonpregnant female plasma assayed with each batch
of samples was 8.6% and 14.2% for oestrone and oestradiol,
respectively (n = 12).
Extraction and purification of radioactive oestrogens -
One hundred dpm of 1 **0-4-oestrone and 150 dpm 11+C-4-
oestradiol as indicators for estimation of losses and 50yg
each of oestrone and oestradiol as carriers were thoroughly
mixed with 10 ml of plasma to which 0.1 ml of N sodium
hydroxide had been added. Extraction with ether and neutral
phenolic partition was performed (Baird 1968). The following
solvent systems were used for thin-layer chromatography
(TLC) on silica gel (GF254) 0.250 mm thick:
I chloroform:acetone 85:15
II cyclohexane:ethylacetate 1: 1
III benzene:ethanol 98: 2
IV chloroform:acetone 97: 3
V chloroform:acetone 92: 8
The phenolic extract of plasma was chromatographed
in System I, and oestrone (Rf 0.68) and oestradiol (R^ 0.46)
eluted separately. Both oestrogen fractions were reacted
separately with pipsyl chloride and the monopipsylates
further purified by chromatography in TLC Systems II and
III. The amount of 3H and ltfC were estimated in the purified
sample and the 3H dpm present in the plasma sample calculated
after correcting for losses. The overall mean recovery was
68% (41-90) for oestrone and 71% (42-87) for oestradiol.
Validity of purification procedure -
In a preliminary experiment 20 ml samples of plasma
were extracted. Following TLC in System I the oestrogen
fractions were further divided. One half was purified in
the usual way by forming the pipsyl derivative; the remain¬
ing half was acetylated (Longcope et al 1968), and the
monoacetates of oestrone and oestradiol were purified by
TLC in Systems IV and V, respectively. The overall recovery
using this procedure was 72% (30-92) and 76% (69-86) for
oestrone and oestradiol, respectively.
The mean concentration (dpm/10 ml plasma) of oestrone
and oestradiol in 6 samples purified by forming the pipsyl-
ates (79 and 748, respectively) were not significantly
different (paired Student's t test p>0.2) from those found
with the procedure involving acetylation (90 and 759). As
the pipsylates are more easily visualized by ultraviolet
light this procedure was adopted as the standard procedure.
Calculation of results -
The metabolic clearance rate (MCR) in liters per day
was calculated from the equation
MCR = -, (Tait 1963).
x 2
When R = the rate of infusion of 3H-oestradiol in dpm
per day and x2 = the concentration of 3H-oestradiol in dpm/
1 obtained from the mean value of the samples at 150, 165
and 180 min. The Blood Production Rate of oestradiol
(PgEz) expressed in yg/24 hr was calculated from the
product of the plasma concentration at 0 min and MCREa.
The conversion ratio of oestradiol and oestrone (CBBE2E2)
was calculated from the ratio of the concentration of
radioactive oestrone (x1) to that of oestradiol (x2).
The ovarian secretion rate of oestrone (SovEl) was
calculated from the formula




Concentration of oestradiol in ovarian venous
rE2 _ plasma (inyE2)
Concentration of oestradiol in arterial
plasma (i&E2)
Concentration of oestrone in ovarian venous
rE1 = plasma (wEM
Concentration of oestradiol in arterial
plasma (i^E1
RESULTS:
Metabolic clearance rates and conversion ratio -
There was no significant change in the concentration of
either 3H-oestrone or 3H-oestradiol in the 3 samples obtained
prior to operation (Tables 2 and 3)- Espressed as a percent¬
age of the mean, the values (±SEM) at 150, 165 and 180 min
were 100.3 ± 1.2, 99.3 ± 1.1 and 100.4 ± 1.0 for oestradiol
and 98.6 ± 1.7, 97.5 ± 2.0 and 104 ± 2.5 for oestrone,
respectively. The regression equation of % of mean value
(y) against time in minutes (x) for samples taken prior to
operation between 150 and 180 min were: y = -0.016x + 102.6,
r = -0.085 p>0.1 for oestradiol and y = -0.005 + 101.3, r
= -0.023 p>0.1 for oestrone. The relatively high SEM of the
mean MCR (1346 ± 152 1/24 hr) in the present series was due to
one value (subject 9) which was well outside the 95% confidence
limits of the mean. Omitting subject 9 the mean value was
1202 ± 55 1/24 hr. There appeared to be no change in MCR
with respect to the stage of the menstrual cycle.
After induction of anaesthesia there was a significant
increase in radioactivity in all subjects except subject 8.
The mean values ± SEM (expressed as a percentage of the mean
value 150-180) collected at approximately 220, 235 and 250
min were 116 ± 4, 121 ± 4 and 125 ± 4 for oestradiol and
130 ± 6, 118 ± 8 and 114 ± 13 for oestrone. The regression
of mean % value against time was represented by the equation
y = 0.324x + 43.9, r = 0.417 p<0.05 for oestradiol and y =
0.176x + 82.1, r = 0.138 p>0.1 for oestrone. Thus, during
the operation the MCR of oestradiol fell to an average of
83% of that prior to surgery. The mean conversion ratio
Table2:
Concentrationof3H- estradiol(x2)i pl smaf l owinginfu iof3H- estradiol into11regularlymenstruatingw men. dpm/10lplasma(x2)afterpri ingdose(min)Rateof— —













































































































































































































































(CBBE2El) from 220-250 min (0.106 ± 0.011) was not
different from that observed from 150-180 min (0.105 ±
0.010) .
Blood production rates of oestradiol -
In 4 subjects (no.9 of this study and 3 subjects in
another study) the concentration of oestrone and oestradiol
in the sample taken at 0 time was compared to that of a
sample obtained by pooling aliquots of collections from
150 to 180 min (Table 4). There was no change in the
concentration of oestradiol and only minor fluctuations in
the concentration of oestrone. In subject no.9 the
concentration of both oestrogens were not markedly different
at 235 min.
Pbe2 (blood production rates of oestradiol) was
calculated from the product of M.CR and plasma concentration
(Table 5). The values increased from 63 yg/24 hr during
menstruation in subject no.l to reach a maximum value of
394 yg/24 hr at 2 days before ovulation (Subject no. 4;
figure 2).
Concentration of oestrone and oestradiol in ovarian venous
plasma -
The concentration of oestrone and oestradiol was very
similar when measured in consecutive samples of ovarian
venous plasma collected in 3 subjects (Table 6). In subject
no.9 the concentration increased 2-fold following ligation
of a vein from the pelvic wall draining into the infundibul-
opelvic ligament.
The concentration of oestradiol was much higher in
plasma from the ovary containing the preovulatory follicle
or corpus luteum ("active" ovary) than from the contralateral
side ("inactive" ovary) (Table 5). The difference in
concentration of oestrone in plasma from the two ovaries
was less marked than that of oestradiol. This is reflected
by the significant difference in ratio of oestradiol to
oestrone between the two sides (6.44 ± 0.97 vs 3.37 ± 0.61
for active vs inactive, respectively).
Table 4:
Concentration of oestrone and oestradiol (pg/ml)
in peripheral venous plasma in 4 subjects at
intervals during this experiment.
Time (min)
0 150-180
Subject Oestrone Oestradiol Oestrone Oestradiol
A (no.9) 111 121 115 122
*87 *141
B 149 318 210 291
C 126 176 79 176
D 104 244 189 309
* At 235 min.
E ?
Figure 2. Blood production (P ) and ovarian secretion
rate (SovE2) of oestradiol (E2T throughout the menstrual
cycle. The subjects have been grouped around the day of
estimated ovulation (Table 1). The Pg for each subject
is indicated by the total height of each column and the
individual components by the corresponding codes i.e.,Hsov 2;£jEa derived from Ei.
Table5:


























































































































Concentration of oestrone and oestradiol





Subject (min) Oestrone Oestradiol
1 226 80 140
231 80 166
3 224 778 9360
232 648 8230
9 222 330 2640
*226 595 4570
238 880 4500
* Connection from lateral pelvic vein clamped after
222 min.
be
The calculated secretion rate of oestrone from the
"active" ovary varied from 9.9 yg/24 hr in the early
follicular phase of the cycle (Subject no.l) to a
preovulatory maximum of 104.9 pg/24 hr (Subject no.4)
(Table 5) .
DISCUSSION:
The studies described in this section were designed
to investigate the secretion and metabolism of oestradiol
and oestrone in women with regular and normal menstrual
cycles for comparison with women with dysfunctional uterine
bleeding. The theoretical and practical aspects of these
techniques have been thoroughly discussed by a number of
authors (Tait 1963; Tait et al 1962; Gurpide et al 1963;
Bardin and Lipsett 1967; Longcope et al 1968; Hembree et
al 1969; Baird et al 1969).
In order to measure accurately the parameters
described in this section, it is necessary to assume that
steady state conditions apply. In this situation the
peripheral plasma concentration of steroid is constant and
the rate of entry of the steroid into the plasma is equal
to its rate of exit. Unfortunately, in practice the system
is not always in a steady state mainly because of circadian
variations in secretion and metabolism, episodic secretion
or postural variations which alter liver blood flow and
metabolism. However, it has been shown that, if the rate
of metabolism is high and the variations in secretion are
relatively slow, the rates of entry and exit of the steroid
from blood are approximately equal and the calculations
reasonably accurate for the time of study. This appears to
apply to oestradiol and oestrone although in some subjects
the steady state is only reached very slowly (Hembree et
al 1969).
The simplest means of measuring the metabolic clearance
rate of oestradiol (the rate of irreversible removal from
plasma; expressed as litres of plasma cleared per 24 hrs)
is to perturb the system by a continuous constant rate
infusion of a radioactively labelled tracer (eg. 3H-
oestradiol) which simulates entry of steroid from a
gland. The achievement of steady state is hastened by a
priming dose. Once the steady state has been reached the
concentration of 3H-oestradiol in the blood is constant
and the rate of clearance equals the rate of infusion of
labelled tracer. The metabolic clearance rate then equals
the rate of infusion divided by the radioactive steroid
concentration (Tait et al 1962). Serial blood samples are
required to confirm that the steady state has been achieved.
The blood production rate of a steroid is the total
amount of steroid entering the blood from all sources in
a given time. In the case of oestradiol in women in the
reproductive years it now appears that almost the entire
blood production rate is accounted for by secretion from
the ovaries, specifically from the developing follicle
or corpus luteum (see Chapters 3, 4 and 5). This means
that secretion rate from the ovary equals blood production
rate, which in the steady state can therefore be calculated
as the product of metabolic clearance rate and peripheral
arterial concentration. Since negligible clearance occurs
in the peripheral tissues of the arm peripheral oestradiol
concentration in the cubital vein is equal to the arterial
concentration. Provided that the metabolic clearance rate
is relatively constant changes in plasma levels of oestra¬
diol should directly reflect changes in ovarian secretion.
Provided that ovarian secretion rate equals blood
production rate for one steroid (eg. oestradiol) the ovarian
secretion rate of a second steroid which enters the blood
from more than one type of gland (eg. oestrone) can be
calculated from the ratio of concentration of the second
steroid in ovarian venous effluent and arterial afferent
blood applied in the formula described earlier in the
chapter (Baird 1970).
The assessment of all these parameters provides
information on several aspects of ovarian oestrogen
secretion and metabolism, and is therefore a good back-
ground for studying possible abnormalities in women
with dysfunctional uterine bleeding (Chapter 3).
The results in the present study confirm the validity
of the constant infusion technique for the measurement
of MCREz and CBBE2El for normal women as has been shown
for men (Longcope and Tait 1971). The lack of any signif¬
icant trend in values from 150 to 180 min indicates that
the steady state for both precursor and product had been
obtained. The maintenance of fasting and the strict stand¬
ardization of position during the infusion may have minimized
variations in hepatic blood flow which would be expected
to alter MCR (Baird et al 1969). The fall in MCR after
induction of anaesthesia was probably related to the fall
in systolic blood pressure (to about 100 mm Hg) with the
associated reduction in hepatic blood flow.
The concentrations of oestrogens in peripheral and
ovarian venous plasma are similar to those previously
published (Baird and Guevara 1969; Lloyd et al 1971;
Korenman and Sherman 1973). Their concentration showed
very little change during the course of the experiment
although the considerable variations in the concentration
of oestradiol which have been described in peripheral
plasma of ambulant subjects (Korenman and Sherman 1973) may
have been missed during the relatively short period of
sampling. The secretion rates may therefore only apply to
the period of measurements and to subjects in the supine
position, although the calculated production rates are in
the same range as those based on cumulative urinary spec¬
ific activity (Vande Wiele 1965; Barlow and Logan 1966;
Kirschner and Taylor 1972). It should be remembered however
that considerable individual variation may occur in
production rate of oestradiol (Brown 1971).
The mean values of MCRE2 (1202 ± 55 1/24 hr) and
Cbbe2E1 (0.105 ± 0.010) are very similar to those reported
for a comparable group of women at various stages of the
menstrual cycle (Longcope et al 1968). PgE2 illustrated
fcj
in Fig.2 was measured directly in each subject, and the
amount of E2 derived from E1 was calculated assuming
MCRE1 of 2210 £ plasma per day and CBBElE2 of 0.041
(Longcope et al 1968).PbEz exhibits a biphasic pattern
with the maximal values occurring preovulatory and in
the midluteal phase of the cycle (Fig.2). That these
peaks of production represent maximal secretory activity
of the preovulatory follicle and corpus luteum respect¬
ively is indicated by the relatively high concentration
of oestradiol in the plasma draining the "active" as
compared to the contralateral "inactive" ovary. Using
the mean ratio of plasma concentrations from active/inactive
ovary (26.1 ± 6.2 SE) and knowing that insignificant amounts
of circulating oestradiol derive from conversion from
oestrone (Longcope et al 1968) or adrenal secretion
(Baird, Uno and Melby 1969), it can be calculated that
about 95% of circulating oestradiol originates from
secretion by the preovulatory follicle or the corpus
luteum.
Having established that oestradiol is secreted
almost exclusively from the active ovary, the ovarian
secretion of oestrone and other steroids can be calculated.
A similar method has been described for the testis and
adrenal using testosterone and Cortisol respectively as
unique secretory products (Baird 1970). This latter
technique was used by Kirschner and Jacobs (1971) to
calculate the adrenal androgen secretion in hirsute women
undergoing retrograde catheterization of adrenal and
ovarian veins via the femoral vein. They commented that
there was no known unique secretory product of the ovary
which could be used to calculate ovarian androgen product¬
ion. Although in normal women oestradiol appears to be
such a unique secretory product, in pathological conditions
e.g. polycystic ovarian disease, an appreciable proportion
of plasma oestradiol may be derived by peripheral conversion
of oestrone (Baird 1973).
In contrast to oestradiol, less than half PBEl is
derived by direct ovarian secretion (Fig.3). In
constructing Fig.3 the total ovarian secretion SovE1 was
E icalculated by adding SQV from the "active" ovary (which
was measured directly) to the eovE1 from the inactive ovary.
This latter value was obtained by multiplying the SovEl from
the active ovary by the ratio of concentration of oestrone in
plasma draining inactive:active ovary. Although this calcul¬
ation assumes that SovE1 is proportional to iovEl/ i.e. the
blood flow from both ovaries is similar, the SovE1 is
relatively small.
Significant amounts of oestrone are produced by extra-
glandular conversion of oestradiol (Fig.3) while the remainder
of Pbe1 originates either from adrenal secration (Baird, Uno
and Melby 1969) or by peripheral conversion of androstenedione
(Baird et al 1969). The extent of this latter source is
likely to vary depending on the stage of the cycle, because
the concentration of androstenedione in peripheral plasma rises
significantly at midcycle (Judd and Yen 1973) corresponding to
the growth of the preovulatory follicle (Baird et al 1973).
In subject no.5 a recently ovulated follicle in the left
ovary (corpus hemorrhagicum) and a follicle 1-2 cm diameter
on the point of rupture in the right ovary were observed at
operation and confirmed by histological examination of
biopsies. The preovulatory peak excretion of total oestrogen
in urine had occurred 2 days prior to the day of experiment
and the endometrial histology showed late proliferative
changes. Taken in conjunction with the day of the cycle
(day 11) there can be little doubt that ovulation had just
occurred in this subject. In spite of the bilateral ovulation,
the PgE2 and the SovE1 are much lower than during the prolif¬
erative or luteal phase of the cycle. Thus the marked mid-
cycle drop in plasma concentration of oestrogens, is due to
virtual cessation of ovarian oestrogen secretion at ovulation
(Baird and Guevara 1969).
It was considered important to ensure that undiluted
glandular efferent blood was collected by clamping any veins
























Figure 3. Blood prgduction rate (P L) and ovarian
secretion rate (S oestrone TEi) throughout the
menstrual cycle. The subjects have been grouped around the
day of the estimated ovulation (Table 1). The P for
each subject is indicated by the total height of each
column and the individual components by the corresponding
codes i*e-/J|Sov 1 ;HKe i derived from E2,*QEi derived from
other sources.
infundibulopelvic ligament. Particular care was taken to
occlude a branch(es) from the uterine plexus which has been
demonstrated by radiographic studies to anastomose with the
contralateral ovarian veins (Jacobs 1969). If ovarian venous
blood were diluted by blood draining the uterus and from the
pelvic plexus, the concentration of steroids would be falsely
low although the calculated ovarian secretion rates would
remain unaltered (Baird 1971). The MCR2 and plasma concentrat¬
ion (iA^2) used when calculating sovE1 were measured prior to
induction of anaesthesia. It is possible therefore that the
PgE2 did not represent that at the time when the ovarian vein
samples were obtained at laparotomy 30-60 min later. However,
the change in peripheral plasma concentration of oestradiol was
negligible (Table 4) and the observed fall in MCREa was less
20%. The error from this source therefore in calculating
SovE1 is unlikely to be large.
The secretion rate of oestrone from the "active" ovary
changed from 9.1 yg/2 4 hr in subject no.l to a maximum of
104.9 yg/24 hr in subject no.4 at 2 days prior to ovulation.
The concentration of oestrone in plasma draining the "inactive"
ovary was about 10% that draining the "active" ovary (mean
ratio concentration in active/inactive = 10.3 ± 3.1 SEM).
Assuming the blood flow to the ovaries is similar, the maximum
ovarian secretion of oestrone is unlikely to exceed 120 yg/24
hr. These results compare with SuE1 based on simultaneous
injection of oestrone and oestradiol labelled with different
isotopes, of 0-76 yg/24 hr (Barlow and Logan 1966) and 4.4,
36.9 and 44.1 yg/24 hr (Vande Wiele 1965).
None of the subjects showed any evidence of endocrine
abnormality. It has been reported that the PUE2 as measured
by the injection of 3H-oestradiol, was higher in premenopausal
women with early carcinoma of the cervix (including some with
Stage 0 lesions) than in control subjects (Fraser et al 1967).
However, there was considerable overlap between the groups and
the increased incidence of dysfunctional uterine bleeding in
this age group may have contributed to the slightly higher
p E2ru
Chapter 3
BLOOD PRODUCTION AND OVARIAN SECRETION RATES
OF OESTRADIOL AND OESTRONE IN WOMEN WITH
DYSFUNCTIONAL UTERINE BLEEDING:
INTRODUCTION:
Abnormalities of oestrogen excretion have been
recognized in women with dysfunctional uterine bleeding
for many years (Jeffcoate 1937; Schroder 1954; Brown et al
1959), but little is known of the underlying changes in
oestrogen secretion and metabolism.
Production and secretion rate of oestrogens have been
measured in normal women by urinary isotope dilution
techniques (Barlow and Logan 1966; Vande Wiele et al 1968),
and by constant isotope infusion and blood sampling tech¬
niques (Longcope et al 1968; Hembree et al 1969). Constant
isotope infusion with direct sampling of ovarian venous blood
and follicular fluid has been applied to the study of blood
production and ovarian secretion of oestradiol-176 and oestrone
in 11 normal women throughout the menstrual cycle (Chapter 2).
In the current study this technique has been applied to the
measurement of blood production and ovarian secretion of




Informed consent was obtained from 10 patients all of
whom had a clinical history suggestive of anovulatory
dysfunctional uterine bleeding sufficiently troublesome
to necessitate hysterectomy. Their mean age was 43 yr
(range 35-48 yr) and all were parous (1 to 10 pregnancies
each: mean = 4.6). All patients except no.10 had a recent
curettage of the uterus and 8 of the 10 (not no.l and no.10)
had measurements of the excretion of total oestrogen and
pregnanediol in the urine at least once per week for up to
50 days prior to the study. The pattern of menstrual cycles
based on endometrial histology and hormone measurements is
<o8
given in Table 1. Most had a history of anaemia but
objective measurements of menstrual blood loss were not
available.
TABLE 1:
Menstrual cycle patterns and endometrial histology for
1 yr prior to hysterectomy in 10 women with dysfunctional
uterine bleeding.
Patient Previous year Previous cycle Current cycle
1 A + 0 A A*
2 A + 0 A A*
3 A A* A
4 A* A A
5 A + 0* A 0
6 A + 0* p 0
7 0 p 0
8 A + 0* 0 p
9 A + 0 0 p
10 p p p
The pattern of menstrual cycles is classified on history,
endometrial histology, hormone measurements and appearance
of the ovary at operation as ovulatory (O), anovulatory (A)
or mixed (A + O) . Three time periods are current cycle,
cycle prior to the one studied (previous cycle) and the
12 months prior to study (previous year). The finding of
cystic glandular hyperplasia of the endometrium is indic¬
ated by the asterisk.*
Dynamic studies were carried out on the day of hysterectomy.
The endometrium obtained at operation was examined histolog¬
ically and dated according to the criteria of Noyes, Hertig and
Rock (1950). The ovaries were examined by the naked eye at
operation for the presence of follicles and/or corpora lutea,
and biopsies taken for microscopic examination, if there was
doubt about the nature of any structure. This information
was taken together with the day of the cycle to estimate the























































































CGH=cysticglandularhyperpla i EP=earlyprolif rative MP=midproliferative LP=lateproliferative ES=earlysecretor MS=midsecretory




The infusion and assay methods and the calculations have
been described and discussed in detail in chapter 2.
RESULTS;
Seven of the 10 patients showed evidence of cystic
glandular hyperplasia of the endometrium either in the cycle
under study or within the previous 12 months (Table 1).
Only 2 patients (no.3 and no.4) had shown evidence of
ovulation at any time in the year prior to study. Three
patients (no's 8, 9 and 10) were studied too soon after the
onset of the last episode of vaginal bleeding to determine
whether the current cycle was ovulatory or not.
TABLE 3:
Concentration of 3H-oestrone (x1) in plasma following
infusion of 3H-oestradiol.







150 165 180 215 230 245
1 1.04x10 8 56 65 64 55 59 59
2 1.15x10 8 75 85 79 95 80 142
3 1.13x10 8 113 92 129 151 142 133
4 0.9 3x10 8 61 69 80 88 85 88
5 1.08x10 8 114 114 114 140 160 144
6 1.03x10 8 92 85 101 95 99 100
7 0.9 8x10 8 49 46 47 46 37 50
8 1.08x10® 69 77 60 84 96 78
9 1.15x10® 76 78 78 87 94 86
10 1.03x10® 97 97 102 108 110 132
TABLE4:
Concentrationf3H-o s diol(x2)i plasmafollowingi fu f3H-oestradiol.
dpm/10l(x2)afterprimingdose(minut s)Cbbe2e1 (200-255)( 15- 70)(230-285)










































































































Metabolic clearance rates (MCR) and conversion ratio
(cbbe2e1)•
There was a small but significant rise in the concen¬
tration of 3H-oestradiol and 3H-oestrone in three samples
obtained prior to the operation (Tables 3 and 4). Expressed
as a percentage of the mean values (±SEM) at 150, 165 and 180
min were 98.4 ± 1.3, 97.7 ± 1.2 and 103.9 ± 1.0 for oestradiol
and 97.3 ± 1.7, 99.9 + 2.1 and 103.4 ± 2.5 for oestrone,
respectively. The regression equations of the percentage of
the mean value (y) against time in minutes (x) for samples
taken prior to operation between 150 and 180 minutes were
y = 0.183x + 69.8 (r = 0.495 p<0.01) for oestradiol and y =
0.205x + 66.4 (r = 0.366 p<0.05) for oestrone. In 6 out of
the 10 patients, there was a rise in 3H-oestradiol between
150 and 180 min indicating that a completely steady state had
not been achieved. The mean MCR for the whole group was 1198
± 971 plasma/24 hr and was not significantly different from
those patients in whom the current cycle was anovulatory
(cases 1 to 4 = 1286 ± 105/24 hr), ovulatory (cases 5 to 7
= 1041 ± 197 1/24 hr) or Povulatory (cases 8 to 10 = 1238 ±
247 1/24 hr).
In 6 patients there was a small increase in plasma levels
of radioactivity after induction of anaesthesia. The mean values
± SEM (expressed as a percentage of the mean value between
150 and 180 min) collected at approximately 220, 235 and 250 min
were 112.5 ± 5.3, 110.1 ± 4.0 and 113.6 ± 8.5 for oestradiol
and 113.6 ± 4.5, 114.2 ± 6.2 and 121.6 ± 7.2 for oestrone.
The regressions of mean percentage value against time were
represented by the equations y = 0.037x + 103.5 (r = 0.307
p>0.05) for oestradiol and y = 0.248x +59.5 (r = 0.256 p>
0.1) for oestrone, respectively. Thus during the operation
the MCR of oestradiol fell to an average of 93% of that
prior to surgery, but a steady state appeared to have been
reached. This intra-operative MCR was not significantly
different from the pre-operative value (p>0.1).
The mean CbbE2Ei from 220 to 250 minutes (0.097 ±
0.010) was not different from that observed from 150 to 180
minutes (0.089 ± 0.005; p>0.2), and there was no difference
between the anovulatory and ovulatory groups.
Blood production rates of oestradiol (Pp^3)
pbea was calculated from the product of mcr and
peripheral plasma oestradiol concentration (Table 5). In
2 patients (no.3 and no.8) the blood production rate was
high (245 and 403 yg/24 hr, respectively) relative to the
values in normal subjects at a similar time after the onset
of the last menstrual period (5 and 7 days). The patient with
the highest PgE2 (no.2; 497 yg/24 hr) had classical cystic
glandular hyperplasia of the endometrium, while the patient
(no.l) with a PBE2 of 251 yg/24 hr showed mild hyperplastic
endometrial changes on day 16. The values obtained from
those patients who had ovulated in the current cycle (no's.
5, 6 and 7) were within the range found in normal subjects in
the luteal phase. These findings are graphically illustrated
in figure 1, which also includes pbE2 in women with normal
cycles. The amount of oestradiol derived from oestrone was
calculated assuming mcr^1 of 2210 £/24 hr and cbbE1E2 of















Figure 1. Oestradiol blood production rates throughout the
menstrual cycle in women with normal cycles (dotted line)
or dysfunctional uterine bleeding (vertical bars). Open
bars indicate portion derived from ovarian secretion;
black bars indicate portion derived from peripheral conversion.
Concentration of oestrone and oestradiol in ovarian venous
plasma
The plasma concentrations of oestradiol and oestrone
are shown in Table 5. In 5 cases (no's. 1, 2, 4, 8 and 10)
the oestradiol concentration from one ovary (the "active"
ovary) was 4.5 to 33 times greater than the other (the
"inactive" ovary). In these 5 cases the difference in plasma
concentrations of oestrone from the two ovaries was less marked
than the oestradiol difference. All 3 patients studied during
the luteal phase (no's 5, 6 and 7) had a corpus luteum on
each ovary and one patient during the late follicular phase
on day 10 (no.9) had a large follicle of preovulatory size
on each ovary. In these 4 cases significant plasma concent¬
rations of oestrone and oestradiol were present in venous
blood from both ovaries. In patient no.3, concentrations from
each ovary were similar, and the values were higher than one
would expect on day 5. The overall mean ratio of oestradiol/
oestrone in plasma from the more "active" ovary (9.67 ± 1.20)
was significantly greater than from the less active ovary
(6.32 ± 1.59; p<0.02). The overall mean ratio in ovarian
venous plasma (9.67 ± 1.20) was significantly higher than the
ratio in peripheral venous plasma (3.33 ± 0.87; p<0.005).
The calculated secretion rates of oestrone from the
"active" ovary in the 4 cases where more than 90% of the
circulating oestradiol was derived from one ovary were all
in the range 29.4 to 46.1 yg/24 hr. Meaningful oestrone
secretion rates could not be derived in the other 6 cases
since a large proportion of oestradiol was being secreted
by the less active ovary.
DISCUSSION:
The validity of the techniques used in this investigation
has been discussed at length (Chapter 2). In the study of
normal women the steady state for both precursor and product
had been obtained between 150 and 180 min, whereas most of
the women with dysfunctional uterine bleeding showed a
small rise in peripheral venous plasma concentration of
?5
3H-oestradiol and 3H-oestrone between 150 and 180 min. The
reason for this difference between the two groups is uncertain,
but it is possible that the 3H-oestradiol infusion was being
made into a larger or more complex endogenous oestrogen
"pool" in the women with dysfunctional bleeding. Although the
steady state had not been reached in the majority of these
women in the preoperative period, it was achieved in the intra¬
operative period and the mean intra-operative MCR was not
significantly different from the preoperative MCR. There was
no difference in the overall MCR and Cbb22^1 of the present
group with dysfunctional uterine bleeding and the group of
normal women studied using identical techniques. This suggests
that the metabolism of oestrogen in the women with dysfunctional
uterine bleeding is similar to that in normal women, although
the inability to reach an early steady state for the precursor
during infusion may indicate that there are some differences
in oestradiol distribution. In both groups a fall in MCR
occurred after induction of anaesthesia and an intra-operative
steady state for precursor was achieved.
The PgE2 in those patients in whom the current cycle was
anovulatory (no's. 1 to 4) was greater than 200 yg/24 hr,
even as early as day 5. Cystic glandular hyperplasia of the
endometrium was present in 2 of these patients, one of whom
(no.2) had the highest PgE2 recorded in this group and in the
group of normal women. In this patient the oestradiol was
demonstrated to be secreted from the right ovary in which
there were five cysts the fluid of which contained high
concentrations of oestradiol (44.1 to 166.0 yg/100 ml).
These were presumably functionally active. These findings
are summarized in Figure 2 and are in agreement with the
reports of elevated urinary excretion of oestrogens over
prolonged periods of time in some women with cystic glandular
hyperplasia of the endometrium (Brown et al 1959) and with
the observation that cystic glandular hyperplasia can be
produced by treatment with large doses of oestrogens
(Schroder 1954). The explanation for this early and persistently
high production of oestradiol is uncertain, but may be due
to a disturbance of the intra-ovarian follicular control
mechanisms (Vande Wiele et al 1970), resulting in large
active follicles which fail to become atretic prior to
the onset of uterine bleeding. It appears either that
the follicles are responding abnormally to pituitary
gonadotrophins or that the pattern of pituitary gonadotrophin
secretion is abnormal such as occurs in adolescent anovulatory
dysfunctional uterine bleeding (Chapter 6).
Day 16
Cystic glandular hyperplasia of endometrium
(E^ and E2 » pg/ml)
Left Right
Figure 2. Oestradiol and oestrone concentrations in differ¬
ent bodyfluids in a woman with endometrial cystic glandular
hyperplasia (Subject No 2).
The 3 women who ovulated showed bilateral ovulations, and
2 other patients (no.3 and no.9) appeared to have bilateral
functioning follicles. This is in contrast to normal women
where only one preovulatory follicle usually develops and in
whom over 95% of circulating oestradiol is secreted by one
ovary. This again suggests a disturbance of intra ovarian
follicle control.
The current investigation has confirmed the intermittent
nature of the disorder in dysfunctional uterine bleeding
(Brown et al 1959). Most of the patients had recent evidence
of both ovulatory and anovulatory cycles and it was impossible
to predict the status of the current cycle on the basis of
recent history (Table 1). Two out of the 3 patients who
ovulated had recent histological confirmation of cystic
glandular hyperplasia of the endometrium while in contrast
both patients who were found to have hyperplastic endometrium
at hysterectomy had not shown this previously at curettage of
the uterus.
The concentrations of oestrone in ovarian venous plasma
of all 10 women were within the same range as the normal group
of women. There appeared to be a slightly greater relative
production of oestradiol than oestrone by both ovaries compared
to normal women, the ratios of oestradiol/oestrone in venous
plasma from the more active ovaries being 9.67 ± 1.20 in the
dysfunctional bleeding group and 6.44 ± 0.97 in the normals;
the figures for the less active ovaries being 6.32 ± 1.59
and 3.37 ± 0.97, respectively. This may reflect the overall




OVARIAN BLOOD FLOW IN WOMEN WITH NORMAL MENSTRUAL
CYCLES OR WITH ANOVULATORY DYSFUNCTIONAL UTERINE
BLEEDING:
INTRODUCTION:
Virtually nothing is known about blood flow in the
human ovary but some information is available in animals
(Bruce and Moor 1975). Measurements of changes in total
ovarian flow mainly come from direct ovarian venous
cannulation at operation (Stormshak et al 1963; Mattner
and Thorburn 1969), from ovarian autotransplants (Baird
et al 1968; Goding et al 1967; Baird et al 1973) or
Doppler ultrasonic transducers (Brown et al 1980) while
capillary flow has been measured by the Sapirstein technique
(Setchell 1969) or more recently by the use of radioactively
labelled microspheres (Abdul-Karim and Bruce 1973; Brown et
al 1974; Mattner et al 1981). It appears that the ovary has
a relatively high rate of blood flow which is mainly due to
high flow around follicles and through the corpus luteum
(Bruce and Moor 1975).
This chapter describes the calculation of ovarian blood
flow in 10 women using data obtained from isotope dilution
techniques described in the previous 2 chapters.
Materials and methods
Ovarian blood flow can be calculated from knowledge
of the secretion rate of a substance uniquely produced by
that ovary and from the arteriovenous concentration difference
of that substance across the ovary (Baird 1970). Oestradiol
(E2) is a substance almost uniquely produced by the ovary
and during a major part of each normal menstrual cycle over
95% of the oestradiol is produced by the one ovary containing
the developing follicle or corpus luteum (hereafter referred
to as the "active" ovary). For practical purposes it can thus
be said that the secretion rate of oestradiol from the active
ovary is approximately equal to the total blood production
rate of oestradiol. A formula for calculating the blood flow









= OPF x (iEz - iE2)
ov a
= secretion rate of E2 from active ovary
= active ovarian plasma flow
= active ovarian venous plasma concentration of E2
= arterial plasma concentration of E2




blood production rate of E2
mcre2 = metabolic clearance rate of E2
Therefore, if sre2 = pe2
and iE2 = iE2, T-rV,Q>*Q n'E^ =
a v
plasma E2 concentration (Baird 1970)
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[this must be multiplied by to convert from
£/24 hr to ml/min]
(5) Ovarian blood flow = OPF (1-haematocrit)
This assumes good mixing of ovarian effluent at the
point of sampling, and no contamination with non-ovarian
blood. It also assumes insignificant transport of oestradiol
into the peripheral circulation via the ovarian lymphatics.
In this study all non-ovarian blood was excluded by clamping
and dividing the ovarian ligament and all tubal and pelvic
wall connections before sampling. Samples were collected
by direct needle puncture of the largest vein in the ovarian
plexus and slow withdrawal of the blood through a 21 gauge
needle into a 20 ml syringe. Preparation and assay of
samples has been described in chapter 2. The isotope dilution
technique and calculation of metabolic clearance rate have
also been thoroughly described in chapter 2.
SUBJECTS:
Six women who gave a history of regular menstrual
cycles (subjects no. 3, 4, 6, 8, 10 and 11 in chapter 2, NI¬
NO respectively) and 4 women with anovulatory dysfunctional
uterine bleeding (subjects no. 1, 2, 8 and 10 in chapter 3,
D3, D4, D1 and D2 respectively) were studied at the time of
hysterectomy. Clinical details have been described in
chapters 2 and 3, and relevant details of cycle day, estim¬
ated day of ovulation and haematocrit are summarised in table
1. Only those subjects in whom 95% or more of the secreted
oestradiol originated from the active ovary have been included
in the investigation described in this chapter. This is
illustrated by the ratio Ez (table 1). This ratioJ inactive E2
is calculated from: active E2 = plasma concentration of
oestradiol in vein draining the active ovary minus peripheral
venous plasma oestradiol concentration; inactive E2 = plasma
concentration of oestradiol in vein draining the inactive
ovary minus peripheral venous plasma oestradiol concentration.
RESULTS ::
Active ovarian blood flow and necessary data required
for the calculations are summarised in table 1. The ratio
of act:L^e E2^ indicates that 95% or over of secreted oestra-mactive E2
diol came from a single ovary in each instance.
Mean ovarian blood flow in 6 women with regular cycles
was 18.9 ± 5.2 ml/min, (mean±SEM) and in 4 women with anovula¬
tory dysfunctional uterine bleeding was 22.3 ± 4.0 ml/min.
The highest blood flow (36.4 and 33.1 ml/min) was recorded in
2 women in the luteal phase and the lowest flow (4.6 ml/min)
was recorded from the late luteal phase, presumably during
luteolysis. There was no obvious difference between ovarian
blood flow in the women with regular cycles and those with
anovulatory dysfunctional uterine bleeding, although numbers
in each group were small. Therefore, it seems reasonable to
calculate mean blood flow for the active ovary for the whole
group of 10 women at 20.2 ± 3.4 ml/min.
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DISCUSSION:
This study was the first investigation of ovarian blood
flow in women although limited data were available on ovarian
blood flow in animals (Bruce and Moor 1975).
It had been noticed that ovarian venous blood was often
a brighter red colour than peripheral venous blood (Fraser,
Baird and Cockburn 1973) suggesting a high rate of ovarian
blood flow or perhaps a reduced rate of tissue oxygen consump¬
tion. It seems unlikely that overall ovarian tissue oxygen
consumption is low since the corpus luteum at least is a
highly metabolically active tissue and individual ovarian
cells have a high metabolic rate invitro(Ahren and Hamberger 1969).
Ovarian oxygen consumption has been calculated at 0.014 ml/
g/min in women (Fraser, Baird and Cockburn 1973) and 0.03-
0.05 ml/g/min in sheep (Baird et al 1973).
Ovarian weight varies considerably with degree of
development of follicles and corpus luteum and with age of the
woman (Wehefritz 1923). In the age group 20-50 years the
weight of each ovary in a non-pregnant woman is generally
between 7 and 11 g with a mean of 8.8 g. With a blood flow
of approximately 20 ml per ovary per min this gives a tissue
blood flow of approximately 2.3 ml/g/min. This can be
compared with thyroid and adrenal blood flow of about 5 ml/
g/min, heart and brain blood flow of 0.5 ml/g/min or kidney
blood flow of 7.5 ml/g/min (Handbook of Biological Data 1956).
The ovary is a complex organ and purely on morphological
and functional grounds it could be expected that blood flow
to metabolically active areas like the corpus luteum or theca
interna would be much higher than to the stroma, as demonstrated
in animals (Bruce and Moor 1975). On the other hand, follicular
(or cyst) fluid and granulosa cells are components of the ovary
with zero blood flow. For example; the three large ovarian
follicles in subject D4 will have contributed substantially
to the non-perfused portion of that ovary which overall had
a blood flow of 18.4 ml/min.
The technique described in this chapter for measuring
85
human ovarian blood flow should be reasonably accurate
allowing for the above limitations and the assumption that
oestradiol is continuously secreted. It is now known that
oestradiol may be secreted in an episodic fashion (Alford et
al 1973) but this is unlikely to introduce a major source of
error.
Ovarian blood flow has been extensively studied in
sheep. Much of the early work was carried out by direct
cannulation of the main ovarian vein at operation (Stormshak
et al 1963; Mattner and Thorburn 196.9). These studies give
a value of up to 8 ml per ovary (with corpus luteum) per min
in the anaesthetised animal which is much lower than the
value of 14 ml/min in non-anaesthetised ewes in whom the
ovary has been transplanted to a skin loop in the neck
(Baird et al 1968; Goding et al 1972; Baird et al 1973). This
difference may be partly related to compensatory hypertophy
in the transplanted ovary (Sundaram and Stob 1967). The
tissue blood flow calculated from above studies of 3-4 ml/g/
min (up to 10 ml/g/min for luteal tissue (Abdul-Karim and
Bruce 1973) was several times higher than capillary flows
measured using indicator techniques for the sheep ovary
(0.2-0.3 ml/g/min; Setchell 1969) or the sow ovary (0.53 ml/
g/min; Rattmacher and Anderson 1968). Although, it now
appears that soluble indicator techniques may give a falsely
low measure of corpus luteum flow (Brown et al 1974), the
difference in total organ blood flow and capillary flow in non-
luteal ovaries (Brown et al 1974) and the relatively high P02
and oxygen content of ovarian venous blood in women (Fraser,
Baird and Cockburn 1973) and sheep (Baird et al 1973) suggest
that a significant proportion of ovarian arterial blood by¬
passes the capillary bed. Arterio-venous shunts which have
been described within the substance of the human ovary (Clara
1956) could explain this. Some recent studies in sheep
support this concept (Mattner et al 1981), although experiments
in rabbits do not (Ahren et al 1974).
Chapter 5
OESTROGENS IN OVARIAN VENOUS BLOOD AND FOLLICULAR
WITH NORMAL MENSTRUAL CYCLES OR DYSFUNCTIONAL
UTERINE BLEEDING:
INTRODUCTION:
It has long been known that oestrone and oestradiol are
present in high concentration in fluid collected from human
Grafian follicles in both the follicular and luteal phase of
the cycle (Smith 1960? Short and London 1961). Both oestro-
gens are secreted into the ovarian veins draining the ovary
containing the preovulatory follicle or the corpus luteum
(Schild 1966; Mikhail 1970; Lloyd et al 1971; Chapters 2 and
3). It is generally assumed that a follicle containing high
concentrations of oestradiol also secretes oestradiol into
ovarian venous blood. However, some studies have suggested
that not all such follicles are functionally active (Gorgi
1965; Edwards et al 1972).
Many women with perimenopausal dysfunctional uterine
bleeding, especially those who are anovulatory, are found
to have several large follicles (or "cysts") on one or both
ovaries (Schroder 1954; Chapter 3). This suggests that there
may be abnormalities of pituitary gonadotrophin secretion or
disturbances of intraovarian control mechanisms, or perhaps
both, in these patients (Chapter 3). However, it is not known
whether these multiple follicles are functionally active.
At the time this study was completed there was very sparse
information on the steroid content of follicular fluid and
virtually none on the relationship between follicular fluid,
and ovarian and peripheral venous plasma concentrations of
oestrone and oestradiol. This study was designed to assess:
1. details of the changes in oestrone and oestradiol
fluid from follicles of different size through the menstrual
cycle in women with normal cycles.
2. the relationship between follicular fluid, ovarian
venous and peripheral venous concentrations of oestrone and
oestradiol in women with normal cycles.
3. variations in follicular fluid, ovarian venous
and peripheral venous concentrations of oestrone and
oestradiol in women with dysfunctional uterine bleeding.
This study was designed, executed and analysed jointly




Samples of follicular fluid and ovarian and peripheral
venous blood were obtained at laparotomy from thirty-four
patients undergoing hysterectomy for various gynaecological
conditions. The indications for surgery were either Stage 0
carcinoma of the cervix (fifteen) or menorrhagia due to
fibroids or dysfunctional uterine bleeding (nineteen). The
former group had regular menstrual cycles and were considered
to be endocrinologically normal (Eleven were studied in
Chapter 2). Of the group with menorrhagia, eleven ovulated
in the cycle under study as indicated by the presence of a
secretory endometrium and of at least one corpus luteum at
the time of surgery. The remaining eight were considered to
be in the mid-late or persistent proliferative phase of the
cycle. Ten of the menorrhagia group were studied in Chapter
3.
The endometrium was examined histologically and dated
according to the criteria of Noyes et al (1950). The ovaries
were then examined macroscopically at the time of surgery
and the presence of corpora lutea and follicles visible on
the surface noted: follicle size was calculated by an
approximate measurement of diameter across the exposed
surface. This information, together with the number of
days since the onset of the last menstrual period, was used
to place the subjects into one of five groups: (a) early
follicular, (b) mid to late follicular, (c) ovulatory,
(d) early luteal, and (e) mid to late luteal.
Collection of samples
Samples of peripheral (50 ml) and ovarian venous
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blood (9-20 ml) were collected within 10 min. of one an¬
other into heparinized containers. Ovarian, venous blood
was sampled by needle puncture of the ovarian vein 2-3 cm
from the ovary after clamping the ovarian and pelvic wall
branches of the uterine vein (Chapter 2). Follicular fluid
was aspirated through a 23G needle into a syringe after the
collection of blood samples had been completed. Plasma
and follicular fluid were stored at - 15° until assay.
Measurement of oestrogens
Oestrone and oestradiol were measured by a double
isotope derivative method (Baird 1968). Details of precis¬
ion and blanks for human plasma and follicular fluid have
been discussed in Chapter 2.
RESULTS:
The concentrations of oestrone and oestradiol in the
thirty-four patients are illustrated in Tables 1 and 2.
In each group there was no difference between the values
obtained for those subjects with Stage 0 carcinoma of the
cervix (0) and those with menorrhagia (M). The results from
all patients have therefore been pooled and the mean values
illustrated in Figs. 1 and 2.
The concentration of oestradiol was similar in venous
plasma draining both the right and left ovaries in the early
follicular phase of the cycle (1.2 ± 0.34 vs. 0.96 ± 0.42
ng/ml ± SEM). In the mid-late follicular phase the concent¬
ration of oestradiol was much higher in venous plasma drain¬
ing the ovary containing at least one large follicle (>1 cm)
than in that draining ovaries containing only small follicles
(13.8 ± 3.1 vs. 0.65 ± 0.14 ng/ml). In subject 8, in whom
the concentrations of oestrogens were similar, both ovaries
contained a large follicle. In both the early and mid-late
luteal phase the concentration of oestrogens was much higher
in venous plasma draining the ovary containing a corpus
luteum (4.5 ± 0.85 and 7.9 ± 2.1 ng/ml). The concentration
of both oestrone and oestradiol in venous plasma draining
the ovary without a large pre-ovulatory follicle or corpus
CONCENTRATION OF OESTRONE AND OESTRAOIOL










































































I OESTRADtOL I lOESTRONE
vO
5"
Figure 1. Concentration of oestradiol (solid columns) and
oestrone (open columns) in ovarian and peripheral venous
plasma throughout the menstrual cycle. The height of each
bar represents the mean +SEM of the number of observations
indicated within the parentheses. (RO = right ovarian;
LO = left ovarian; LFO = draining ovary with large follicle
Ol cm diameter!; SFO = draining ovary with small follicles
(<J. cm diameter).; CLO = draining ovary with corpus luteum;
no CLO = draining ovary with no corpus luteum.)
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Figure 2. Concentration of oestradiol (solid columns) and
oestrone (open columns) in follicular fluid of women at
different stages of the menstrual cycle. The height of each
bar represents the mean +SEM of the number of observations
indicated within the parentheses. L = follicles >1 cm
diameter; S = follicles <1 cm diameter. The values for two
small follicles from subject 18 have been omitted from the
overall mean for that group and are indicated individually.
TABLE1.

















































































































































































































































































































































































































































luteum was similar at all stages of the cycle.
The concentration of oestradiol in follicular fluid
was approximately 100 times greater than in ovarian venous
plasma while that of oestrone was about 50-fold greater
(note difference in scale in Figs. 1 and 2). The concent¬
ration of oestradiol from both large and small follicles
was similar (20-300 ng/ml) at all stages except during the
mid-late proliferative phase of the cycle. In eleven of
the fourteen large follicles sampled in this latter group,
the concentration of oestradiol exceeded 400 ng/ml with a
mean value of 1520 ± 375 ng/ml.
The concentration of oestradiol in follicular fluid,
ovarian venous blood (from 'active' and 'inactive' separ¬
ately) and peripheral venous blood from the same women in
mid-late follicular phase is graphically illustrated in
Figure 3. Oestradiol to oestrone ratios in the same fluids
are illustrated in Figure 4.
DISCUSSION:
This study has confirmed that the largest follicle
of diameter 1 cm or greater in the mid to late follicular,
and the corpus luteum in the luteal phase of the cycle, are
the major source of ovarian oestradiol. The concentration
of oestradiol in venous plasma draining the ovary contain¬
ing these structures was 20-fold greater than that draining
the contralateral ovary. The concentration of oestrone was
also higher in plasma from the 'active' ovary but the
difference was not as marked as that of oestradiol (Fig. 1).
The very high concentration of oestradiol in follicular
fluid (up to 3750 ng/ml) is within the same range as found
by other workers in normal (Smith 1960; Sanyal et al 1974)
and gonadotrophin stimulated ovaries (Edwards et al 1972)
and must be near the limit of its solubility. A specific
binding protein of high affinity for oestradiol in follicular
fluid would help to concentrate oestradiol (Takikawa 1966;
Giorgi et al 1969). Detailed work by several groups of


















Figure 3. Comparison of oestradiol concentrations (log
scale) in peripheral and ovarian venous blood and follicular
fluid. Samples of each fluid were collected at approximately








p<0.0 2 p<0.01 p<0.001
peripheral inactive active active
venous ovary ovary ovary
venous venous follicular
fluid
Figure 4. Comparison of the ratios of the concentration of
oestradiol to oestrone in peripheral and ovarian venous
blood and follicular fluid. Samples of each fluid were
collected at approximately the same time from each woman.
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and extended these findings described in this study
(McNatty et al 1975; McNatty et al 1976; Channing and
Louvert 1976; McNatty and Baird 1978; McNatty et al 1979;
Hodgen 1982). The function of the high concentration of
oestradiol within the follicle was unknown at the time of
this study but was thought to act locally by increasing the
rate of granulosa cell mitosis (Payne and Hellbaum 1955)
and by increasing the sensitivity of the granulosa cells
of the developing follicle to gonadotrophins (Goldenberg
et al 1972). It is now known that oestradiol also has an
important role in stimulating the synthesis of FSH receptors
in granulosa cells (Louvert and Vaitukaitis 1976).
In the mid-late follicular phase large follicles were
invariably associated with high concentrations of oestrogens
in the corresponding ovarian venous plasma, indicating that
they were functionally active. In six of the ten subjects
in this group the concentration of oestradiol in at least
one of the follicles exceeded 1250 ng/ml. In contrast large
follicles at other stages of the cycle were never associated
with high concentrations of oestradiol and were presumably
atretic. Unfortunately histology was not carried out to
assess the viability of follicles or oocytes. These findings
suggest that when the concentration of oestradiol in a
follicle is greater than 1250 ng/ml it is likely to be
functionally highly active, (i.e. contributing significantly
to circulating oestradiol) and in the preovulatory phase.
The only other follicles in which the concentration of oestra¬
diol exceeded 1250 ng/ml were found shortly after ovulation
in subject 18 in whom the concentration of oestradiol in
both ovarian veins was relatively high. It seems that any
follicle containing a concentration of oestradiol greater
than 1250 ng/ml is likely to be contributing to the peripheral
circulating levels.
The concentration of oestradiol exceeded that of oestrone
in follicular fluid, ovarian and peripheral venous plasma at
all stages of the cycle (figure 4). The higher ratio of
oestradiol/oestrone in ovarian venous plasma from the 'active'
ovary (9.73 ± 0.79, n = 29) relative to peripheral plasma
(2.43 + 0.27 n = 31) reflects the extra-ovarian production
of oestrone (Baird 1971). The ratio of oestradiol/oestrone
in follicular fluid of large follicles in the mid-late phase
of the cycle in which the concentration of oestradiol
exceeded 400 ng/ml (18.0 ± 1.0 n = 10) was significantly
higher (P<0.001) than the ratio in corresponding samples
of ovarian venous plasma (10.7 ± 1.4 n = 11). This supports
the presence of a specific binding protein in follicular
fluid with a relatively higher affinity for oestradiol than
oestrone (Giorgi et al 1969). Although the concentration
of oestrone in large follicles in the mid-late follicular
phase rose significantly as compared to the concentration
in follicles at other stages of the cycle, the mean
maximum value (90 ± 20 ng/ml n = 14) was lower than that
reported by Sanyal et al (1974) using radioimmunoassay
(mean value of large follicle 200 ng/ml). The reason for
these differences is not apparent although the range in
both studies was considerable.
Although the numbers in this study are small there
does not appear to be any major difference between oestra¬
diol and oestrone concentrations in follicular fluid and
ovarian venous blood in women with normal menstrual cycles
or dysfunctional uterine bleeding. However, it seems likely
that the intra-ovarian control mechanisms can be disturbed
in some women with anovulatory dysfunctional bleeding. For
example, Subject no.14 had 4 large follicles in one ovary.
All of these were functionally active and contained greater
than 430 ng/ml of oestradiol. The inter-relationships of
oestrone and oestradiol in different fluids in this patient
have been pictorially illustrated in Chapter 3. Three or
four of the women with menorrhagia (Numbers 12-15) presum¬
ably had a persistent follicular phase with anovulation
(days 15-18 of the cycle) and two of these had cystic
glandular hyperplasia of the endometrium (Subjects no's.
12 and 14). These women had presumably embarked on the
prolonged follicular oestradiol secretion seen in adoles¬
cents with anovulatory dysfunctional bleeding (Chapter 8)
and all had moderate to high peripheral plasma levels.
Although very high ovarian venous and peripheral levels
were seen in the subject with multiple active follicles
the correlation between follicular fluid, ovarian venous
and peripheral venous levels was not close in the other
3 subjects. However, it can be seen that when high concent¬
rations of oestradiol are present in follicular fluid there
are almost always high concentrations of oestradiol in
ipsilateral ovarian venous blood.
SECTION 3
DYSFUNCTIONAL UTERINE BLEEDING IN ADOLESCENTS
%
DYSFUNCTIONAL UTERINE BLEEDING IN ADOLESCENTS:
Most adolescents with DUB are anovulatory and in the
majority of these the episodes of excessive bleeding are
isolated. Girls with persistent DUB are uncommon and those
in whom cystic glandular hyperplasia of the endometrium
(CGH) is found are rare. In our study which covered the
whole population (1,100,000) of the South-Eastern Region
of Scotland only 5.3 new cases were diagnosed per year
over a 10 year period. This represented 4.0 percent of
all cases of abnormal uterine bleeding in girls under 21
years in the Region requiring curettage, and 1.9% of cases
of CGH in all age groups. Mild hyperplastic changes were
found almost as frequently as the more classical "Swiss-
cheese" CGH. All 17 of the cases diagnosed at the Royal
Infirmary of Edinburgh between 1955 and 1964 were followed
up in 1971. Patients showing more marked hyperplastic
changes had a worse prognosis than those who only showed
mild changes, and this condition appears to be the severe
end of the spectrum of anovulatory DUB. These girls
exhibited a high incidence of persistent menstrual abnorm¬
alities, repeated curettage, repeated requirement for hormone
therapy, primary infertility, gynaecological laparotomies
and possible polycystic ovarian disease.
Pituitary and ovarian relationships were assessed
over a 3 month period in 4 adolescents with a history of
confirmed CGH using daily measurements of oestrogen and
pregnanediol excretion in urine and FSH and LH concentration
in plasma. Three of the 4 patients showed 2 successive
spontaneous anovulatory cycles with marked increases in
oestrogen excretion but with a failure of the normal mid-
cycle surge of LH. Clomiphene initiated a rise in plasma
FSH and LH with subsequent follicular development suggesting
that the negative feedback relationship between oestrogens
and gonadotrophins was intact. The concentrations of
oestradiol and oestrone in peripheral venous plasma were
within normal limits for women in the reproductive age
group.
These results suggested that the absence of ovulation
in these adolescent women was associated with a failure
to discharge LH in response to increasing levels of
oestrogen - a failure of positive feedback - and this was
tested in more detail in a further 9 young women with
persistent anovulatory DUB. Ovarian activity was studied
by twice weekly urinary excretion of oestrogen and preg-
nanediol over a 3-4 month period, and results were comp¬
ared with 6 regularly menstruating women. All control
women had ovulatory cycles, but 7 of the 9 with DUB failed
to ovulate during at least 3 consecutive cycles. The
profiles of urinary oestrogen excretion in these 7 women
were consistent with regular follicle development, but
the follicular phase was prolonged and the amount of oestrogen
excretion increased greatly compared with controls. In 4 of
these 7 patients the endometrium had previously shown CGH.
After injection of 50 yg of gonadotrophin - releasing
hormone, the release of LH and FSH was normal in all subjects.
However, the surge of LH induced in response to exogenous
oestrogen (ethinyl oestradiol 200 yg per day for 3 days) was
significantly lower in patients than controls (16.2 ± 3.7 mu/
ml compared with 35.0 ± 5.5 mu/ml; p<0.005). It is concluded
that the failure to ovulation in young women with anovulatory
DUB is due to inadequate release of LH in response to oestrogen,
supporting the hypothesis that the basic defect is a decrease
of hypothalamic sensitivity to positive feedback.
Chapter 6
LONG TERM FOLLOW-UP OF ADOLESCENT GIRLS PRESENTING
WITH ENDOMETRIAL CYSTIC GLANDULAR HYPERPLASIA;
INTRODUCTION;
Menstrual disorders in adolescence are common and the
great majority of these comprise irregularities of menstru¬
ation associated with anovulation or irregular ovulation.
Oligomenorrhoea with scanty menstrual loss is a very common
problem during the first few years after the menarche, but
is not usually associated with any serious health hazard.
It is much less usual to see adolescent girls who experience
persistent, heavy dysfunctional uterine bleeding, and there
is no information on the true incidence in any population.
The majority of these are also associated with anovulation
and may sometimes present a difficult management problem.
A proportion of adolescents with menorrhagia and anovul¬
ation have high circulating levels of endogenous oestrogens
which cause excessive proliferation of the endometrium
resulting in the histological appearance of cystic glandular
hyperplasia (Schroder 1954). This condition of irregular
heavy menstrual bleeding associated with cystic glandular
hyperplasia of the endometrium in an adolescent girl is at
the severe end of the spectrum of anovulation and is sometimes
known as juvenile metropathia haemorrhagica.
There is suggestive evidence that the small group of
girls with this type of serious menstrual disorder have a
high risk of continued gynaecological abnormalities over
many years (Southam 1960; Southam and Richart 1966), but
adolescents with proven cystic glandular hyperplasia have
not been followed specifically.
Jeffcoate (1937) at one stage indicated that all or
almost all cases of adolescent dysfunctional uterine bleeding
were associated with endometrial hyperplasia, while Southam
(1960) found hyperplasia in almost 50% but other studies have
found it much less frequently (Sutherland 1953). It is often
taught that endometrial hyperplasia shows peak incidence at
both ends of the reproductive life span in the perimeno-
pausal and immediate postmenarchal age groups (Cope 1971),
but the evidence for a peak in adolescence is inconclusive
(Sutherland 1949; Schroder 1954).
This study was designed to record clinical details of
all new cases of endometrial cystic glandular hyperplasia in
adolescent girls presenting over a ten-year period at the
gynaecological clinics of the Royal Infirmary of Edinburgh.
In this study we have limited the term "adolescent" to
include girls aged 20 or under. These cases were then
followed-up over a period of 8 to 18 years. The incidence of
adolescent CGH was compared with cases of cystic glandular
hyperplasia of the endometrium in all age groups presenting
in the whole South-Eastern Region of Scotland over the same
period. Adolescent hyperplasia was also compared with other
types of endometrial pathology in all cases of abnormal uterine
bleeding in adolescents which required curettage during the
same time period.
This study was jointly designed and analysed by
Dr. D. Baird and myself, and executed predominantly by myself.
Clinical material and methods
Full details were obtained from the gynaecological path¬
ology records for the South-Eastern Region of Scotland for
the years 1955 to 1964 for all patients aged 20 years or less
with endometrial curettings showing cystic glandular hyper¬
plasia. Details of the histology of endometrial curettings
were also obtained for all girls aged 20 years or less who
had undergone curettage for abnormal bleeding but in whom
cystic glandular hyperplasia was not found. Details of
patients in other age groups with a diagnosis of endometrial
cystic glandular hyperplasia were also recorded. The
indication for curettage, the year of curettage and the age
of the patient were recorded. The fullest possible details,
including clinical case records, were obtained for the 17
adolescent patients with cystic glandular hyperplasia who
had attended the Gynaecological Outpatient Department of
loo
the Royal Infirmary of Edinburgh between 1955 to 1964.
These patients were contacted by letter in 1971. Twelve
were later interviewed personally and up to date clinical
details were obtained from the other 5 by telephone, letter
and questionaire. A full gynaecological, obstetrical and
medical history was obtained, with particular emphasis on
the years since the initial curettage.
The histological sections from all curettings from the
17 patients were critically reassessed and graded according
to the degree of hyperplasia present. As a consequence of
the small numbers the cases were only divided into two
groups according to whether "mild"/"early" or "classical"/
"moderate" (hereafter referred to as "marked") changes of
cystic glandular hyperplasia were present. The degree of
hyperplasia was assessed mainly on the number and diameter
of the dilated glands, but stromal hyperplasia was also
taken into account.
RESULTS:
Table I details the number of cases of adolescent cystic
glandular hyperplasia diagnosed in the South-Eastern Region
of Scotland as a whole and at the Royal Infirmary of Edinburgh
in each of the years 1955 to 1964. Thirty-two percent of
the cases were seen at the Royal Infirmary. The incidence
by age of adolescent cystic glandular hyperplasia in the
South-Eastern Region of Scotland in the years 1955-1964 is
illustrated in table 2. The peak incidence was seen at age
17, but the youngest patient in whom the diagnosis was made
was aged 9 years and 4 months.
TABLE 1;
Number of cases of adolescent cystic glandular hyperplasia
occurring in the South-Eastern Region of Scotland in the
years 1955 - 1964.
YEAR 1955 '56 '57 '58 '59 '60 '61 '62 '63 '64 TOTAL
Total number 6 883441838 53
of cases




Incidence of adolescent cystic glandular hyperplasia by age group
in the South-Eastern Region of Scotland in the years 1955-1964.
Age(years) 9 10 11 12 13 14 15 16 17 18 19 20 Total
Number of
years
1 0 0 2 3 3 2 9 12 6 8 7 53
The endometrial histology in all girls aged 20 or under who
underwent curettage for disorders of menstruation and from whom
curettings were obtained in the South-Eastern Region of Scotland
during the year 1955 is detailed in table 3.
TABLE 3;
Histology of endometrial curettings from 151 girls aged 20 or
under who underwent curettage for disorders of menstruation in
the South-Eastern Region of Scotland during 1955.
Atrophic Proliferative Secretory Menstrual Adenomatous hyperplasia Cystic glandular hyperplasia Retained productsof conception Endometrial polypi Chronic endometritis Tuberculous endometritis
Age Total
14 2 1 1
1
15 0 |
16 9 4 2 1 1 1
17 17 8 5 1 1 2
18 20 11 8 1
19 54 1 19 24 2 1 6 1
20 49 16 17 4 1 2 6 1 1 1
Total 151 1 59 57 7 1 6 I 14 2 2 2
10.
Only 6 patients out of 151 (4%) were found to have cystic
glandular hyperplasia, and one additional patient had
typical adenomatous hyperplasia. Normal proliferative
changes were noted in 39%, while secretory changes were
found in 37%. Other histological diagnoses were noted in
19%.
The population incidence of cystic glandular hyper¬
plasia in the South-Eastern Region of Scotland in 1955 and
1964 by five-year age groups is shown in figure 1:
The peak incidence was seen in the 41 to 50 year age
group and only a very small proportion of cases (1.9%) were
seen in the 20 year and under group.
Table 4 summarises clinical findings in the 17 patients
with adolescent cystic glandular hyperplasia who were diag¬
nosed at the Royal Infirmary of Edinburgh during the years
1955 to 1964, and followed up in 1971. The mean age at
menarche was 13.2 years and the mean age at the time of
first curettage was 17.8 years. Of the ten girls who had
an established normal menstrual pattern prior to the onset
of symptoms leading to curettage only three have had
persistently abnormal cycles since. By contrast, six out
of the remaining seven girls have had abnormal cycles at all
times. Several girls were given repeated hormone therapy
with oestrogens, progestogens, androgens or a combination
TABLE4;

















































































































































































































































































































































































over a period of at least 3 years. It was surprising
to find that seven of the girls had been treated with a
course of 'oestrogen' alone on at least one occasion,
usually without significant benefit. Only six had been
specifically treated with progestogens alone or in combin¬
ation although six others had tried the combined pill for
contraception. One girl (no.4) had received a course of
androstalone, a weak androgen.
In addition to the five patients with at least three
years of involuntary primary infertility one further patient
has had at least two years of secondary infertility. Thus
43% of the girls exposed to the risk of pregnancy have shown
significant infertility. Only one patient (no.10) had had
a normal full term pregnancy before curettage.
The clinical and histological findings at curettage
are shown in table 5. At the initial curettage the utero-
cervical canal length was greater in the group of patients
with "marked" cystic glandular hyperplasia (mean 8.3 cms)
than in those showing "mild" changes (mean 7.2 cms). The
appearance of the curettings at the time of curettage was
recorded as profuse in all patients who were found to have
marked cystic glandular hyperplasia, while in all those
showing mild changes the curettings were described as
moderate or scanty. One or both ovaries were found to be
palpably enlarged at the time of curettage in four patients.
Two of these have since required laparotomies: one (no.7)
for removal of a benign ovarian dermoid cyst and the other
(no.10) for bilateral ovarian wedge resection of typical
polycystic ovaries. Of the ten patients who required
repeat curettage, six showed marked cystic glandular
hyperplasia initially, and only three never showed more
than mild changes. Patient no.l showed markedly hyperplastic
endometrium in all seven curettages.
In five patients the haemoglobin concentration at first
curettage was less than 11.0 g percent, which suggests a
significant amount of haemorrhage. Three patients required
TABLE5:
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Profuse Scanty Mod. Profuse Scanty Profuse Mod. Profuse Mod. Profuse Profuse Profuse Profuse Mod. Profuse Scanty Scanty
Yes Yes Yes Yes
CGH++ CGH CGH CGH++ CGH CGH++ CGH CGH++ CGH CGH++ CGH++ CGH++ CGH++ CGH CGH++ CGH CGH





14.1 11.4 13.3 11.3 12.0 10.6 7.4 12.9 12, 8, 11, 7, 9. 13,
CGH++=Markedcysticglandularhyperplasia CGH=Mildcysticglan ularhyperplasia Prol.=proliferative Sec.=ecretory
N.B:Caseo1h d7curettages CaseNo10h d5curettages
lot,
transfusion with two or more bottles of blood.
Table 6 summarises the difference in the clinical
findings and prognosis between the group of girls who showed
cystic glandular hyperplasia on at least one occasion and the
group who never showed more than mild changes. There was
a higher incidence of repeat curettage, primary infertility
and menstrual abnormalities from the menarche until at least
3 years after curettage, and a smaller number of pregnancies,
in the group showing marked hyperplasia. However, the other
group showed a higher incidence of gynaecological abnormalities
than expected in a normal population.
TABLE 6:
Comparison of clinical findings and prognosis in adolescent
girls showing marked or mild changes of cystic glandular hyper-
plasia of the endometrium.
P S 44
44 4-1 i—i O p <d
0 "H td 1 44 • O tn
tn i—1 G G tn G G -—. CD en G
G CO -H P CD tn p A •P CD • G ai •H
•P 4-1 44 CD 4-> 4-1 a CD td td A tn i—! O •p O
p o 0 (0 P tn rP CD O td a a p tn p
•H . td cd G CD O >1 5P r4 44 p id P O
G p • P tn O 44 CD O >1 rH q> 44 o O > CD >i
tn ■ CD tn CD <D G a c O CN 4-> • O (D o JG O ts >1 CX
<d <D CD A •H 44 -H •H G tn a p r-4 c a O
p tn a tn a o 0 i—t en r4 -P CD CD CD G T5 ts G O
44
CD
<d G rd G G Jp id td tn 44 1 td O P CD >i CD en
p -P G +J G td P P a tn . a <c tn o A CD 44 CU tn P O O
CD ■P -P c CD td p CD CD P CD •P >4 44 cr td id P a) p P
43 <d G CD G tn a a 0 r-4 A O rH tn o G tn CD P td 43 Id id
a p (0 P td <d a -p c o O G P td P . CU CD rH S CU &
g 0 CD G 0) p G P A >1 P A 4J CD rH (D -P tn CD A G G td id
2 o £ O 2 a z a <1 V G <d td a. td 2 44 •—• CG 44 W 2 -p rH
Group showinq marked hyperplasias





(10) (10) (10) (10) (10
3 1.4 2.8 1 2 3 3 11.1 3 2 1
(7) (6) (7) (7) (7) (7) (7) (7)
(total numbers in each group are shown in brackets) .
Only one patient (no.10) was confirmed to have poly¬
cystic ovaries, but four others (no's 1, 9, 11 and 13) had
several clinical features suggestive of the polycystic ovary
syndrome or one of its variants. All five were overweight
with persistently abnormal menstrual cycles and marked
endometrial hyperplasia; four showed mild hirsutism; four
have had repeated curettages: three out of four showed
I°?
significant primary infertility and two had palpably
enlarged ovaries. Patient no.l had normal sized, white,
apparently "sclerocystic" ovaries seen at laparoscopy.
Unfortunately, none of the modern endocrine investigations
were available at the time to investigate this diagnosis
more accurately.
Three patients had urinary total oestrogen measurements
carried out (in the laboratory of Dr. J. B. Brown and
R. J. Kellar) immediately following the curettage at which
cystic glandular hyperplasia was originally diagnosed, and
the results are illustrated in fig. 2. In no case was
total oestrogen excretion elevated above 20 yg/24 hours
during the few days after the curettage, in spite of the
histological diagnosis of cystic glandular hyperplasia.
One patient (no.6) was studied with urinary oestrogen
estimations on three separate occasions over a period of
5 years. On two occasions she was clearly anovulatory
while on the third occasion normal ovulation had occurred
without assistance from ovulation - inducing drugs. This
case illustrates the variable nature of the endocrine
defect which occurs in many of these patients.
DISCUSSION:
Cystic glandular hyperplasia of the endometrium is a
histological diagnosis which was first studied extensively
by Schroder (1954), but many other groups of workers
have also contributed to knowledge of the pathology, histo-
pathology and variability of this condition. • In most cases
it is probably due to the prolonged or excessive and unopposed
action of endogenous or exogenous oestrogens on the endomet¬
rium (Paschkiss and Rakoff 1950; Schroder 1954; Brown et al
1959).
Brown and colleagues (1959) carried out a very extensive
and thorough study of the changes in urinary oestrogen
excretion associated with different types of endometrial
pathology, including cystic glandular hyperplasia. They found
that cystic glandular hyperplasia occurred when urinary
let
total oestrogen excretion was constantly elevated above 30 ug/24
hours for several weeks or when oestrogen excretion rose to much
higher levels (eg. 80-100 yg/24 hours) for shorter periods of
time. These studies were mainly conducted on women with peri-
menopausal bleeding abnormalities. The limited oestrogen measur-
ments conducted by Dr. J. B. Brown and his colleagues on the three
girls reported in this study (fig.2) contrast markedly with their
findings in perimenopausal women. In all three adolescents with
cystic glandular hyperplasia the oestrogen excretion was low after
curettage, in spite of prolonged bleeding before curettage. Brown
et al (1959) carefully emphasised the dangers of trying to analyse
urinary oestrogen data collected over short periods of time.
However, the adolescent data did suggest that in their cases
cystic glandular hyperplasia was probably associated with fluct¬
uating rather than constant oestrogen levels but that much more
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Figure 2. Urinary oestrogen excretion in 3 adolescent patients
following D and C at which endometrial cystic glandular hyper¬
plasia was diagnosed. Horizontal bars indicate bleeding.
It is well recognized that menstrual irregularities are
common in adolescent girls (Arey, 1939; Dewhurst et al 1971) and
are associated with a high incidence of anovulatory cycles.
Excessively heavy menstrual bleeding is much less common in
adolescence than irregularities, and may occur from any
type of endometrium (Southam 1959).
Dysfunctional uterine bleeding and cystic glandular
hyperplasia are much less common in adolescence than near
the menopause. Sutherland (1953) found that only 3.9% out
of a group of 1000 successive patients with abnormal uterine
bleeding requiring curettage were aged 20 or under, and out
of 265 cases of cystic glandular hyperplasia only 6(2.3%)
were in this age group. In this study only 6 out of 322
cases (1.9%) of cystic glandular hyperplasia seen in 1955
were aged 20 or under. These two reports agree closely
with the incidence of 2.7% calculated from the extensive
data of Schroder (1954) for German women over a 40 year
period. The age distribution of cystic glandular hyperplasia
shown in the present study (fig.l) is also in agreement with
the data of Schroder (1954), except that he showed a small
peak in late adolescence. However, by combining fig.l and
table 2 it does appear that there may be a small peak
incidence around the age of 17, but it would require very
many cases to confirm this.
Out of 151 cases of abnormal uterine bleeding in
adolescents in the South-Eastern Region of Scotland in 1955
only six (four per cent) showed cystic glandular hyperplasia.
This finding is in direct contrast to the reports of many
previous authors who found endometrial hyperplasia in almost
all adolescent girls with dysfunctional uterine bleeding
(Jeffcoate, 1937). However, Sutherland (1949) found an
incidence of cystic glandular hyperplasia of only 15.5 per
cent in 200 girls with dysfunctional bleeding. Part of this
difference in incidence may be explained by the variation in
definitions of "dysfunctional" or "functional" uterine
bleeding, by the histological interpretation of the curettings
and by the reluctance or otherwise of the gynaecologist to
carry out a curettage in an adolescent girl.
During the ten-year period 1955-64 only 53 cases of
adolescent cystic glandular hyperplasia were diagnosed
at the gynaecological pathology laboratory for the South-
Eastern Region of Scotland, covering a population of about
1,100,000 people. The incidence of adolescent cystic
glandular hyperplasia in this region can therefore be
estimated as approximately one case per 208,000 of the
population per year.
The number of adolescent girls (aged 10-19) in the
Region was approximately 78,000 (Population census 1961),
permitting the calculation that at that date approximately
1 adolescent per 14,700 was presenting with cystic glandular
hyperplasia per year. Overall, a girl in this Region would
have had approximately one chance in 1470 of curettage for
cystic glandular hyperplasia during adolescence. It seems
reasonable to assume that this calculation still gives a
fair estimate of the incidence of this uncommon condition
in the community. The present series includes all the
cases having a curettage in a geographically defined area
and may reflect the true incidence in the population more
accurately than selected populations referred to a special
clinic (Southam 1960).
This study indicates that there is a high incidence
of persisting reproductive pathology in adolescents with
a proven diagnosis of cystic glandular hyperplasia of the
endometrium. This risk may also apply to certain other
persistent or recurrent menstrual disorders in adolescence.
In a large group of adolescent girls referred to a
specialist endocrine clinic after recurrent menstrual
abnormalities of all types, and followed over many years,
similar findings to those in the present series have been
reported with regard to continuing menstrual abnormalities,
anaemia, blood transfusion and probable polycystic ovarian
disease (Southam 1960; Southam and Richart 1966). In the
earlier series (Southam 1960) nearly 50 per cent of the
cases showed hyperplastic endometrium with a lower incidence
of repeated curettage than the present series (37.3 per
cent against 56 per cent) but a higher incidence of laparotomy
for ovarian cysts or polycystic ovarian disease (29.2 per cent
compared with 11 per cent). Their series showed a high
incidence of infertility; 75 per cent of those married women
with continuing heavy menstrual bleeding had persistent
primary infertility, and 20 per cent of those who regained
normal cycles still showed primary infertility. However,
patients with oligomenorrhoea alone appeared to have
relatively normal fertility in spite of persistent irregul¬
arities. Chamlian and Taylor (1970) have reported a rather
similar incidence of persistent gynaecological abnormalities
in a group of 97 women aged less than 35 years with adeno¬
matous endometrial hyperplasia, except that their series
includes a 14 per cent incidence of carcinoma of the endo¬
metrium occurring within one to 14 years of the diagnosis
of endometrial hyperplasia. Southam and Richart 1966)
reported four cases of carcinoma at ages of 20 to 33 years
following persistent adenomatous hyperplasia (two of which
also showed cystic glandular hyperplasia) out of a total
of 291 patients with excessive adolescent dysfunctional
bleeding. No cases of endometrial carcinoma occurred in the
present small series, but patient No.l must be a high risk
and has been kept under close review and treatment with
progestogens.
The small numbers in this series suggest that there is
a trend for the prognosis to be less favourable in the patients
who show the most marked changes of cystic glandular hyper¬
plasia on at least one occasion during adolescence. It seems
probable that the endocrine conditions necessary for the
development of marked cystic glandular hyperplasia in adoles¬
cence are generally produced by a more persistent defect of
the hypothalamo-pituitary-ovarian axis than in those patients
who never show more than mild changes.
Ill
Chapter 7
PLASMA CONCENTRATIONS OF PITUITARY AND OVARIAN
HORMONES OVER 3 CYCLES IN 4 ADOLESCENTS WITH
DYSFUNCTIONAL UTERINE BLEEDING:
INTRODUCTION:
Following the demonstration of a high incidence of
subsequent clinical problems in adolescent girls with
dysfunctional uterine bleeding associated with endometrial
cystic glandular hyperplasia (Chapter 6) and the evidence
that this is probably the severe end of a spectrum of
anovulatory dysfunctional uterine bleeding (Brown et al
1959) it was decided to investigate the mechanism of this
anovulatory phenomenon in more detail. It was known that
cystic glandular hyperplasia is almost always associated
with anovulation (Schroder 1954) and relatively high
oestrogen levels (Brown et al 1959; Brown and Matthew 1962).
However, different patterns of urinary oestrogen excretion
(reflecting different patterns of ovarian follicle develop¬
ment) had been described varying from high intermittent
levels to moderate, more or less constant levels. Virtually
no information was available on plasma levels of oestrogens
or the simultaneous changes in pituitary gonadotrophins and
the 'feedback' relationships in patients with this type of
disorder, although abnormal hormonal feedback mechanisms
at a hypothalamic-pituitary level had been suspected in
young women with amenorrhoea and oligomenorrhoea (Dignam
et al 1969; Newton 1972; Boon et al 1972).
In this study the daily concentration in plasma of
luteinising hormone (LH) and follicle stimulating hormone
(FSH) and the daily excretion in urine of 'total' oestrogen
and pregnanediol were measured over 3 month periods in
4 adolescent girls with histories of persistent dysfunctional
uterine bleeding associated with cystic glandular hyper¬
plasia of the endometrium. The functional integrity of
the hypothalamo-pituitary-ovarian axis was tested further
by the administration of the anti-oestrogen clomiphene.
This study was planned and analysed by Dr. D. T. Baird
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and myself and organised and executed predominantly by
myself. Dr. L. Wide and Dr. E. A. Michie gave valuable
assistance in planning the hormone assays and arranged
for these assays to be carried out in their laboratories.
MATERIALS AND METHODS;
Urinary 'total oestrogens' were measured by fluor-
imetry using a semi-automatic extractor and an Aminco-
Bowman Spectrophotofluorimeter (Brown et al 1968). Urinary
pregnanediol was measured by the method of Klopper, Michie
and Brown (1955) incorporating an Allen correction factor.
Plasma follicle stimulating hormone and luteinizing hormone
levels were measured by a radioimmunosorbent technique
(Wide and Porath 1966; Wide 1969), FSH was measured by
utilizing highly purified human pituitary FSH (Wide 1969)
labelled with 1251 and guinea-pig anti-human pituitary
FSH. The results were expressed in ng/ml using the FSH
preparation which had a biological activity of 12,000
IU (2nd IRP-HMG) as a standard. One ng of the FSH
preparation was equivalent to 369 ng and 0.14 ng of LER-
907 in the FSH-immunoassay and LH-immunoassay respectively.
LH was measured by utilizing highly purified human
pituitary LH (Roos 1968) and rabbit anti-human pituitary
LH. The results were expressed in ng/ml using the LH
preparation which had a biological activity of 14,000 IU
(2nd IRP-HMG) per mg as a standard. One ng of the LH
preparation was equivalent to 84 ng and 0.096 ng of LER-
907 in the LH-immunoassay and FSH-immunoassay respectively.
All assays were made on 0.1 ml plasma in duplicate with the
standard diluted in a serum with a very low gonadotrophin
concentration. The limit of sensitivity was 0.2 - 0.3 ng/
ml and the coefficient of variation for a mean of duplicate
falling between 20% and 80% inhibition was about 5% for both
FSH and LH assays. Plasma oestradiol and oestrone were
assayed by a complex but sensitive double isotope method
using S35-pipsyl chloride (Baird 1968 See Chapter 2).
Each patient was studied over a three month period
tt<1
with daily blood samples collected between 7 and 9 a.m.
and continuous, accurate 24 hour urine collections.
Informed consent was obtained from each patient, to whom
the nature of the study was explained personally. An
information sheet was given to each subject. Blood
samples (5-10 mis) were collected in the patient's home
within one hour of rising and placed in a heparinized
container on ice. Plasma was separated within one to two
hours of collection following centrifugation at 2,000 rpm
for 20 minutes at 4°C, and was stored at -20°C until
assayed. Urine samples were usually assayed on the day
that each collection was completed or were stored at 4°C
over the weekend.
Towards the end of the second month of the study the
hypothalamic-pituitary axis was stimulated by giving
clomiphene in a dose of 50 mg per day by mouth for 5 days,
from day 5-9 of the cycle. Collections of blood and urine
were continued for a further four weeks after the adminis¬
tration of the clomiphene (Figure 1-4).
Endometrial biopsies were collected without
anaesthetic using a Novak curettage in the outpatient
clinic at the start of each investigation, and were
repeated in three of the patients at a later stage (Table 1).
All patients were given iron supplements (ferrous sulphate
200 mg three times daily) for treatment of the heavy vaginal
bleeding as well as for replacement of iron loss due to
daily venepunctures. Haemoglobin concentrations remained
within the normal range throughout the study except in one
instance after one month of sampling (Table 2).
TABLE1:
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Patient No.l (J.M.)
Menarche occurred at 14 years with a six week cycle
and a light menstrual flow lasting two to three days.
Menses became more regular until 19 years when suddenly,
very heavy bleeding occurred three weeks after a normal
period and lasted six days. Heavy and persistent bleeding
occurred in the following month and curettage showed
marked endometrial cystic glandular hyperplasia. Her
cycle has remained irregular and sometimes very heavy.
She was 20 years during this study.
Patient No.2 (L.R.)
Menarche occurred at 12 years with a regular 28 day
cycle and seven day menstrual flow for two years. She
then had three months amenorrhoea followed by continuous,
often very heavy, vaginal bleeding for two months.
Curettage showed classical changes of cystic glandular
hyperplasia. Haemoglobin at this time was 8.8 g per 100
ml but returned to normal following therapy with intra¬
venous iron. Two very heavy periods then occurred at
eight and six weeks intervals, and at the start of this
study at 15 years she had had amenorrhoea for three months.
Since the study she has had several periods of amenorrhoea
followed by very heavy bleeding, and is now symptomatically
controlled on norethisterone 5 mg three times daily from
day 18 to 23 of each cycle.
Patient No.3 (I.H.)
Menarche occurred at 10 years with regular 28 to 30
day cycle and five day menstrual flow for three years. At
13 years she had persistent vaginal bleeding for four months.
Curettage showed classical changes of cystic glandular
hyperplasia. Haemoglobin was 6.4 g per cent and a blood
transfusion was given. Symptoms were controlled with a
cyclical oestrogen-progestogen combination for 18 months,
but menses became very heavy, although regular, when hormone
therapy was stopped. Bleeding became increasingly irregular
and heavy, but at 17 years after six months of marriage she
became pregnant without artificial induction of ovulation.
She later aborted triplets at 24 weeks gestation..
Following this she had several episodes of irregular,
heavy and prolonged bleeding. Further curettage showed
only fragments of menstrual endometrium without secretory-
changes. Irregular, heavy periods continued until the
onset of this investigation at 19 years. Mild hirsutism
developed after the age of 15 years.
Patient No,4 (L.S.)
Menarche occurred at 13 years with a regular 28 day
cycle and light seven day flow. The length of flow
increased markedly from 17 years onwards for up to four
weeks at a time and often became very heavy. Curettage at
17 years showed marked endometrial cystic glandular
hyperplasia. The subsequent menstrual pattern has been
persistently irregular and heavy, with temporary improve¬
ments while taking norethisterone 5 mg twice daily or a
combined oestrogen-progestogen pill. Laparoscopy has been
carried out since this study and bilateral slightly
enlarged sclerocystic ovaries were found. She was aged
19 years during this study.
All four girls had normal development of secondary
sex characteristics, and were of normal stature and body
build. They have all shown persistent menstrual abnorm¬
alities over 12 months since the conclusion of this
investigation.
RESULTS:
The daily excretion of total oestrogen and pregnanediol
in the urine and the concentration in peripheral venous
plasma of LH and FSH are illustrated in Figure 1 to 4.
The hormonal patterns demonstrated by Patient No. 1
(J.M., Figure 1) were compatible with two ovulatory cycles.
These were characterized by a progressive rise in oestrogen
excretion indicating follicular development. Around the
time of maximum oestrogen excretion there was a sharp increase
in the concentration of LH in plasma followed by a fall in
oestrogen excretion. The rise in oestrogen and pregnanediol
MWa JNitAga 20)
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Figure 1. (Miss J.M.). The excretion of total oestrogen
(jjg/2 4 hr) and pregnanediol (mg/24 hr) in the urine, and
concentration in plasma of FSH and LH (ng/ml) in Patient
no. 1. This demonstrates a spontaneous cycle of ovulatory
pattern and a normal cycle in response to clomiphene.
//// = uterine bleeding.
Mfss L R (age 15)
Figure 2. Patient No 2 (Miss L.R.). Legend, as for figure 1
This shows no evidence of a midcycle LH surge or ovulation
even in response to clomiphene.
Mr* i K(AoaiO)
Figure 3. Patient No 3 (Mrs I.H.). Legend as for figure 1.
This shows no evidence of a midcycle LH surge or ovulation,
although excessively high estrogen excretion peaks have
occurred on three occasions.
Miss LS. (Aqg 18)
VZZZZZZ1 r/////JH a V////A 0 EZ2
Figure 4. Patient No 4 (Miss L.S.). Legend as for figure 1.
There is no evidence of a midcycle LH surge or ovulation
even after clomiphene. Estrogen excretion is high and
irregular and is associated with heavy, irregular bleeding.
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excretion following the LH peak reflects the production
of oestradiol and progesterone from the corpus luteum.
Menstruation with average blood loss occurred following
regression of the corpus luteum as indicated by the
falling excretion of oestrogen and pregnanediol. During
the first spontaneous cycle heavy vaginal bleeding
suddenly occurred for four days in the follicular phase
of the cycle at a time when the oestrogen levels were
rising. Following a prolonged period of low oestrogen
excretion and a small irregular rise in LH, clomiphene
was given. This was associated with an immediate rise in
LH and FSH levels with a subsequent ovulatory cycle
confirmed by pregnanediol levels and an endometrial
biopsy.
In contrast, the hormonal patterns throughout all
cycles in the remaining three patients were distinctly
abnormal. The failure of pregnanediol excretion to rise
consistently above 1.5 mg per day and the lack of mid-
cycle peaks of LH in plasma both indicate a failure of
ovulation.
Patient No.2 (L.R., Figure 2) showed two spontaneous
high oestrogen peaks neither of which were associated with
ovulation. The second spontaneous cycle started at about
28th August with a rise in concentration of FSH following
the onset of heavy prolonged menstrual bleeding. Twelve
days after this the oestrogen excretion began to rise
rapidly, the two minor peaks on 9th and 11th September
being associated with small peaks of LH. Follicular
activity continued as indicated by a further rise in
excretion of oestrogen. The main oestrogen peak on
14th September was not followed by a pre-ovulatory
discharge of LH. Urinary pregnanediol did not rise above
1 mg per day and an endometrial biopsy showed proliferative
endometrium. Menstrual bleeding did not occur even after
the sharp fall in oestrogens. After three weeks of low
excretion of oestrogen a five day course of clomiphene
was started. A very rapid rise in oestrogen excretion
la
occurred with peaks on 16th October and 20th October.
Although there was a small rise in the concentration of
LH, there was no pre-ovulatory surge of LH or subsequent
rise in the excretion of pregnanediol. Heavy menstrual
bleeding began on 27th October (day 18 after starting
clomiphene).
Patient No.3 (I.H., Figure 3) showed a similar
pattern to Patient No.2, but with even higher oestrogen
peaks. Small rises in the concentration of LH were
associated with the rises in excretion of oestrogen but
there were no pre-ovulatory discharges of LH. The very
high levels of oestrogen following clomiphene were
associated with very little change in levels of
gonadotrophin apart from a small discharge of FSH. Heavy
prolonged menstrual bleeding occurred following the first
cycle and was even heavier after the clomiphene cycle.
The second spontaneous cycle, which showed a smaller
total excretion of oestrogens, was only associated with
moderate bleeding for four days. The excretion of
pregnanediol fluctuated slightly but was never above
1.5 mg per 24 hours.
Patient No.4 (L.S., Figure 4) showed the same type
of pattern as Patients No.2 and No.3, although the base¬
line excretion of oestrogen was higher. The spontaneous
oestrogen peak in November was associated with a small
LH peak of the same type as seen in the other two patients.
During clomiphene there was a rise in FSH concentration
followed by a marked increase in oestrogen excretion. There
was a small increase in the concentration of LH followed
by a further increase in excretion of oestrogen. Urinary
pregnanediol remained very low throughout the investigation.
Heavy irregular vaginal bleeding occurred throughout the
study. The initial endometrial biopsy on 5th November
showed some cells with basal vacuolation (positive for
glycogen staining) compatible with a small increase in
progesterone production as may occur with luteinization
of an unruptured follicle. There was also multilayering
of glandular epithelial cells suggestive of increased
unopposed oestrogen secretion. The biopsy following
clomiphene showed early proliferative endometrium.
The significance of the rise in plasma FSH and LH
levels during clomiphene administration was assessed by
comparing the FSH and LH levels for five days before and
for the five days during clomiphene administration by
Student t test (Table 3). In three of the four subjects
there was a statistically significant rise in the concen¬
tration of FSH during clomiphene therapy.
Oestrone and oestradiol-176 were measured in samples
of peripheral plasma (14-20 ml) obtained by pooling
collections over five to six consecutive mornings at two
stages during the first cycle in each patient (Table 4).
The absolute values and the ratio of oestrone to oestradiol
were similar to those of normal women in the same age
group during the follicular phase of the menstrual cycle.
DISCUSSION:
Three of the four patients failed to show evidence of
ovulation throughout the duration of the study. Follicular
development, as indicated by progressive rise in the
excretion of oestrogen, occurred spontaneously and following
clomiphene. However, although there was sometimes a small
rise in the concentration of LH in plasma, the rising oestro¬
gen levels were not followed by a massive surge of LH such
as occurs at midcycle in normal menstrual cycles (Henzl and
Segre 1970; Ross et al 1970), except in patient No.l who
demonstrated a defective spontaneous surge. In the other 3
patients, this indicates a major failure of the positive
feedback mechanism by which oestrogen evokes an ovulatory
discharge of LH from the pituitary (Vande Wiele et al 1970;
Nillius and Wide 1971). The continued rise in oestrogen
excretion may represent the stimulation of further follicular
secretion of oestrogen by the small rise in basal levels
of LH, or the failure of inhibition of ovarian oestradiol
secretion in the absence of the massive normal midcycle LH
surge.
TABLE3:







































































































Administration of clomiphene in all the patients was
followed by a marked increase in excretion of oestrogen.
Clomiphene is thought to work mainly by an antioestrogenic
action at the hypothalamic level (Newton and Dixon 1971)
and normally causes increased secretion of pituitary FSH
and LH which stimulate ovarian follicle development. In
Patients No.2 and No.3 follicular development had possibly
already been initiated by the spontaneous release of FSH
a few days prior to the administration of clomiphene. The
rise in plasma concentration of FSH during the treatment
with clomiphene in Patients No.l, No.2 and No.4 suggests
that the negative feedback effect of oestrogen may be
operating in these patients.
The excretion of oestrogen in Patient No.3 was high
enough to suggest the development of more than one follicle.
Eighteen months previously evidence of multiple ovulation
had been obtained when she aborted triplets. Dysfunctional
uterine bleeding in the perimenopausal age group is
frequently associated with multiple follicular cysts in the
ovaries (Schroder 1954) which are functionally active
(See Chapter 5). In the absence of any obvious abnormality
in the concentration of gonadotrophins during the follicular
phase, it is possible that multiple follicular development
may be due to a failure of the intra ovarian mechanism which
normally inhibits development of all but the pre-ovulatory
follicle (Vande Wiele et al 1970). However, minor abnorm¬
alities in the pattern of FSH and LH secretion could be
responsible.
Cystic glandular hyperplasia of the endometrium is
rare in adolescent girls in the geographical region
involved in this study but is associated with a very high
incidence of persistent menstrual disturbance, infertility,
ovarian cysts and variants of the polycystic ovary syndrome
(Chapter 6). None of the girls in this study were found
to have recurrent changes of cystic glandular hyperplasia
during the period of investigation, but this may have
been related to the infrequency with which endometrial
Ill
biopsies could be carried out. It is often, difficult to
correlate endometrial patterns with absolute endocrine
changes and patients with a history of anovulatory dys¬
functional bleeding show proliferative changes in one
cycle, cystic glandular hyperplasia in another, and
occasionally even ovulation with secretory endometrium
(Brown, Kellar and Matthew 1959). This suggests that
the basic defect, presumably in the hypothalamic control
mechanisms, may vary from cycle to cycle. The signific¬
ance of the finding of sclerocystic ovaries in Patient
No.4 in relation to the endocrine findings is uncertain,
although this appearance may occur in any state of
persistent anovulation.
The concentrations of oestrone and oestradiol and the
oestrone to oestradiol ration in peripheral venous plasma
were within the range found in normal women during the
menstrual cycle (Baird and Guevara 1969). This would
suggest that the bulk of circulating oestrogen is derived
from secreted oestradiol rather than by peripheral
aromatization of androstenedione as in postmenopausal
women (MacDonald, Rombaut and Siitteri 1967) and in women
with polycystic ovarian disease in whom cystic glandular
hyperplasia of the endometrium may develop (MacDonald,
Grodin and Siitteri 1971). Anovulatory dysfunctional
uterine bleeding of this adolescent type appears to differ
from patients with typical polycystic ovarian disease
although there may be some overlap. Patients with typical
polycystic ovaries usually have a markedly elevated plasma
LH to FSH ratio (Yen and Vela and Rankin 1970) and an
elevated plasma oestrone to oestradiol ratio (MacDonald,
Grodin and Siitteri 1969) whereas the women in this study
had normal ratios of all four hormones. Women with
adolescent dysfunctional bleeding differ from women with
the commoner "hypothalamic" type of anovulation with
oligomenorrhoea or amenorrhoea in that these women
typically have low plasma levels of FSH and LH and a defect
of the negative oestrogen feedback mechanism (Jacobs 1976).
In a few cases there may also be a defect of the positive
feedback mechanism but this is unusual.
This investigation has demonstrated a major defect in
the positive oestrogen feedback mechanism which clearly
requires more precise definition (See Chapter 8). Additional
information about the pathophysiological mechanisms of
adolescent dysfunctional uterine bleeding could be provided
by serial ultrasound studies of follicle growth compared
with circulating endocrine patterns, as well as study of
local changes in intra ovarian regulatory peptides.
Chapter 8
DYNAMIC REPRODUCTIVE ENDOCRINE STUDIES IN YOUNG
WOMEN WITH ANOVULATORY DYSFUNCTIONAL UTERINE
BLEEDING:
INTRODUCTION:
The previous study of daily measurements of plasma
gonadotrophins and urinary oestrogen and pregnanediol
excretion demonstrated a complete absence of the mid-
cycle LH peak in three adolescent girls with -persistent
anovulation and a history of cystic glandular hyperplasia
of the endometrium (Chapter 7). The fourth individual
with a previous history of cystic glandular hyperplasia
demonstrated a small midcycle LH peak and reduced
progesterone levels following spontaneous ovulation.
The present study was undertaken to test the hypo¬
thesis that the failure to ovulate may be due to a failure
of the positive feedback mechanism whereby oestrogen
evokes an LH discharge from the pituitary at midcycle.
I was jointly involved in the planning, execution and
analysis of the study with Dr. Van Look and Dr. Baird,
and Dr. Van Look was responsible for performing the plasma
oestrogen assays and for most of the statistical analyses.
MATERIALS AND METHODS:
Nine young women (designated aDUB 01-09) with ages
ranging from 16-27 yr, were recruited from patients
attending the Gynaecology Department, Royal Infirmary,
Edinburgh, because of a history of DUB since adolescence,
the latter being defined as the first 10 yr after menarche
(Southam and Richart 1966). In all nine patients,
irregular and heavy vaginal bleeding had been present
for at least 2 yr (range, 2-8 yr) before the date of
entry to the study and in six of them, DUB had started
soon after menarche. One patient (DUB 02) had previously
aborted triplets and had had one full term pregnancy.
She was also studied in the previous investigation
(Chapter 7, subject I.H.). The remaining two married
women were nonparous. Before entering the study, all of
the subjects had undergone at least one uterine curettage
in order to control the excessive bleeding, which in four
of the patients was associated with cystic glandular
hyperplasia of the endometrium. In the other five subjects,
a proliferative endometrium was found.
Six regularly menstruating women (designated Con 01-06),
aged 23-45 yr, served as controls. Control subjects
were of proven fertility (parity range, 2-5), had
regular menstrual cycles of 26-30 days' duration, and
were in good health.
Design of study
Basal measurements and dynamic tests. Menstrual records
were kept by all participants. Spontaneous ovarian
activity was monitored throughout the entire duration
of the study (3-5 months) by serial measurements of
total oestrogen and pregnanediol excretion in 24-hour
urine samples collected three times a week on Sundays,
Tuesdays, and Thursdays. These measurements enabled us to
determine the most appropriate time for performing the
dynamic tests (see below) which were started during the
early follicular phase of the cycle, i.e. when urinary
total oestrogen and pregnanediol excretion were less
than 12 yg and 1 mg/24 hour, respectively. The general
layout of the study is illustrated in Figure 1.
Oestrogen provocation test. To assess hypothalamic-
pituitary sensitivity to oestrogen plasma levels of
FSH, LH, 178-oestradiol, and ethinyl oestradiol were
estimated daily before (days 1-4), during (days 5-7),
and after (days 8-10) oral administration of ethinyl
oestradiol (4x50 yg/day for 3 days).
Gonadotrophin-releasing hormone (GnRH) test. Pituitary
sensitivity to GnRH was assessed by measuring plasma
gonadotrophin levels before and after the rapid intra¬
venous injection of 50 yg synthetic GnRH (Hoechst Pharm¬
aceuticals) . Blood samples were collected daily for 6
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the cycle. On the morning of day 5, the GnRH was injected
at time 0 and blood samples were collected at 15-min inter¬
vals from -180 to -30 min, at 5-min intervals from -30 to
+30 min, at 15-min intervals from +30 to +180 min, and
hourly thereafter until +360 min. All samples were assayed
for FSH and LH, and hourly samples also were assayed for
178-oestradiol. All blood samples were centrifuged at
2,000 rpm for 20-mins, and plasma stored at -20°C until
assayed.
Hormone analyses
Urinary excretion of total oestrogen was measured
fluorimetrically (Brown et al 1968) and urinary pregnanediol
was measured by a gas-liquid chromatographic procedure
(Chamberlain and Contractor 1968).
131
Plasma gonadotrophins were measured by specific
double antibody radioimmunoassay (Hunter et al 1974).
Preparations 68/39 (assuming a potency of 32.8 U/amp),
both from the National Institute of Biological Standards and
Control, were used as standard in FSH and LH assay, respect¬
ively. Concentrations of both gonadotrophins are expressed
in milliunits per ml plasma where 1 mU FSH = 44.6 ng LER
907, and 1 mU LH = 11.6 ng LER 907. Within-assay precision
(expressed as coefficient of variation) was 11.8% for FSH
and 15.4% for LH. All samples from one subject were measured
in duplicate in the same assay.
17B-oestradiol and ethinyl oestradiol concentrations in
duplicate aliquots of plasma were estimated by using estab¬
lished, specific radioimmunoassays (Van Look et al 1977).
Antisera were provided by Dr. H. Lindner, Dr. P Dean and
Dr. R. Nieuweboer and exhibited no significant cross-
reactions with relevant steroids. The assay procedures were
virtually identical and involved diethyl-ether extraction
followed by direct assay of the dried extracts without
preparatory chromatography. Sensitivity of the method,
defined as the amount of unlabelled 176-or ethinyl-oestradiol
required to displace 10% of the traces bound in buffer
control tubes, was 5.0 pg ± 1.0 (S.D.) for 17B-oestradiol and
8.5 pg ± 2.5 for ethinyl oestradiol. Within-assay and
between-assay precisions were 6.1 to 13.3% and 9.3% respectively
for 176 oestradiol and 8.8% respectively for ethinyl oestradiol.
Statistical analyses
Results are given as arithmetic means ± SEM, unless
indicated otherwise. Differences between mean values were
analysed for statistical significance using Student t test or




Normal women. The pattern of urinary total oestrogen and
pregnanediol excretion in all six control women confirmed
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the presence of normal follicular development and ovulation.
The mean length of the first (control) and third (post -
GnRH) cycle was 29.0 ± 0.4 and 32.0 ± 3.0 days, respectively
(P>0.05). In contrast, the second cycle (i.e. the cycle
after the oestrogen provocation test) was significantly longer
(39.5 ± 3.7 days, P<0.05). The profiles of urinary total
oestrogen and pregnanediol excretion during this cycle indic¬
ated that the delay in the onset of menstruation could be
attributed to a prolongation of the follicular phase (from
16.3 ± 1.5 to 27.0 ± 3.5 days, P<0.05) and the development
of a new crop of follicles. There were no significant
differences between the three cycles in either the height of
the total oestrogen peak at midcycle (30.7 ± 3.1, 45.7 ± 6.7,
and 40.1 ± 4.3 yg/24 hour for first, second, and third cycles,
respectively), the length of the luteal phase (13.0 ± 1.1,
12.5 ± 1.1, and 14.5 ± 1.2 days), or the maximal luteal
pregnanediol excretion (4.1 ± 0.7, 4.3 ± 0.9, and 4.1 ± 0.3
mg/24 hour).
Women with DUB. Although the profiles of urinary oestrogen
excretion were consistent with co-ordinated follicular growth
in all nine women with DUB, seven patients consistently failed
to ovulate during the study period, as evidenced by urinary
pregnanediol excretion which remained below 1.5 mg/24 hour.
Two representative examples are illustrated in Fig.2. The
midcycle oestrogen peak in the remaining two patients (DUB
08 and 09) was followed by an increase in urinary excretion
of pregnanediol, but the rise was small and short-lived and
menstrual bleeding started prematurely 9 or 10 days later.
Both patients, therefore, were considered to represent cases
of defective corpus luteum function and their results were
excluded from further analysis.
As anovulatory cycles were not always followed by vaginal
bleeding and, conversely, menstrual bleeding could be present
despite rising oestrogen levels (Fig.2), cycle length, as
judged from the menstrual record charts of the patients, was
highly variable and no valid comparison with the control
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Profiles of urinary total
oestrogen and pregnanediol
excretion in two young
women with anovulatory DUB.
Each open vertical bar
represents a 24-h urine
specimen. Days of ethinyl
oestradiol (left) or GnRH
(right) administration ;^///A,
days of menstrual bleeding.
D + C, Dilatation and
curettage showing cystic
glandular hyperplasia of the
endometrium.
oestrogen excretion, however, indicated that the length of
the cycle, when calculated from one oestrogen nadir to the
next, was on the average about 5-6 days longer in patients
than in controls, and that this was due to a prolongation of
the follicular phase. The oestrogen excretion during the
initial stages of follicular development was comparable in
both groups and reached a level of 30-40 yg/24 hours after
approximately 2 weeks (Fig.3). In control women, this
concentration appeared to represent the threshold required
for inducing LH release and ovulation, as evidenced by the
subsequent rise in urinary pregnanediol. In the patients'
group, however, ovulation did not occur and oestrogen levels
continued to rise for an additional period of 5-6 days.







Figure 3. Mean (+SEM) urinary total oestrogen and pregnane-
diol excretion in normal women (open bars, n = 6) and patients
with anovulatory DUB (black bars, n = 7). Each bar
represents a 24-h urine collection. Collections were made
three times a week and results in each group were centred
around the midcycle oestrogen peak which occurred on the
average 5-6 days later in patients than in controls.
(P<0.05) greater in patients (62.8 ± 12.6 yg/2 4 hour) than
in controls (30.7 + 3.1 pg/24 hour). Within the patients'
group, increased oestrogen excretion was not always related
to the severity of bleeding or the endometrial histology at
previous curettage, although the two highest oestrogen
peaks (125.8 and 88.0 yg/24 hour) were found in patients
with a history of cystic glandular hyperplasia of the
endometrium.
Urinary pregnanediol remained low in all seven
anovulatory women throughout the study. On several occasions,
a short-lived rise in pregnanediol excretion, coincident
with the midcycle oestrogen peak, could be observed, partic¬
ularly in those patients who had high urinary oestrogen levels
(e.g. DUB 02 in Fig.2), but normal luteal function never
developed.
Oestrogen, provocation test
The results are graphically presented in Fig.4.
Normal women
The concentration of FSH was rapidly suppressed to 60%
of the mean initial level within 24 hours after the start
of ethinyl oestradiol treatment. FSH levels remained low
during the remainder of the treatment period, after which
they gradually returned to pretreatment values. Under our
experimental conditions, no evidence for a positive feed¬
back effect of ethinyl oestradiol on FSH release could be
obtained. There was, however, a significant inverse corr¬
elation between peripheral concentrations of FSH and ethinyl
oestradiol (y = 107.2 - 62.7 log x, where y = the percentage
of change in FSH from mean pretreatment value and x = the
peripheral ethinyl oestradiol concentration; r = -0.5575;
n = 27; P<0.01), suggesting that FSH secretion under these
conditions was regulated by negative feedback only.
Plasma levels of LH, on the other hand, showed a
pronounced biphasic pattern, consisting of a brief initial
period of suppression followed by a marked rise to a peak
value of 35.0 ± 5.5 mU/ml on day 9, i.e. a mean increase
of about 250% above pretreatment levels (P<0.01). The
magnitude of the induced LH surges, which in five out of
six women occurred on day 9 and in the remaining subject
(Con 01) on day 8, ranged from 23.8-58.0 mU/ml with a
mean of 36.1 ± 4.8 mU/ml, a value not significantly
different from that of the spontaneous midcycle LH peak
(39.4 ± 2.5 mU/ml). The LH rise began during the period
of ethinyl oestradiol treatment. Unlike FSH, peripheral
concentrations of LH were not correlated with circulating
levels of ethinyl oestradiol.
The initial decrease in concentration of gonadotrophins
was associated with a rapid decline of plasma 178-oestradiol
which in five of six women remained low throughout the


































in normal, early to mid
follicular phase women ( )
and in patients with
anovulatory DUB ( ).
Asterisks indicate values
which were significantly
different between the two
groups.
Women with DUB
Pretreatment values of FSH (overall mean of days 1-
4, 5.51 ± 0.43 mU/ml) and LH (6.58 ± 0.80 mU/ml) in the
seven patients with persistent anovulation were signific¬
antly (P<0.05) lower than those in control women (8.40 ±
1.02 and 10.26 ± 0.80 mU/ml), but concentrations of 178-
oestradiol were on the average about 50% higher in the
former (83.2 ± 8.7 pg/ml vs. 55.0 ± 5.1 pg/ml; n = 49; P<
0.01).
Changes in the concentrations of FSH and LH during and
after oestrogen administration were qualitatively similar
to those seen in controls. After an initial decrease, LH
levels started to rise 48-72 h after the start of treatment
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and reached a peak of 16,2 ± 3.7 mU/ml on day 9. The
magnitude of this oestrogen induced LH surge was signif¬
icantly (P<0.005) smaller than that seen in controls and
in only two out of the seven patients did the value fall
within the range found in controls. Peak levels of LH in
the four patients with a history cystic glandular hyperplasia
were significantly lower than those of the remaining three
patients, in whom the endometrium showed proliferative
changes only (9.70 ± 2.20 vs. 25.74 ± 2.82 mU/ml; P<0.01).
Differences in peak magnitude between patients or between
patients and controls could not be attributed to differences
in plasma ethinyl oestradiol concentrations. Circulating
levels of the latter hormone were on the average higher in
patients (mean of days 6-8, 285.0 ± 67.3 pg/ml) than in
controls (197.7 ± 16.6 pg/ml), but the difference was not
significant.
As in control women, ethinyl oestradiol treatment did
not stimulate the release of FSH; and changes in the plasma
level of FSH were inversely related to plasma concentrations
of ethinyl oestradiol (y = 142.1 - 70.1 log x, where y =
the percentage of change in FSH from basal value and x =
the plasma level of ethinyl oestradiol; n = 35; r = 0.6678;
P<0.001). Neither slope nor intercept of this regression
line was significantly different from the corresponding values
found in control women, suggesting that the negative feedback
sensitivity of FSH secretion to oestrogen was similar in the
two groups.
GnRH test
The administration of GnRH to control women resulted
in a rapid increase in the level of both gonadotrophins with¬
in 5 min of injection. The magnitude of the pituitary
response was greater for LH (23.9 ± 4.7 mU/ml) than for FSH
(11.0 ± 2.7 mU/ml; Fig.5). The FSH response in the patients'
group (8.5 ± 0.5 mU/ml) was on the average somewhat smaller
and LH response (26.2 ± 8.1 mU/ml) was somewhat greater than
those of controls, but the differences were not statistically
significant.
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Figure 5:
Mean (+SEM) plasma levels
of FSH (upper panel) and LH
(lower panel) in normal
women ( , n = 6) and
patients with anovulatory
DUB (—, n = 7) before and
after the injection of
50 yg synthetic GnRH.
-2 O *2 *4 *6
HOURS
In every subject, the GnRH-induced rise in gonadotrophins
was followed by a significant increase in the circulating
levels of 17B-oestradiol, which became manifest 4-5 h after
GnRH injection. The relative magnitude of this rise varied
between 111 and 387% of the pre-GnRH value and was similar
in both groups.
DISCUSSION:
In all patients in this study dysfunctional uterine
bleeding had been present for 5 years or more, and all
seven with persistent anovulation had recently undergone
therapeutic curettage with the finding of cystic glandular
hyperplasia in four. By contrast approximately half of
an unselected group of adolescents presenting for the first
time with dysfunctional uterine bleeding will establish a
pattern of normal, regular cycles within 4 years (Southam and
It*
Richart 1966) . This suggests that the more severe end of
the spectrum is represented by the women studied here.
This is substantiated by a history of blood transfusions
in 3, diagnostic laparoscopy for infertility in one and
laparotomy and unilateral salpingo-oophorectomy for a
large fimbrial cyst in another.
The profiles of urinary total oestrogen excretion in
these patients (Fig.2 and 3) confirm earlier work, (Brown
et al 1959) which showed that urinary oestrogen levels
are often elevated in anovulatory DUB, particularly if
the latter is associated with cystic glandular hyperplasia.
As there is no difference in oestrogen metabolism between
older women with DUB and regularly menstruating women
(Chapter 4) it is reasonable to assume that this enhanced
oestrogen excretion is a direct reflection of an increase
in ovarian secretion of 17B-oestradiol. The data shown
in Fig.3 indicate that this increase becomes manifest only
during the latter part of the prolonged follicular phase.
The cause for this prolongation of follicular oestrogen
secretion beyond the normal 14-day period found in ovulatory
cycles is unknown, but may be due to the absence of the
spontaneous midcycle LH surge observed in these patients
(Chapter 7). This view is supported by the finding that
preovulatory Graafian follicles obtained from pregnant
mare serum gonadotrophin (PMSG)-treated sheep continue
to secrete oestrogen for at least 7 days when cultured
in vitro, but that they lose this ability when an ovulatory
dose of LH is given to the animals before removal of the
follicles (Moor 1974).
Despite the presence of regular apparently adequate
follicular development, seven out of nine patients consist¬
ently failed to ovulate, as indicated by the absence of
a significant rise in urinary pregnanediol excretion. When
challenged with oestrogen, four of these women failed to
release LH, and the response in the remaining three
subjects was small and fell below or just above the lower
limit of the range found in normal women. Thus, the
present study confirms the earlier suggestion that the
failure to ovulate in these patients is associated with
an inability to discharge an adequate amount of LH in
response to oestrogen (Chapter 7). In addition, the
present investigation indicates that this failure is
probably of hypothalamic origin, as pituitary secretion
of LH in response to GnRH (Fig.5) was similar to that
found in women with regular ovulatory cycles. It should
be emphasized, however, that this latter conclusion requires
additional proof. Indeed, the amount of LH released after
the acute injection of 50 yg GnRH is small compared to that
secreted at midcycle and, therefore it cannot be excluded
that there may be a relative failure of the pituitary to
synthesize and/or secrete enough LH to induce ovulation.
Further studies involving continuous infusion or repeated
administration of GnRH to test the secretory "reserve" of
the pituitary gland (Wang et al 1976) are indicated to
investigate thus possibility.
The presence of regular, co-ordinated follicular
growth and oestrogen secretion and the normal rise of
plasma 173-oestradiol after GnRH indicate that the primary
defect in this condition is not of ovarian origin. Follic¬
ular cysts and variants of the polycystic ovary syndrome
have been described in women with DUB (Southam and Richart
1966), but these ovarian abnormalities are probably secondary
to chronic anovulation. In this respect, these patients
might be comparable to adult female rats made permanently
anovulatory by neonatal administration of androgens or
oestrogens (Barraclough 1973).
Although the results of this study leave little doubt
that oestrogen-induced LH release in young women with
anovulatory DUB is deficient as compared to normal, regularly
menstruating women, they also tend to indicate that this pos¬
itive feedback failure is not absolute. From clinical exp¬
erience, it is well known that these patients may ovulate
spontaneously on occasions. The two pregnancies in one of
our volunteers are direct proof of this. It is possible,
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therefore, that the basic defect in this condition is a
relative insensitivity of the hypothalamic-pituitary unit
to the positive feedback effect of oestrogen. As the
magnitude and duration of the abortive LH peaks observed
in our patients are very similar to those described in female
rhesus monkeys after the administration of a subthreshold
dose of oestrogen (Karsch et al 1973), it may be that these
patients require a more potent oestrogen stimulus than normal
women in order to release an adequate amount of LH at mid-
cycle. It is also possible that this defect is a failure
of maturation of the hypothalamo-pituitary-ovarian axis,
since the positive feedback response normally appears at
mid-puberty (Reiter et al 1974).
It is of interest to note that the LH peaks in all
four patients with a history of cystic glandular hyperplasia
were significantly smaller than those in the remaining three
women without such history. This might indicate that hypo¬
thalamic sensitivity to positive feedback in the former
patients was more markedly imparled and, hence, that spont¬
aneous ovulations were less likely to occur. Evidently,
these two factors, namely the presence of markedly elevated
oestrogen levels for prolonged periods of time and the
absence of ovulation and, hence, of progesterone, constitute
the ideal endocrine environment for the development of
cystic glandular hyperplasia and possibly endometrial
carcinoma (Schroder 1954; Fox 1976).
A point of clinical importance is well illustrated by
this study. Subject DUB 02 (Fig.2) experienced erratic
bleeding which sometimes continued even with rising oestrogen
levels. This emphasises that abnormal bleeding can occur
when oestrogen levels are falling, stable or rising (Brown
et al 1959; Chapter 7).
SECTION 4
PERCEPTION AND MEASUREMENT OF MENSTRUAL FLOW
PERCEPTION AND MEASUREMENT OF MENSTRUAL FLOW:
Several authors have suggested that individual per¬
ception of volume of menstrual blood loss is often inacc¬
urate, and a number of methods for the objective measurement
of blood loss have been described. A correct assessment
of blood loss is important for a diagnosis of "true"
menorrhagia/DUB, and the alkaline haematin method used by
several investigators was developed for routine use with a
semi-automatic extractor. This only gave a measure of the
whole-blood component of the menstrual flow and an accurate
sanitary towel weighing technique was also used to assess
the total fluid volume on a daily basis through one menstrual
period in 28 regularly menstruating women. The percentage
contribution of blood (equivalent to mixed venous blood from ,
the cubital fossa) to the total varied very greatly from
subject to subject (1.6 - 81.7%) with a mean of 36.1 ± 3.6%
(±SEM). There was a highly significant correlation between
total fluid loss and blood loss (r = 0.911; p<0.001). The
proportion of blood remained approximately the same for
different total volumes and on different days of the cycle.
In the one woman with objective menorrhagia the contribution
of whole blood to the total was only 52%. Subjects using
no contraception or who had undergone tubal sterilization
had similar ratios of blood to total fluid loss whereas
IUCD users had a higher ratio (p<0.025) and oral contra¬
ceptive users had a lower ratio (p<0.05). It seems probable
that the major component of the fluid loss which cannot be
accounted for by blood is from endometrial tissue fluid
(? a transudate) rather than vaginal or cervical secretions.
Variations in the endometrial tissue fluid component may
contribute to some of the errors in perception of menstrual
bleeding exhibited by many women.
Sixty-nine women with a convincing complaint of
menorrhagia took part in a double blind treatment trial where
menstrual blood loss was accurately measured and the subjects'
own perception was carefully recorded. Only 38% of the women
had objective menorrhagia with a measured loss greater than
80 mis, although 59% would qualify with an upper limit of
normal of 60 mis. Overall, the measured loss in the
"heaviest" periods (69.6 ± 7.3 mis) was significantly
greater than the "lightest" periods (42.7 ± 4.7 mis;
p<0.001), but there were many major errors in perception
by individuals. Perceived daily blood loss volume on a
4 point rating scale gave the following group means and
ranges: spotting: 2.5 mis (0.1 - 15.5 mis); light:
5.7 mis (0.1 - 63.1 mis); moderate: 16.1 mis (0.5 - 108
mis); very heavy: 22.0 mis (1.4 - 215.8 mis); illustrating
very wide individual ranges of assessment. As a whole the
group was also able to distinguish between a day to day
volume increase or decrease, but again there were many
major errors. Some subjects who experienced a reduction
in measured blood loss from one day to the next actually
perceived this as a large increase. Menstrual pain and
duration of bleeding were not found to influence perception
of menstrual blood loss volume, whereas younger subjects
(26 and under) were significantly more likely to regard
a moderate loss as very heavy than older women (37 and over).
There was no significant correlation between number of
pads/tampons used and the measured menstrual loss, and some
individuals showed extreme variations between blood loss
and pad usage. This study suggests that the only reliable
assessment of menstrual blood loss volume and changes in
volume in women complaining of menorrhagia is obtained by
objective measurement of blood loss using a technique such
as alkaline haematin extraction.
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Chapter 9
BLOOD AND TOTAL FLUID CONTENT OF MENSTRUAL DISCHARGE:
INTRODUCTION:
Most physicians and patients implicitly assume that
the fluid discharged at menstruation is whole blood or
altered whole blood containing a small amount of endometrial
tissue, debris and other fluids, and objective measurements
of menstrual volume have usually used techniques which
measure the haemoglobin present in the fluid discharge.
Most of these methods give a reliable assessment of haemo¬
globin content and therefore presumably total blood loss
(Shaw 1977). However, there is evidence from earlier
studies in very small numbers of women that the haemoglobin
concentration in menstrual fluid is lower than in blood.
Measurement of menstrual blood collected directly from the
uterus or upper vagina has given haemoglobin concentrations
ranging from 40 to 103 g/Z (Ebert and Nold 1956; De Merre
et al 1967) .
Many women have great difficulty in assessing the
volume of their blood loss and even in detecting major
day to day and cycle to cycle changes in blood loss
(Chapter 10). Some of these women made the observation
that on some days the fluid in their pads or tampons appeared
to be very dilute blood. It seemed possible that a major
source of error in perception of the volume of menstrual
bleeding could be the presence of a significant, and perhaps
variable, amount of endometrial tissue fluid or cervical
and vaginal secretion.
The present study was designed to assess the total
volume of fluid lost per day at menstruation and compare
this with the volume attributable to whole blood.
This study was planned, executed and analysed by myself,
with the assistance of a research sister (Miss G. McCarron)
and technical staff (Mr R. Markham and Miss T. Resta).
MATERIALS AND METHODS:
Twenty-eight women volunteers with no gynaecological
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symptoms were studied on a daily basis through one
menstrual period and were very carefully instructed in
the details of the study. None were of asian origin.
None of these women had any detectable gynaecological
abnormality, menstrual cycles were regular (24-35 days)
and all ovulatory except for the 5 women using oral contra¬
ceptives. All women had plasma progesterone measured by
standard radioimmunoassay (Shutt et al 1975) on one occasion
within ten days before menstruation to confirm ovulation.
No subject complained of an excessive vaginal discharge.
All women used the sanitary pads or tampons which
were provided. These were accurately weighed and placed in
individually labelled self-sealing polythene bags until
used. After use each pad or tampon was immediately placed
back into its original bag which was resealed. Analysis was
carried out within 2-3 days of the end of the menstrual
period. Each pad and tampon was accurately reweighed and the
total fluid content calculated by subtracting the original
weight.
Alkaline haematin technique for menstrual blood loss
measurement
Haemoglobin content of each daily pad and tampon
collection was measured by a modification of the alkaline
haematin technique of Hallberg and Nilsson (1964a) using
a semi-automatic extractor (Newton et al 1977).
This is colourimetric method which quantifies the
haemoglobin present in sanitary towels and tampons and
involves 3 main steps: 1) the complete collection of all
menstrual blood lost by the woman by the use of disposable
sanitary towels; 2) the extraction and conversion of
haemoglobin to alkaline haematin with sodium hydroxide;
3) followed by quantitation in a spectrophotometer.
Complete collection of the menstrual loss is crucial to
the accuracy of the method, and subjects required careful
verbal and written instructions to avoid inadvertent loss
of "clots" while in the shower or on the toilet. This
was often best achieved by a combination of tampon and pad
use, and controlled "bearing down" to expel vaginal "clots"
onto the pad. Women with true menorrhagia required special
care. Sanitary towels were immediately placed in thick
opaque polythene bags and collected in the same bag on a
daily basis. At the end of the day the bag was rolled up
and sealed. All bags for one menstrual period were kept in
a cool place until returned to the laboratory within a few
days of the end of the period. Women were permitted to
continue use of their usual brand of sanitary pads or
tampons since none of the brands available in Australia
contain coloured material which interferes with the photo¬
metric measurement.
Extraction procedure
The original collection bag containing one daily
sanitary towel collection was placed inside a strong
plastic bag (14" x 20" x 200 g thickness, Cryovac, Seward
Laboratories, Bury St Edmunds, Suffolk) and 2 litres of
5% sodium hydroxide solution added. The bag was then placed
inside a model 3500 Stomacher Lab-Blender (Seward Laborat¬
ories) which pummeled the bag for 15 minutes to produce
complete disintegration of the towels and conversion of
haem to alkaline haematin. An aliquot of homogenate was
filtered through Whatman No 4 filter"paper to remove suspended
particles and the optical density of the supernatant at 550
nm determined at approximately 30 minutes after addition of
the sodium hydroxide using a Corning 253 colourimeter.
At the sametime as the sanitary towel extraction 100 ml
of 5% sodium hydroxide was added to 1 ml of peripheral
venous blood from the same individual for comparison. The
optical density of peripheral blood was also read at 30
minutes and usually immediately before the menstrual sample.
Menstrual blood loss was calculated from the following
equation:
(O.D. 550 M) x Vol
Menstrual blood loss(mis) =
(O.D. 550 V) x 100
Where (O.D.550 M) = optical density (550nm) of menstrual
eluate
(O.D.550 V) = optical density (550nm) of venous
blood
Vol = added volume of 5% sodium hydroxide
100 = volume of 5% sodium hydroxide added
to venous blood
Assessment of completeness of recovery of added blood
Two brands of tampon (Meds Super; Carefree Super) and
two brands of pad (Modess Super: Sure and Natural) were
tested by the addition of 10 mis, 20 mis or 100 mis of
whole blood (expired blood from the Red Cross Blood Bank,
Sydney). Each assessment was done in quadruplicate. The
mean percentage recovery overall was 92.2 ± 0.48 (SEM; n =
32). No difference was seen in percentage recovery of
different volumes of added blood (range 89.0 to 94.4%
recovery). Coefficient of variation = 2.6%.
Sanitary towel storage
The method of storage of the pads and tampons in
individual sealed bags following use and prior to analysis
was checked for evaporation by adding known volumes of water
to each of 20 test pads and accurately reweighing after
storage. Twenty pads were weighed individually, approxim¬
ately 10 mis of water was added and they were then indiv¬
idually reweighed and stored in the polythene bags at room
temperature. Ten were reweighed after 2 days and 7 days
and replaced in the bags immediately after each weighing.
All were finally weighed at 14 days after initial storage.
Fluid loss attributable to evaporation or to loss on the
inner surface of the bag was 2.7% in the group weighed at
2, 7 and 14 days and 2.1% in the group weighed at 14 days
only. This volume of loss was highly significant (paired
t test: t = 17.49; p<0.001), but would be negligible in
relation to menstrual blood loss.
Each subject kept a daily menstrual diary card with
details of her perception of volume of menstrual blood
loss, dysmenorrhoea and other menstrually related symptoms
rated on a 3 point scale (slight, moderate, heavy).
Statistical analyses were made using the Student t
test, or linear regression correlation.
RESULTS:
Measurements of total fluid loss and blood loss from
each individual subject over one complete menstrual period
and arranged from heaviest to lightest are illustrated in
figure 1. These indicate that those women with heaviest
total fluid loss also tended to have the highest blood
loss, although the proportional contribution from whole
blood varied considerably at all volumes.
Figure 1:
Blood loss and total fluid
loss at menstruation in 28
women.
□ = total fluid loss
blood loss
The total fluid loss, blood loss, percentage contribution
of blood to the total, and the non-blood fluid loss are
listed for each subject in table 1. The mean percentage
contribution from whole blood was only 36.1% ± 3.6.± S.E.M.
(range 1.6-81.7%), which indicates that the majority of
the fluid volume of the menstrual discharge is derived
from sources other than blood.
TABLE 1 - Blood loss and total fluid loss at menstruation in
28 women using different methods of contraception.
Subject Total fluid Measured % of blood Fluid Contra¬
No. content of blood loss out of total comoonent ceptive
sanitary (mis) not due to usage
towels (mis) blood (mis)
1 270.9 140.7 51.9 130.2 TL
2 153. 2 73.3 47.8 79.7 NC
3 146.1 75.7 51. 8 70.9 IUCD
4 139.0 70.0 50.4 69. 0 IUCD
5 111.1 47. 6 42. 8 63.5 NC
6 106.0 18.7 17.6 87. 3 TL
7 104.1 60.2 57.8 43. 8 IUCD
8 93.5 47. 0 50.3 46.5 NC
9 91.0 11.4 12.5 79.4 NC
10 87.4 71. 4 81.7 16. 0 IUCD
11 74 . 6 19 . 2 25.7 55 . 4 NC
12 72.9 40 . 6 55.7 28 . 7 TL
13 71.7 1.2 1.6 70.0 OC
14 53.7 21. 9 40 . 8 31. 8 IUCD
15 53.5 29.8 55.7 24.6 NC
16 53.1 15.5 29 . 2 37. 6 NC
17 53.1 14 . 5 27. 3 38.6 NC
18 43.2 16.2 37.5 27 . 0 NC
19 42.4 9.8 23.1 32.6 NC
20 37.5 7.0 18.7 30.5 OC
21 37.3 8.8 23.6 28.5 NC
22 35.8 15. 2 42.5 20.6 TL
23 33.7 4.5 13.5 29.2 TL
24 32.3 6.7 20.7 25.6 OC
25 28 . 4 19. 2 67 . 6 9.2 NC
26 21.9 5.2 23.7 16.7 NC
27 19.7 2.1 10.6 17.6 OC
28 15.8 4.7 29.7 11.1 OC
Mean 74 . 4 30.6 36.1 43. 3
SEM 10.3 6.1 3.6 5.4
TL tubal sterilisation OC = oral contraceptive
IUCD = intrauterine contraceptive NC = no contraception
device
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There was a highly significant overall correlation
between the total fluid loss and the measured blood loss
(r = 0.911; p<0.001) in spite of individual exceptions
(figure 2a). There was also a significant but lesser
correlation between measured blood loss and the volume of
fluid which was not derived from blood (total fluid minus
measured blood loss) (r = 0.602; p<0.01; figure 2b). This
correlation remained significant at the 5% level when the
only subject with previously unrecognised objective
menorrhagia (ovulatory dysfunctional uterine bleeding) was
excluded from the analysis (r = 0.324; p<0.05).
The comparison between total fluid loss and blood
loss for each day of the menstrual period for the whole
group is shown in figure 3. The proportion contributed by
whole blood did not change significantly from day to day.
Subjects were allocated to groups according to contra¬
ceptive usage and each group analysed separately. There
was no significant difference for the fluid composition of
the menstrual discharge between the groups using no contra¬
ception (13 women; whole blood component = 35.5 ± 4.5%) or
those who had undergone tubal interruption (5 women; 36.2 ±
8.8%) for sterilization (figure 4). However, the 5 sub¬
jects who used oral contraceptives all had a low blood loss
and a low proportion of blood to total fluid which was
significantly different from those not using contraception
(17.3 ± 5.1%; t = 2.281; p<0.05). Those using an intra¬
uterine device had a significantly greater proportion of
blood in the total discharge (5 women; 56.5 ± 6.9%; t =
2.490; p<0.025).
Eight subjects used sanitary pads only during the
study. The fluid losses per day (total fluid = 17.4 ±
4.1 mis; blood loss = 9.4 ± 2.3 mis; mean ± SEM) were
slightly different from the losses in the larger group of
15 who exclusively used vaginal tampons (total fluid =
15.6 ± 1.5 mis; blood loss = 5.3 ± 0.9 mis). Blood loss
but not total fluid loss, was significantly more in the pad
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Figure 2. (a) Relationship between total fluid loss and
measured blood loss in 28 women.
(b) Relationship between measured blood loss





Figure 3. Comparison between total fluid loss and blood
loss during each day of menses in 2S women (mean and S.E.M.)
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Figure 4. Daily blood loss and total fluid loss in 28
women using different methods of contraception (mean + SEM).
Upper line indicates total fluid loss. Lower line indicates
blood loss.
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of blood to total fluid in the pad users (50.0 ± 6,5%)
was significantly higher than the tampon users (30.0 ±
4.1%; t = 2.726; p<0.02), suggesting either an increased
evaporation or reabsorption of fluid in the pad users or
an excessive vaginal secretion in the tampon users.
TABLE 2: Subjective rating of volume of menstrual discharge
in 28 women.
Subjective Measured loss (mean t SEM)~
rating of Total fluid Blood loss Percentage due
daily loss loss (mis) (mis) to whole blood
A) Heavy (n=6) 42.7 ± 14.6* 20.5 ± 7.7* 48.0
B) Moderate (n=21) 25.3 ± 3.1* 12.0 ± 2.1* 47.4
C) Light (n=26) 9.5 ± 1.2* 2.6 ± 0.4* 27.3
* P<0.001 = A compared with C for both total fluid and
B compared with C blood loss perception
A is not significantly different from B
Subjective rating of daily menstrual blood loss
volume on each point of the 3 point scale was analysed for
each subject, and then as a group using the subject as the
unit for analysis (table 2). Although the subjects were
able to distinguish "heavy" from "moderate" from "light"
bleeding days as a group, there was a substantial overlap
between individuals in the absolute volumes which were
rated in each category. The proportion of the total fluid
loss accounted for by whole blood was virtually identical
on the "heavy" and "moderate" bleeding days, whereas it
was much less when bleeding was rated as light. This may
indicate that vaginal and cervical secretions were making
a proportionately larger contribution to the total fluid
when the menstrual flow was less. To assess vaginal and
cervical secretions, six subjects were asked to use
tampons over a 24 hour period on 2 days when they were not
menstruating. This gave a mean 24 hour tampon fluid content
of 4.4 mis (± 0.4 S.E.M; range; 2.8 to 6.3 mls/24 hours).
DISCUSSION;
Blood is obviously an important component of the
menstrual discharge. However, the physiological necessity
for this cyclical bleeding in women and subhuman, primates
is far from clear, especially when the considerable
cyclical growth and regression of the endometrium which
occurs without bleeding in the oestrus cycle of subprimates
is considered (Finn 1977). In women an excessive monthly
blood loss can be of considerable psychological concern and
may even lead to a health hazard from anaemia. Yet, accurate
perception of the volume of blood loss may be extremely
difficult (Chapter 10). It has been known for some time
that blood does not account for all the menstrual discharge
(Ebert and Nold 1956; De Merre et al 1967; Hahn 1980) but
little is known of the variation in blood content of the
discharge and the way in which this may be manifest to the
woman, that is to say in her sanitary towels.
A very detailed study of menstrual discharge collected
directly from the uterus of 3 women found menstrual haemo¬
globin concentrations of 40, 42 and 50 q/l (i.e. approximately
35% of venous concentrations) on days 1-2 of the cycle (Ebert
and Nold 1956). This finding has been confirmed in the
present study which relied upon the collection of fluid
discharged into the vagina. In view of the agreement between
these two studies it seems likely that the major contribution
of fluid not derived directly from blood must come from the
endometrial cavity. This is presumably derived from endo¬
metrial tissue fluid exudation and perhaps a small component
from glandular secretion. It is not known whether the
Fallopian tubes secrete enough fluid to make a significant
contribution. Cervical and vaginal secretions must make some
contribution to the fluid absorbed by sanitary tampons or pads,
but the close agreement of studies of uterine and vaginal
discharge suggests that the contribution of the cervical and
vaginal components is usually small. The observations that the
proportion of blood out of total fluid is similar on different
days of menstruation and in women with different total menstrual
fluid volumes would also be consistent with an endometrial
origin for the majority of the fluid. Cervical and vaginal
secretions probably only make a significant contribution
when total menstrual fluid loss is small. It is possible
that this factor may contribute to the high total fluid
to blood loss ratio in oral contraceptive users.
There is great variability in the proportion of blood
in menstrual discharge and it is likely that this contributes
to some errors in perception of menstrual bleeding. However,
evidence for this was not found in the present study. The
contribution by tissue fluid of probable endometrial origin
to total fluid loss in menorrhagia is unknown and requires
further investigation. The finding that the tissue fluid
contribution is particularly high in oral contraceptive
users is in agreement with the report of De Merre et al
(1967). The demonstration of different fluid compositions of
the menstrual discharge with IUCD and oral contraceptives
indicates that there are factors which can indeed alter the
tissue fluid component independently of the blood loss.
Nevertheless, in clinical terms the volume of blood lost,
or more accurately the amount of haemoglobin and iron lost
from the body, is of more crucial importance to the health
of the woman.
It is of interest that the proportion of "tissue"
fluid in the woman with objective menorrhagia was as high
as in women with less blood loss and therefore the absolute
volume of fluid was much greater. If the tissue fluid
component was due to exudation across a denuded surface it
could be expected to be proportional to the endometrial
surface area. However, the variation in surface area is
not large and does not correlate with measured blood loss
(Chimbira et al1980 ). Therefore, it seems likely that other
mechanisms may sometimes be contributing. Exudation could be
greater if blood flow through the endometrium was increased
or if capillary permeability was increased. The answer to
this question awaits future research.
This study indicates that the alkaline haematin method
of menstrual blood loss measurement generally underestimates
blood loss by about 10%. However, a correction factor has
not been applied in general usage because there is a
small error due to the blank value and almost certainly an
added error of variable degree during the sanitary towel
collection process. This will also tend to underestimate
the menstrual loss. Other investigators have not applied
a correction factor and it seems sensible for users of the
same method to be consistent in comparison of results. The
comparative study of Hallberg and Nilsson (1964a) shows a
good correlation with menstrual loss measured simultaneously
with the alkaline haematin and a radioactive iron labelling
method. Most of the recently published work on menstrual
blood loss has been based on the alkaline haematin technique,
which has been found satisfactory by all groups which have
used it (Hallberg et al 1966; Shaw 1973; Guillebaud et al
1966; Newton et al 1977; Shaw 1977; Haynes et al 1977).
It has the added advantages of converting old and dried blood
efficiently to alkaline haematin, as well as measuring most
breakdown products of haemoglobin (produced by drying or
micro-organisms; Hallberg and Nilsson 1964a). It does not
appear to be affected by proteins or glycoproteins which
may be present in menstrual "clots" (Beller 1971).
Using this method Hallberg and Nilsson (1964b) have
shown a reasonable constancy of individual menstrual blood
loss from month to month in normal women. Although the
variation between periods may be much more in some individuals
with menorrhagia the coefficient of variation for menstrual
blood loss from one period to the next in a group of women
with menorrhagia is the same as normal women (Haynes et al
1977). However the variation in loss between individuals
is very much greater and may show substantial differences in
different ethnic groups (Hallberg et al 1966; Cole et al 1971;
Hefnawi et al 1979; Gao et al 1981). This has been discussed
in Chapter 1.
Chapter 10
PERCEPTION OF MENSTRUAL BLOOD LOSS VOLUME IN WOMEN
COMPLAINING OF MENORRHAGIAt
INTRODUCTION:
For many patients the assessment of the volume of
menstrual blood loss is probably the most important single-
parameter of the menstrual history, since it is on this
that the decision to perform the very final and invasive
procedure of hysterectomy is usually based. It is widely
recognised that this assessment is not very reliable,
(Barer and Fowler 1936; Millis 1951; Hytten et al 1964;
Jacobs and Butler 1965; Hallberg et al 1966; Chimbira et
al 1980), but surprisingly little has recently been written
about it.
In a large population study (Hallberg et al 1966) of
476 women in whom menstrual blood loss was objectively
measured by the alkaline haematin technique (Hallberg and
Nilsson 1964a) it was found that 45% of the women who rated
their blood loss as "heavy" had a measured loss within the
mid to low normal range. By contrast, only 4% of women
who rated their loss as light had a measured loss of greater
than the generally accepted upper limit of normal of 80 mis.
Chimbira et al (1980) found no correlation between the
patient's subjective assessment c:f sanitary pad usage and
measured blood loss. These studies give an indication of
the difficulty which some women have in assessing the
absolute volume of flow but give no information on their
ability to assess change in flow from cycle to cycle or
day to day.
In contrast, a great deal has been written about the
way in which women perceive other parameters of the menstrual
cycle and the factors which may influence this. It is clear
that multiple cultural, religious, familial and individual
factors have an influence on this overall perception, but
one important message is that retrospective recall is
notoriously unreliable and should not be used in any accurate
study (Gray 1980).
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This Chapter presents the results of a prospective
investigation of menstrual blood loss in 69 women over 4
cycles each and compares this with the patients' own sub¬
jective assessment of her menstrual loss on a day to day
and cycle to cycle basis. These subjects all took part
in a clinical trial of the efficacy of the prostaglandin
inhibitor, mefenamic acid, for the treatment of menorrhagia
(Fraser et al 1981).
Methods
Sixty-nine women who presented with a complaint of
menorrhagia completed a 4 cycle double-blind placebo-
controlled cross-over trial using the prostaglandin inhib¬
itor, mefenamic acid. Each subject was interviewed in
detail and was only admitted to the trial if a convincing
history of menorrhagia was obtained. Virtually all subjects
gave a history of passing "clots" and/or using 2 pads at a
time and/or flooding underclothes or bedclothes. Almost
all used "super" pads and/or tampons routinely. A full
medical history and examination was recorded.
Considerable time was spent with each subject at the
initial interview to explain the details of the trial and
an information sheet was given. Each subject was provided
with treatment bottles labelled A and B for the first two
cycles and two detailed calendars for the daily prospective
recording of menstrually-related symptoms, possible drug
side-effects, number of capsules ingested and number of
menstrual pads/tampons used. The women were treated for
two cycles each with mefenamic acid and with placebo given
in a randomised order. Subjects were seen again between
cycles 2 and 3, and provided with bottles C and D and two
further menstrual calendars. The subjects' perception of
changes in menstrual symptoms, pad and tampon usage and any
drug side-effects was carefully checked and recorded.
Each subject was seen for a final interview after all 4
cycles were completed, and her perception of each aspect
of the whole trial was carefully recorded before her
individual treatment code was broken.
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All subjects were carefully instructed to grade the
severity of menstrually related symptoms on a four point
scale (0,+,++ or +++) on a daily basis in each cycle, and
to record the result on the chart each evening. Only 60
subjects provided perception data which was accurate enough
for analysis. Subjects collected all their menstrual pads/
tampons on a daily basis in thick blue labelled polythene
bags. They were very thoroughly instructed in the collection
of all the menstrual flow including the necessity to avoid
loss of "clots" down the toilet. Most subjects had no
trouble with these collections.
Mefenamic acid was taken as 500 mg (two 250 mg capsules)
three times daily with food from the onset until the end of
menstruation. If menstruation was prolonged a maximum of
50 capsules was taken in any one cycle. In the placebo
cycles two identical lactose-filled capsules were taken
three times daily in the same manner.
Laboratory methods
Menstrual blood loss was measured using the alkaline
haematin method of Hallberg and Nilsson (1964a) as modified
by Newton et al (1977) and described in Chapter 9.
Statistical comparisons were made using the Student t
test and a coefficient of variation. Measurements of
menstrual blood loss have been recorded as mean ±SEM.
The perception of day to day changes in measured menstrual
blood loss in each category (e.g. + to ++, ++ to +++, etc)
was averaged for each individual prior to comparison by
Student t test. In assessing accuracy of perception from
one cycle to the next an allowance was made for any error
up to 15% compared with objectively measured losses. For
example, if measured loss in one cycle was 80 mis, an error
of ± 12 mis would be accepted as not being detectable in
the subsequent cycle. Thus, any measured value between
68 and 92 mis would be regarded as indistinguishable from
the prior cycle.
Results
The measured menstrual blood losses (mean of 2 consec¬
utive placebo-treated cycles) of 69 women with a complaint
of menorrhagia are illustrated in fig. 1. It should be
noted that all these women gave a good clinical history







Figure 1. Measured menstrual blood loss (mean of 2
consecutive placebo treated cycles) of 69 women with a
convincing complaint of menorrhagia.
However, only 26 (38%) had a mean loss greater than 80 mis,
another 6 (9%) had one cycle greater than 80 mis and a
further 9 (13%) had a mean loss between 60 and 80 mis. This
gives a total of 41 (59%) who could be considered to have
objective menorrhagia. It is noteworthy that 14 (20%) actually
had a mean loss of less than 35 mis.
At midway and at the conclusion of the four study cycles
each patient was asked to rank the menstrual periods from
"lightest" to "heaviest" according to her perception of the
volume of menstrual flow in each. Measured menstrual loss in
60 women with complete perception records in "lightest" through
"heaviest" cycles was respectively 42.7 ± 4.7 mis; 49.5 ± 7.2;
61.5 ± 6.7; 69.6 ± 7.3 and the volume in the "lightest" cycles
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was significantly less than in the "heaviest" cycles
(t = 3.098; p<0.001). However, there were a large number
of errors in the perception of lightest and heaviest cycles
by individual patients, and only 45% of women correctly
selected the order of all four periods from lightest to
heaviest. Nineteen (32%) made an error in selecting the
"lightest" period and 17 (28%) made an error in selecting
the "heaviest" period. Nine (15%) selected the period
with the heaviest measured loss as "lightest" or vice-versa,
and in some individuals this represented a major error in
volume assessment. The most unusual individual experienced
small losses during placebo treatment (34.6 and 24.8 mis)
and high losses during mefenamic acid treatment (70.6 and
148.0 mis), yet perceived both mefenamic acid treated cycles
as being lighter than placebo cycles.
The duration of bleeding during each of the "lightest"
and "heaviest" periods was compared. There was a small but
not a significant difference between them (lightest =4.7 ±
0.4 days; heaviest = 5.8 ± 0.8 days). Only 9 of the subjects
had periods which regularly lasted longer than 7 days and
their mean placebo cycle loss was 68.2 ± 9.4 mis. This was
not significantly different from the measured loss of the
remainder of the group (61.3 ± 4.9 mis).
Sixty subjects recorded the volume of blood lost each
day on a four point scale of S (spotting or scanty), +
(light), ++ (moderate), to +++ (very heavy). Measured
menstrual blood loss and daily subjective rating are com¬
pared in Table 1. There is a highly significant difference
in menstrual blood loss in the anticipated direction between
the four different points on the daily rating scale in both
mefenamic acid and placebo treatment categories. However,
the range of measured differences in each category was
extremely wide: S = 0.1 to 15.5 mis; + = 0.1 to 63.1 mis;
++ = 0.5 to 108.6 mis; +++ = 1.4 .to 215.8 mis.
TABLE 1
Comparison of measured daily menstrual blood loss and
patients subjective rating of volume (mis; mean t SEM;































t tests: * p<0.02; p<0.005; *** p<0.001
The ability of each individual to assess change in
volume of blood loss from day to day was investigated by
comparing the day to day difference in measured blood loss
with the subjective ratings on successive days. These can
be summarised for the group (n = 60) as follows: + to ++ =
13.1 ± 1.2 mis; ++ to + = 10.6 ± 0.9 mis; ++ to +++ = 15.6
± 2.3 mis; +++ to ++ = 10.0 ± 2.6 mis; + to +++ = 24.9 ±
5.1 mis; +++ to + = 21.7 ± 4.6 mis. The measured difference
for a perceived increase in bleeding from + to ++ compared
with a major perceived increase from + to +++, was barely
significant (t = 2.252; p<0.05). A similar result was
found comparing perceived decreases from ++ to + with +++
to + (t = 2.368; p<0.02). Although these results indicate
that the women as a group were able to make some distinction
between the volume of menstrual blood loss on successive
days there was a very large variation in day to day percep¬
tion by most individuals. The day to day perception diff¬
erences have been compared with the measured menstrual
blood loss differences in Fig. 2. Figure 2a illustrates
the day to day perceived differences after they have been














Perceived day to day differen¬
ces in menstrual bleeding
compared with objective measure¬
ments of the actual differen¬
ces in 60 women over 2 placebo-
treated menstrual cycles.
(a) Average data for each
woman so that each individual
does not appear in any column
more than once.
(b) All data from all cycles
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In figure 2b every day to day change in the whole trial
has been recorded rather than using the patient as the
unit for analysis. This clearly illustrates the difficulty
which most women had in assessing individual day to day
changes in blood loss. It is only necessary to look at
the third column (+ to +++) in figure 2b to see that four
subjects who actually experienced a reduction in blood
loss have perceived this as a large rise (from light to
very heavy)!
In discussing these changes with the women in retro¬
spect it was not possible to identify any factors which
were obviously responsible for influencing errors in
perception. However, it was suspected that accompanying
dysmenorrhoea might have some influence. This proved to be
quite incorrect when perception was compared with measured
menstrual loss on those days when pain was mild or absent
and on those days when pain was recorded as moderately or
extremely severe. When pain was mild or absent perception
of volume of loss (+, ++ or +++) compared with measured loss
was as follows: + = 7.5 ± 0.7 mis; ++ = 19.4 ± 1.6 mis;
+++ = 26.6 ± 4.1 mis; and on days with severe pain the comp¬
arison was very similar: + = 6.3 ± 1.2 mis; ++ = 14.2 ±
1.6 mis; +++ = 23.6 ± 3.0 mis.
It seemed that age of the patient might also be a
factor which influenced perception, and a clear trend was
indeed identified. There were very few teenagers in the
study so that a "younger" and an "older" group (aged 26
and under, n = 9; and 37 and over, n = 15) were selected for
comparison. In the under 27 group perception compared with
daily measured loss as follows: + = 5.1 ± 1.7 mis; ++ =
13.8 ± 2.4 mis; +++ = 11.6 ± 2.2 mis. In the over 36 group
the corresponding figures were: + = 10.1 ± 1.6 mis; 20.1 ±
1.8 mis; 32.0 ±3.3 mis. There was a significant difference
between the age groups in their perception of moderate (t =
2.118; p<0.05) and very heavy loss (t = 4.421; p<0.001).
The younger age group had the same measured loss for days
which they had recorded as moderate (++) or very heavy (+++).
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There was no significant correlation between the numbers of
menstrual pads or tampons used per cycle and the measured menstrual
blood loss in the same cycles for all 69 women followed over 4
cycles each (figure 3; r = 0„138; p>0.1).
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Figure 3:
Scattergram comparing
average number of menst¬
rual pads or tampons used
per cycle from 2 placebo-
treated cycles with the
average measured menstrual
blood loss per cycle from
the same 2 placebo cycles.
In Table 2 it can be seen that the coefficient of variation of
number of pads/tampons used per menstrual period is much less
than the coefficient of variation of measured menstrual blood loss
in the same periods, suggesting that the adjustment which most
women make to their pad usage from cycle to cycle is less than any
change in actual menstrual loss.
Five examples of the wide variation which can occur is given
by the following examples:
1. Subject A used 58 pads/tampons in each of 2 successive
cycles. Measured loss in one was 102.5 mis and in the
next was 202.2 mis.
2. Subject B used 21 pads in cycle one where the measured
loss was 101.1 mis. In cycle 2 she used 23 pads and
measured loss was 275.8 mis. Six cycles later she also
used 21 pads and the measured loss was 336.3 mis.
3. Subject C used 11 pads/tampons in cycle one where measured
loss was 103.7 mis. In cycle 2 she used 8 pads/tampons
and the measured loss was only 15.1 mis.
4. Subject D used 19 pads in cycle one where measured loss
was 15.6 mis. In cycle two where the measured loss was
also 15.6 mis she used 29 pads.
5. Subject E used 48 tampons in one cycle where the loss was
9.6 mis, and 2 cycles later used 42 tampons when the loss
was 16.1 mis.
TABLE 2:
Comparison of pad/tampon usage with measured menstrual blood
loss during menstruation (2 cycles with each treatment in
each of 60 women).
Coefficient of Coefficient of Mean (±SEM) Mean (±SEM)
variation of variation of pad/tampon measured
number of pads measured usage per menstrual
and/or tampons menstrual period blood loss
per period blood loss per period
(mis)
Placebo








This treatment trial was carefully planned to allow an assess¬
ment of subjective perception by the patient of her menstrual blood
loss for comparison with the objective measurement of changes in
blood loss. The women were very carefully instructed and given an
information sheet at the outset of the trial and were questioned
again in detail midway and at the end of the trial.
The first striking finding was that the majority of women
who were enrolled into the trial and who gave a clear history of
excessively heavy bleeding did not really have objective
"menorrhagia", if the criterion of over 80 mis per menstrual period
is taken (Hallberg et al 1966) . Hallberg and colleagues have
calculated the 95th percentile of the normal range at 76.4 mis but
have indicated that some women who lose between 60 and 80
mis per cycle may also be at some risk of developing
increasing iron deficiency. If this criterion is taken
then 59% of the women in the present study could be said
to qualify as suffering from true menorrhagia. Sixty mis
may be a more realistic upper limit of normal. However,
this still leaves a substantial proportion (41%) who cannot
by any objective measurement be said to exhibit menorrhagia,
but who still perceive their periods as being excessively
heavy. Many of these women use large numbers of pads and/
or tampons per period although some of these pads are barely
discoloured after use. In one extreme case 48 tampons were
used when the measured loss was only 9.6 mis. This finding
accords with the Swedish population study of Hallberg et al
(1966) who recorded that 45% of the women who reported "heavy"
periods had measured blood loss of less than 40 mis, and 13%
less than 20 mis. However, it is not so clearly in agreement
with the study of Haynes et al (1977) who investigated women
presenting to a gynaecological clinic in the United Kingdom
with heavy periods. These authors found that 53% of the women
had a measured loss which was repeatedly greater than 80 mis
and of the 24% with measured loss consistently less than 80 mis
almost all admitted to a recent subjective decrease in loss and
required no treatment.
The present study indicates that when a woman states that
she has had very scanty bleeding or spotting on a particular
day she will probably have lost about 2.5 mis. However, the
range of daily blood loss volumes recorded for "scanty" or
spotting was from 0.1 up to 15.5 mis! Findings in the other
3 categories indicate a similar wide variation: with "light"
bleeding equivalent to 5.7 mis (0.1 to 63.1 mis); moderate =
16.1 mis (0.5 to 108.6 mis); very heavy = 22.0 mis (1.4 to
215.8 mis).
It has been suggested that some women confuse duration
of menstruation with "heaviness" of the menstrual flow
(World Health Organization 1979) and it has been demonstrated
previously that women with longer menstrual periods do tend
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to have a heavier loss (Barer and Fowler 1936), No
evidence for a relationship between perception of volume
and duration has been found in the present study. It is
generally accepted that "normal" menstrual periods may
last between 2 and 8 days (Guillebaud and Bonnar 1978), and in
this study only 13% of subjects had a menstrual flow of
greater than 7 days. Also in this study, it has not been
possible to implicate simultaneous dysmenorrhoea as a
factor in the incorrect perception of heavy menstrual
bleeding. It does seem likely that age may be a factor in
the perception of heavy bleeding, in that younger women may
tend to have a lower tolerance of heavy bleeding, or older
women may tend to accept heavier bleeding than they would
have been prepared to tolerate when younger. The younger
women in this study did have lighter measured menstrual loss
than the older women and also perceived their daily menstrual
loss as being excessively heavy when the older women per¬
ceived a similar loss as light or moderate. Larger popul¬
ation studies will be needed to confirm these findings.
It was demonstrated many years ago (Barer and Fowler
1936) that the number of "napkins" used per menstrual
period was not very reliable as a measure of the volume of
menstrual flow in an individual. However, that study did
suggest that in general the number of napkins used para¬
llelled the menstrual blood loss. The criterion of pad
counting has been successfully used to demonstrate the response
of patients with menorrhagia to treatment (Jacubowicz and
Wood 1979), but under most circumstances this method cannot
be considered satisfactory. In the present study no signif¬
icant relationship could be demonstrated between pad and
tampon counts and the measured blood loss, and there were
some extreme examples of lack of correlation in individuals.
Some of the women in this study felt that at some stages of
their period they were losing fluid which was very dilute
compared with pure blood. It appeared that the perception
of volume might be based partly on a loss of endometrial,
cervical or vaginal fluid which was not measured by a method
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based on detection of haemoglobin. In normal women the
percentage contribution of blood to the total menstrual
loss varies greatly from subject to subject with a mean
of only 35% (Chapter 9). No information is available in
women complaining of menorrhagia. It has been stated that
completely wet pads will absorb approximately 90 mis of
blood while a tampon will absorb approximately 40 mis
(Beller and Schweppe 1979), but it is quite obvious that1
no woman will allow a single pad or tampon to reach such
a degree of saturation. Therefore, it is likely that
frequency of changing of pads and tampons will be influenced
by many factors apart from volume of flow, and these may
include personal factors (ideas of hygiene and cleanliness),
age, racial factors, education, climate, physical activity,
menstrually-related urinary frequency or diarrhoea, avail¬
ability of toilet facilities and, recently, recommendations
about tampon use in relation to toxic shock syndrome.
This trial has demonstrated that many women have great
difficulty in determining whether their menstrual loss is
heavy or light and in detecting any change in blood loss
from one cycle to the next and from one day to the next
with any accuracy. There is much need for a detailed study
of those factors which influence each woman's perception
of her blood loss, with a view to defining, if possible,
means of obtaining a more accurate historical assessment
of menstrual blood loss.
Many doctors are not aware of the extent of errors in
menstrual perception and it seems likely that large numbers
of hysterectomies are performed for "menorrhagia" which cannot
be objectively confirmed. One physician has even gone so
far as to say "I am unaware of any other important organ that
is electively removed without first assessing its degree of
malfunction" (Greenberg 1981). In Australia it is calculated
that about 40% of women will undergo hysterectomy (Selwood
and Wood 1978) and in many the indication is likely to be
"menorrhagia".
It should be recognised that, at present, the only
reasonably accurate means of assessing volume of menstrual
blood loss is to measure it by an objective technique such
as that described by Hallberg and Nilsson (1964a) and
modified by Newton et al (1977). This should become a





Two methods utilizing inert gas clearance have been
developed for the measurement of endometrial blood flow
(EBF) in non-pregnant women. A Krypton-85 rebreathing
technique allowed measurement of superficial EBF by use of
an intra uterine semiconductor B~detector probe. Intra¬
uterine instillation of Xenon-133 in saline allowed EBF
measurement by gamma camera recording of the rate of
clearance. Both these methods permitted calculation of
absolute rates of EBF and comparison of cyclical changes.
Several types of equipment have been developed and
evaluated in women and a computer analysis programme has
been developed. The two techniques have been directly
compared in 3 women with close correlation, and the Xe-133
technique has been carried out on 2 or 3 successive
occasions on the same day in 5 women with similar close
correlation. Vaginal blood flow measured by Xe-133 clear¬
ance (3 women) was always much lower than EBF measured
simultaneously by Xe-133 clearance in the same women.
The Kr-85 (10 comparisons) and Xe-133 (11 comparisons)
methods have both been assessed by direct comparison with
a radioactively-labelled microsphere (15 y diameter)
technique in sheep. In seven instances, the Kr-85 clearance
curve had only one component while in the remaining 3 instances
the curves could be resolved into 2 components. The flow
rates derived from the single component curve and the mean
flow rates calculated from the curves with 2 components were
of the same order as, and highly correlated with, estimates
of capillary blood flow obtained with microspheres for either
the caruncles, the intercaruncular endometrium or the total
endometrium (r = 0.832, r = 0.822 and r = 0.841, respectively;
p<0,005). There was no correlation between the flow rates
obtained with the Kr-85 technique and estimates of myometrial
capillary blood flow obtained with microspheres.
Seven of the Xe-133 clearance curves in sheep exhibited
* Caruncles are specialised areas of endometrium
found in sheep and related species on which
placental adherence occurs during pregnancy.
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2 components ("fast"and"slow") with flow rates approximating
the rate of capillary blood flow in the caruncular and inter-
portions of the endometrium, respectively. In each of the
remaining 4 curves which provided a single estimate of flow,
the derived blood flow rate was similar to the rate of
capillary blood flow in both the caruncular and inter-
caruncular portions of endometrium.
Overall comparison with caruncular (r = 0.974; p<0.001)
and intercaruncular (r = 0.959; p<0.001) flow was excellent,
and the respective mean flow rates did not differ significantly.
No relationship existed between myometrial capillary blood
flow and the flow rates derived from Xe-133 clearance curves.
The bicornuate uterus of the ewe allowed an assessment
of local effect of an intrauterine probe on endometrial
capillary blood flow. A significant elevation of local
endometrial flow was found in the region in contact with the
probe while myometrial flow was usually unchanged.
A detailed study of EBF was carried out in 17 women
with normal menstrual cycles (28 estimations) and 20 women
with dysfunctional uterine bleeding (32 estimations; 6
anovulatory and 14 ovulatory women). A mean blood flow of
27.7 ml/100 g/min (± 2.6, SEM) was recorded in the women
with normal cycles, but marked changes were seen at different
phases of the menstrual cycle: early follicular phase 19.3
ml/100 g/min (n = 6); mid follicular 39.6 ±5.5 (n = 8);
periovulatory 12.5 (n = 4); early luteal 23.5, (n = 3),
mid luteal 32.8 (n = 4); late luteal 30.1 (n = 3). A
significant correlation with plasma oestradiol levels was
found in the normal follicular phase (r = 0.760; p<0.05).
Luteal phase EBF did not correlate with plasma levels of
oestradiol or progesterone.
Similar cyclical changes were seen in women with
ovulatory DUB, but mid follicular phase EBF was significantly
lower than in controls (25.2 ± 3.5 ml/100 g/min; n = 9;
p<0.05). As with normal controls a moderately high rate of
EBF was recorded in the late luteal phase (38.8 ml/100 g/min).
Anovulatory women exhibited variable and frequently elevated
rates of EBF.
Chapter 11
METHODOLOGY OF ENDOMETRIAL BLOOD FLOW MEASUREMENT IN
WOMEN:
INTRODUCTION:
It seems probable that there is a relationship between
the volume of blood lost at menstruation and the rate of
blood flow through the endometrium over the same period of
time. However, there is virtually no information on changes
in endometrial blood flow through the menstrual cycle in
women with normal or abnormal cycles.
Several techniques have been used in an attempt to
study different aspects of human uterine blood flow. Electro
magnetic flowmeters can give a measure of flow through a
single uterine artery for a short period of time during
operation and immediately following a period of acute
handling of the vessel (Klingenberg 1973). A variety of
clearance techniques have been investigated including heat
(Loeser 1948; Prill and Gotz 1961; Akerlund, Bengtsson and
Carter 1975) hydrogen (Klingenberg 1969; 1974) and Xenon-133
(Munck et al 1964; Jansson 1969; Secher et al 1973; Forssman
1973). Heat clearance allows repeated or continuous measure
ments of relative changes in flow in the conscious patient
but does not give an absolute measure of flow. However,
it is sensitive to very rapid changes in flow. The inert
gas clearance techniques will theoretically give a measure
of absolute flow in a portion of tissue, and can be used
repeatedly but not continuously in the conscious woman.
Inert gas clearance can only be used to assess slow changes
in flow rate (e.g. hour to hour rather than minute to
minute). There are no published studies where two methods
have been simultaneously compared, and with some techniques
it is not always clear exactly what is being measured.
In this chapter two different inert gas clearance
techniques are described. These methods should both be
capable of providing an absolute measure of blood flow in
the human endometrium with safety and with only minor
m
inconvenience to the subject. Validation of these tech¬
niques in ewes is described in Chapter 12. Results of
application of the Xenon-133 clearance in women is described
in Chapter 13.
The work described in Chapter 11, 12 and 13 was designed,
executed and analysed solely by the author apart from valuable
technical assistance from Dr P. E. Mattner and Mr B. W. Brown
with the sheep experiments, Dr D. Macey with refinement of
the clearance techniques and Mr B. Hutton with development
of the computer programmes.
MATERIALS AND METHODS:
Isotope characteristics and radiation hazards.
1. Krypton-85 (Kr85)
Greater than 99% of radioactive emission is in the
8-particle range; maximum energy 670 KeV. Maximum range of
penetration is about 230 mg/cm2 which is equivalent to about
2.2 mm in tissue. It is calculated that greater than 90% of
the observed counts by a surface 8-detector arise from the
superficial 0.7 mm of tissue (Thorburn, Casey and Molyneux
1966). Less than 1% of radioactivity is ^-emission with
peak energy of 514 KeV. Radioactive half-life is 10.6
years.
2. Xenon-133 (Xe133)
Main radioactive emissions is in the ^-range with an
energy peak at 81 KeV. A weak 8-particle with energy of
340 KeV (maximum tissue penetration of 1.1 mm) and &-rays
of 34 KeV are also released. Radioactive half-life is
5.3 days. Gamma rays will penetrate through soft tissue
without significant attenuation .
3. Krypton and Xenon are both biologically and chemically
inert, non-toxic gases which diffuse very rapidly through
tissues. Ninety five percent of each is excreted from the
bloodstream in one passage through the lungs (Bentivoglio
et al 1963), and therefore recirculation is minimal.
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Although fat has a 9-fold greater affinity for these gases
than other body tissues, it is still rapidly cleared from
fat into the bloodstream as blood levels are reduced through
excretion by the lungs. The equilibrium concentration of
Xenon in air in contact with water is 10 times higher than
the concentration in water (Ladefoged and Andersen 1967).
The principles of inert gas washout techniques have been
studied in several tissues (Kety 1951; Lassen 1971;
Hoedt-Rasmussen and Veall 1971).
Radiation hazards are very low. For example a 1 m Ci
intravenous injection of Xe133 delivers only 14 mrads to
the lung and 0.1 to 0.4 mrads to the gonads (International
Commission on Radiological Protection 1971). Intrauterine
Xe133 (100-200 yCi) will give a gonadal radiation dose of
less than 0.5 mrads (Forssman 1974). Rebreathing techniques
for Krypton-85 and Xenon-133 will give slightly higher
gonadal exposures from 0.7 to 1.2 mrads (calculated from data
of Jones 1950). Lung exposure in rebreathing techniques with
0.35 m Ci/Z is 10-20 mrads.
Isotopes were obtained commercially from the Radio¬
chemical Centre, Amersham, Bucks,from New England Nuclear,
Boston, Mass., and as a special order from the Australian
Atomic Energy Research Establishment, Lucas Heights, New
South Wales.
Description of techniques.
1. Krypton-85 clearance from the endometrium measured with
an intrauterine detector probe sensitive to g-particles.
In principle the endometrium is partially saturated to
a steady state with Krypton-85 while a sensitive 8-detector
probe lies in the lumen of the uterus. Krypton administrat¬
ion is then abruptly ceased by switching the rebreathing
apparatus to open circuit. The gas in solution in endomet¬
rial tissue is then removed at a rate which is determined
by the rate of blood flow through the endometrial capillaries,
by the rate of transfer of Krypton across cell membranes
and through tissue (which is rapid) and by the blood/tissue
(??
partition coefficient. The rate of this tissue "washout"
from a cylindical core of endometrium 1-2 mm thick is
detected by the luminal 3-probe, and the blood flow can
then be calculated (see below).
An intrauterine probe of diameter less than 4 mm is
inserted througth the cervix until the fundus is gently
touched and then withdrawn 2-3 mm. Antiseptic precautions
are observed as for insertion of an intrauterine device,
the cervix being cleaned with 1% Cetrimide solution and the
probe previously being sterilised by immersion in a 3%
Cetrimide solution. Care is always taken to minimise
handling of the uterus and a tenaculum is not used if it
can be avoided. In this way it is hoped to minimise
iatrogenic influences on local blood flow. The patient
is allowed 15 minutes resting time following insertion
before any recordings are made, and flow measurements are
always carried out in a quiet environment.
Background counts are measured twice before the
subject partially saturates her tissues by rebreathing
Kr85 (2 m Ci in air) from a 5 litre closed system spiro¬
meter for 90 seconds. Preliminary studies indicated that
60 seconds was sufficient to achieve maximum counts. The
three way valve is then switched to open circuit through
an outdoor vent and excretion of absorbed Kr85 permitted
through lungs. The rate of decrease in radioactivity in
the endometrium is detected by the luminal 3-probe and
registered by standard recording equipment at 10 or 20
second intervals over a 45 minute period. The analysis
is discussed below.
Three semiconductor 3-detector probes were tested
inside the uterus. The most sensitive was a Studsvik needle
detector (Type 5435-B-100; A.B. Atomenergi, Nykoping,
Sweden) of outside diameter 2.2 mm with a lithium drifted
silicon detector of sensitive volume 12.5 mm3 (figure 1).
This was connected through a preamplifer and amplifer to
a standard Ortec Counting System (discriminator, single











Studsvik needle detector (type 5435-
B100)
(a) complete probe in outline (1Q = 8mm;
li = 100 mm; 12 = 114 mm; di = 2.2 mm;
d2 = 4.8 mm)
(,b) Enlarged probe tip containing
detector.
Oakridge, Tenn, USA). This gave acceptable g-sensitivity
for the purposes of this study, but manufacture of the
probe was discontinued in 1975 and further supplies could
not be obtained. A 4 mm probe was developed specially
by the United Kingdom Atomic Energy Research Establishment,
Harwell, Bucks, but even with careful attention to the
amplification system could not be made sensitive enough to
detect the small amounts of Kr8 5 6-particle emission from
the endometrium. A third type of semiconductor probe of
teflon coated catheter type and 3 mm external diameter
(Catelix probe, Tokyo Shibaura Electic Co; Ueda et al 1969)
was found satisfactory for the high levels of Kr-85
administered in sheep (Chapter 12) but was not adequately
sensitive for human studies.
2. Xenon-133 clearance from saline solution instilled into
the uterine cavity and recorded by a gamma camera.
In principle, Xe133 is instilled in a small volume of
normal.saline solution into the uterine fundus. This is
followed by steady uptake into endometrial tissue and
clearance into the venous circulation followed by pulmonary
excretion. The depth of diffusion before removal by the
circulation is unknown and was a concern before animal
testing was carried out (Chapter 12). Radioactivity in the
uterine cavity is detected by an external gamma camera
/Sf
(Searie Pho-Gamma 4; with 28 cm field and a high sensitivity
collimator) and blood flow calculated (see below).
A fine catheter with moderate pliability (Portex
Instruments, Hythe, Kent; Size 4FG, external diameter:
1.34 mm) is inserted through the cervix in a manner which
has recently become popular with embryo transfer technology.
Immediately before insertion the catheter is filled with
Xe133-saline solution from a preloaded syringe whose
radioactivity has been measured, and extreme care is
taken to ensure that there is no air bubble at the tip.
Care is taken to minimise manipulation of the uterus and
a tenaculum is not used. The cervix is gently cleansed with
1% cetrimide solution before insertion. The catheter is
advanced slowly until the fundus is lightly touched and
then withdrawn about 2 mm. Accurate positioning under
the gamma camera is then confirmed (figure 2). Xe133
(100-400 yCi) is instilled within 5 seconds in a volume of
approximately 50 y£ of normal saline solution. The catheter
is then withdrawn slowly and recording immediately resumed.
Background counts are recorded prior to insertion of the
catheter and subtracted from counts before analysis. The
rate of clearance of radioactivity is recorded over a 45
minute period by a computer interfaced with the gamma, camera.
Preliminary studies were recorded as described in Chapter
12 and analysed by hand.
Figure 2:
Gamma camera centred over lower
abdominal region of subject about




The theoretical aspects of inert gas clearance from
tissue have been well described and evaluated by Kety (1951)
and have been applied by a number of investigators to the
study of human myometrial (Munck et al 1964; Jansson 1969;
Klingenberg 1969; Secher et al 1973; Forssman 1973) and
endometrial blood flow (Secher et al 1973).
In applying these methods it is assumed that a highly
diffusible inert gas such as Xenon-133 or Krypton-85 will
achieve diffusion equilibrium between blood and tissue in
a single passage through a capillary bed, provided the
intercapillary distance is relatively small (Kety 1951) .
Under these conditions, the rate of clearance of Kr85 or
Xe-133 will provide a measure of nutrient or capillary
blood flow. Flow through arterio-venous anastomoses will
not be measured.
Figure 3. Simplified Xe-133 clearance curve recorded by
gamma camera following intrauterine instillation of 200 yCi
in 0.05 mis of saline; also illustrating the method of cal¬
culation of fast component and the relative sizes of the two
compartments (Ni & N2).
The washout curves are analysed graphically by hand
or by computer into 2 or 3 single exponential components
on log-linear scales (figure 3). The analysis of the
curves obtained assumes a bimodal distribution of blood
flow into 2 or 3 distinct homogeneously perfused compart¬
ments which are arranged in parallel. The flow rates (F)
in each compartment are calculated from the following
equation assuming a tissue/blood partition coefficient
for Krypton and Xenon of 1.0 (Thorburn, Casey and Molyneux
1966; Chapter 12), and a specific gravity for endometrium
of 1.0:
100 k ml/100 g/min
0.693
th
the half time of the exponential in minutes
The relative sizes of each of the compartments as a
percentage of total tissue mass (m'% and m"%) was calculated
by back extrapolation of the exponents to time zero to
obtain the initial distribution of counts to each compartment
(Ao' and Ao"):
, _ F' x M'%
°
F" x M"%
And the mean endometrial blood flow (F)from the relation:
~
_ (F* x m'%) + (F" x m"%)F " " Too
Experimental data from Chapter 12 indicate that the
mean flow obtained using both compartments gives a more
accurate assessment of total endometrial flow for intra
luminal Xe-133, while the slow compartment (compartment I)
can be discounted for intraluminal probe use with Kr-85.
Analysis of curves by hand involves initial identif¬
ication of the slowest component (after background subtraction)
which is then subtracted from the original raw data curve to
leave the faster component. In occasional experiments an




subtracted. The existence of different components or
compartments points to the existence of portions of endo¬
metrial tissue with different blood flow rates. The time
in minutes taken for counts in each component to fall by
50% is recorded as washout half time (t^).
Analysis is now carried out by computer programme,
although initial studies described in this chapter were
plotted and calculated by hand. Data were analysed with a
computer programme (modified by Dr. Brian Hutton) by fitting
a multi-exponential curve by the least-squares method util¬
izing an iterative function minimisation programme (Powell
1964). The formula for the washout curve was:
A (t) = E [Bj exp (Ajt]
j
Where A is the activity at time t and Bj and Aj (j =
1,2 or 3) are the unknown constants to be estimated for a
2 or 3 component exponential.
Early development of the computer programme allowed
variable sized moveable windows to be drawn around the area
of maximum radioactivity on the visual display screen. This
allowed an assessment of the extent of any leakage into the
vagina (which occurred only once, during the study series in
a patient who was menstruating at the time) or into the
Fallopian tubes (not detected). The computer used was
manufactured by Digital Equipment Corporation (Model PDP
11/34 Gamma II). Steps in the computer analysis are illustrated
in Figure 4.
Ethical approval for studies described in Chapters 11
and 13 was obtained from the Medical Research Council (United
Kingdom), University of Oxford, Oxford Area Health Board,
National Health and Medical Research Council (Australia)
Australian Radiation Laboratories, Royal Prince Alfred Hospital
Ethics Review Committee and the University of Sydney Medical
Ethical Review Committee. It was recommended that no more
than 3 separate measurements be carried out in each individual
subject.
Figure 4. Calculation of Xe-133 clearance data using
computer.
(a) Xe-133 clearance over 45 minutes (10 second segments)
from the specifically delineated uterine area (.ROl A) and
total screen area.
(b) Log-linear plot of count rate against time over 45
minutes. Computer instruction is asking for manual
selection of the section of the curve most representative
of the slow component.
(c) Computer has automatically subtracted the slow component
and is asking for selection of the section of subtracted
curve most likely to represent a straight line fast component.
(d) Computer has automatically calculated clearance data
for each component and checked the best fit to the original
data by the method of least squares; full details of the data
appear on the typed print-out.
I SO
Intrauterine Xe'33 (tOO^Ci)
Figure 5. Two successive Xe-133 clearance curves from the
same subject carried out 20 minutes apart. Only the first
20 minutes of each curve is shown.
Informed consent to participation was obtained
by the author from all individuals who took part in the
studies, and a detailed information sheet was provided.
RESULTS:
Krypton-85 rebreathing.
Six women were studied with this method utilising the
Studsvik needle probe (Table 1). The slow component
(component 1) was always greater than 50 mins. Flows varied
between 14.1 and 59.2 ml/lOOg/min. Insufficient numbers
were studied to assess menstrual cycle changes with any
accuracy, but three of these women also had intraluminal
Xe-133 studies on the same day (Table 2). There was a close
correlation between the two methods, although blood flow
measurements using Kr-85 were higher than the Xe-133 calcul¬
ations in all cases.
Intraluminal Xenon-133 instillation.
A series of investigations were carried out to assess
the validity of the technique.
(i) Repeatability was assessed by giving 2 successive
instillations to 5 women on the same day (Table 3; Figure 5).
An excellent correlation was obtained; the mean (±SEM) of the
first measurement being 28.9 (± 6.0 ml/lOOg/min) compared
with 27.3 ± 4.9 for the second measurement.
(ii) Volume of instillation fluid was increased in 3 women
until spill was recorded in the Vagina by the gamma camera.
Volumes of 0.1; 0.5 and 1.0 mis were used. Spill into the
vagina was recorded in all cases with 1.0 ml, in one case with
0.5 ml and no cases with 0.1 ml. The only exception to this
rule was seen later when one woman on day 2 of menstruation
expelled a small volume of isotope into the vagina about 3
minutes after instillation of Xe-133 in less than 0.1 mis
of saline.
Spread within the endometrial cavity was assessed by
instilling 0.1 mis of crystal violet solution into the uterus
of 3 women after hysterectomy and measuring the area of spread
TABLE1:
























































































































































































































after 5 minutes. Spread was a little irregular but in 2
instances reached the region of one tubal ostium and in
each case was 2-3 cms diameter.
(iii) Air bubbles were a major concern because of the
possibility of Xe-133 sequestration in a bubble. In one
case a normal washout was obtained and then followed by a
washout when 0.1 mis of air was also deliberately instilled.
The washout component half times changed from 78 and 320
sees to 102 and 560 sees suggesting that very small volumes
of air are unlikely to make major differences.
(iv) Vaginal blood flow was compared with endometrial
blood flow at the same time in 3 women (Table 4) utilising
instillation of 0.1 mis of Xe-133 in saline into the posterio
fornix. Those instillations were clearly shown as separate
areas of y-activity on the computer screen (figure 6) and
could be analysed independently. The vaginal slow component
was small and greatly prolonged in 2 cases and absent in
one.
Figure 6. Gamma camera recording of Xe-133 instillation
simultaneously into uterine cavity and vagina. Clearance
curves for each area (A = uterine; B = vaginal) are shown
separately. Clearance from the vagina is substantially
slower than from the uterine cavity.
TABLE4;













































Mean vaginal flow was substantially less than endometrial
flow in all cases but they were not closely correlated.
Statistical comparisons were not attempted in view of the very
small numbers.
(v) Computer analysis of components using the method of
least squares was compared with curve fitting by eye in 10
cases (Table 5) with generally close correlation. In all
cases except one computer calculated mean flow was less than
that derived from curve fitting by eye. Computer-derived
mean flow was 24.5 ± 2.1 (SEM, ml/100 g/min) and eye-derived
mean flow was 26.9 ± 2.3. This is unlikely to lead to major
variation by comparison with biological variation in flow.
DISCUSSION:
Two techniques for the measurement of human endometrial
blood flow have been described in this chapter. Both tech¬
niques give a valid measure of endometrial blood flow (see
Chapter 12), but each may be measuring blood flow in different
depths of tissue. Kr-85 may only give a measure of very
superficial endometrial flow while Xe-133 may diffuse deeper
into the tissue before it is removed. Kr-85 gives a single
component curve relating to endometrial flow while each of
the 2 or 3 components of the Xe-133 curves appear to relate
to some aspect of endometrial flow (Chapter 12).
At first it appeared that Kr-85 might give a measure of
flow which was more relevant to abnormalities of menstrual
bleeding by assessing superficial flow only. In addition,
the method should remain valid during menstruation, whereas
Xe-133 in solution was sometimes expelled into the vagina
after intrauterine instillation during menses if bleeding
was heavy. However, studies in sheep clearly indicated that
the presence of the intrauterine B-probe induced a significant
local increase in endometrial blood flow (Chapter 12). In
view of this and of the difficulty in obtaining adequately
sensitive B-probes the Kr-85 studies were discontinued.
Nevertheless, the small number of studies carried out showed
a close correlation with blood flow calculated from Xe-133
TABLE5:
Comparisonfbestfittwocomponentsadet r edyyncomputera aly is usingmethodofleastsquares. Component1ponent2Meaflow











































































































clearance, and the cyclical pattern was not substantially
different from endometrial blood flow calculated for rhesus
monkey ocular auto transplants (Markee 1950) and for the
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Figure 7. Comparison of endometrial blood at different
stages of the menstrual cycle measured by Kr-85 clearance
in 6 women (ml/10Og/min), and compared with the data of
Markee (1950) in rhesus monkeys (mm/sec;dotted line) and
prill and_Gotz (1961) using a heat clearance technique in
women (.10 Cal. cm x. sec 1 . °C 1 ; continuous line) .
The theory of inert gas clearance as a measure of
capillary blood flow in several tissues including the uterus
has been thoroughly discussed by several authors, and has
been addressed earlier in this chapter. Validation of the
techniques described here has been carried out with radio-
active-labelled microspheres in sheep (Chapter 12). However,
it is necessary to pay moderate attention to detail in order
to obtain consistent results. This includes resting the
subject for 15-30 minutes beforehand in a supine position
in a quiet room with two investigators only. Very gentle
manipulation of the uterus was attempted and great care
was exercised to ensure that air bubbles were not instilled
with the Xenon.
Some consideration was given to the method of analysis
and it was decided that compartment analysis (Thorburn et
al 1966; Forssman 1975) would give a more accurate result
than the initial slope method (Secher et al 1973). Computer
analysis using the least squares method should give more
accurate curve fitting than an attempt by eye, but direct
comparison of these two approaches did not show marked
differences in the assessment of mean flow with Xe-133.
The origin of the 2 or 3 components of the Xe-133
clearance curves is obscure, but presumably relates to regions
within the endometrium which have genuinely different flows.
Theoretically, one might expect different rates of flow in
the superficial endometrium, in the stroma and perhaps around
the glands. It is also possible that endometrium over the
fundus might have different flow from regions nearer the
cervix. This requires study using precise microsphere
techniques in animals.
Initially, great care was taken to assess the safety
of these isotope techniques and radiation dosage calculations
were reviewed. The inert gases, Krypton and Xenon, have rapid
diffusion properties and rapid lung excretion that minimise
radiation risk and several prestigious Scientific and Ethical
Committees reviewed the protocols before human studies began.
These techniques clearly have considerable value for
assessing slow changes in flow with repeated assessments at
intervals of hours, days or weeks. However, they are laborious
and time consuming and are not capable of assessing rapid
changes in flow. In fact, rapid changes in flow of moderate
magnitude during Xe or Kr clearance could make calculation
of the clearance components difficult. This was not found
to be a problem in practice.
In 3 women vaginal blood flow was measured simultaneously
with endometrial flow and was found to be substantially lower
(36-64% of endometrial flow). Calculations of vaginal flow-
were in the same range as those recorded by Wagner and Otteson
(1980), using the same technique.
Chapter 12
VALIDATION OF INERT GAS CLEARANCE TECHNIQUES IN EWES;
INTRODUCTION;
Theoretical considerations suggested that both
Krypton-85 (Kr85) and Xenon-133 (Xe133) techniques should
give reasonable measures of endometrial blood flow without
any interference from flow in the myometrium. However,
these techniques had never been compared directly or
validated against any other method. This could only be
done in an animal species with a uterus large enough for
insertion of a 8-probe, with an endometrium greater than
1 mm in thickness and in whom the radioactively labelled
microsphere technique could also be used. Ideally, a
subhuman primate such as the rhesus monkey (macaca mulatta)
or baboon (papio sp.) with endometrial spiral arterioles
and regular menstruation would have been preferred, but
these were not available. The sheep was chosen because
it fitted the essential criteria and a great deal is known
about its reproductive (oestrous) cycle.
With appropriate care and attention to experimental
details the radioactively-labelled microsphere technique
will provide an accurate measure of absolute capillary
blood flow in a portion of excised tissue (Hales 1973) and
for this reason was chosen as the yardstick for comparison
with the inert gas clearance techniques.
This study was planned, executed and analysed by
myself with the invaluable technical assistance of
Dr. P. Mattner and Mr B. Brown.
MATERIALS AND METHODS:
Measurement of capillary blood flow with the microsphere
technique.
The procedures used to measure capillary blood flow
and cardiac output with microspheres were those of Hales
(1973). Radioactive microspheres were injected into the
left ventricle. These are distributed to body tissues in
proportion to the blood flow to each tissue. Thus, if
the dose of microspheres administered is D counts per
minute (cpm) and d cpm/g is located in a tissue:
J
Fraction of cardiac output to tissue = —
If the cardiac output (CO, mJi/min) is known, a
quantitative measure of blood flow (Q, m£/min) is obtained:
Q = CO x -p-
Cardiac output may be measured from this equation by
introducing an artificial reference organ into the system,
in the form of a constant rate withdrawal pump; if blood
is sampled at f mJl/min and d' cpm is contained in the
sample then:
CO = f x —?Td1
Spheres were injected into the left side of the heart
and sampled through the right femoral artery. In the
present study f was calculated from the weight and specific
gravity of the blood and the duration time of sampling.
By combining the above equations measurement of tissue
capillary blood flow rates (Q m£/100 g/min) may be obtained
without accurately determining the dose of isotope, thus
obviating a possible source of error:
Q = f x —gY x 10°
Microspheres (15 ± 5 urn; mean ± SD diameter) were
suspended in isotonic saline and a drop of Tween 20 added.
Samples were ultrasonicated before injection to prevent
aggregation. A sample from each new batch was examined
through the light microscopic to check diameter and
uniformity of shape.
For the Xenon-133 experiments the intraventricular
dose contained 9-14 x 10s microspheres labelled with either
51chromium, ^scandium or 113tin (New England Nuclear
Company, Boston, MA, U.S.A.) and was delivered in 0.9%
(w/v) saline at 39°C. For the Krypton-85 experiments
15 urn microspheres from the 3M Company, St Paul, Minnesota
(141Cerium, 46Scandium and 85Strontium) were used. Doses
were prepared using an RIDL pulse height analyzer and
scintillation probe (Model 910, Nuclear Chicago, Des Plaines,
111.). Certified nuclide standards accurate to ± 2%
(Australian Atomic Energy Commission) were used in the
calibration of instruments. The 'reference organ' blood
sample from the right femoral artery was withdrawn at
25 m£/min-1. At autopsy, a length of the left uterine
horn extending 1.5 cm either side of the site at which
13 3Xe had been injected or the (3-probe tip had been
positioned was removed. The section was divided into its
myometrial and its caruncular and inter-caruncular endomet¬
rial components. These were weighed and the radioactive
content of each was determined in an autogamma spectrometer
(Packard Instruments, Model 5320, La Grange, 111. U.S.A.;
51Cr, 250-350 keV; "6Sc 840-1220 keV; 113Sn, 355-445 keV) .
Subsamples were taken from each kidney, from fallopian tubes
and ovaries, and sometimes from other tissues to confirm
adequate mixing and bilateral distribution of microspheres.
Portions of tissue counted always yielded counts of >1000
per minute. The gamma spectrometer count was markedly
influenced by geometry of the sample, but this effect was
avoided by filling sample tubes to less than 2 cm high.
Krypton-85 experiments.
Animals
Six mature, parous, Merino ewes were used. Three
ewes were near oestrus and three were at the mid-luteal
stage of the oestrous cycle. The day of oestrus (Day 0)
was determined using a vasectomized ram.
Surgical procedures
On the day prior to the experiment, each ewe was
anaesthetized with halothane while polyethylene catheters
(1.0 mm ID, 1.5 mm OD) filled with heparin saline were in¬
serted into (a) the left ventricle via a small puncture in
the left carotid artery, (b) the left and right femoral
arteries via the saphenous arteries and (c) the left
recurrent tarsal vein. The following day, each ewe was
m
anaesthetized with sodium pentobarbitone for the duration
of the experiment (l-2h). After Laparotomy, the tip of the
detector probe was inserted into the uterine lumen through
a needle puncture made in the middle third of one uterine
horn (fig. 1). It was advanced until the end window lay
in the middle or posterior region of the anterior third
of the same horn and was held in position with a fine
suture through the serosa The genital tract was handled
as little as possible during these procedures. The
catheter in the left femoral artery was advanced so that
the tip was approximately 4 cm cranial to the bifurcation
of the abdominal aorta. After closure of the laparotomy
incision, the animal was kept in a supine position for
approximately % h before administration of 85Kr. Rebreathing
of expired 85Kr was prevented by the use of polyethylene
Figure 1:
Location of the intra¬
uterine 6-detector
probe in the lumen of the




A 3.0 mm diameter, catheter-type, semi-conductor,
silicon p.i.n. type, g-radiation detector (Catelix probe,
Tokyo Shibaura Electric Co.) with a teflon-coated end
window mounted in the tip [Ueda, Sasaki, Iio, Kaihara,
Machida, Ito, Takayanagi, Kobayashi and Sugita, 1969] was
used to monitor g-emissions from 85Kr. The probe output
was analysed by a preamplifier, an amplifier, a single
channel analyser and a counter (Ortec Incorporated,
Oakridge, Tennessee). The printout appeared on a line
printer controlled by a counter timer.
Experimental procedures.
A dose of 7-14 mCi of 8 5Kr (Australian Atomic Energy
Commission, Lucas Heights, N.S.W.) in 5-10 ml of saline
was injected through the aortic catheter and the outputs
of the probe over 10 sec periods were recorded for 40-60
min. Approximately 5 min after the administration of 85Kr,
a dose of 15 urn diameter microspheres (9-14 million spheres)
labelled with either 14-'-Cerium, ^6Scandium or 35Strontium
(3M Company, St. Paul, Minnesota) were injected into the
left ventricle whilst arterial blood was being withdrawn
from the right femoral artery (at approximately 25 m£/min_:L
over 1 min 10 sec) for the determination of cardiac output.
In four ewes, a second dose of 85Kr and of microspheres with
an alternate label to that used previously was administered
after the counts had fallen to background levels.
After completion of each experiment, the animal was
killed with an overdose of anaesthetic and the position of
the probe tip within the uterine horn was determined and
marked with a small suture through the serosa.The probe
was withdrawn and a 2-3 cm length of the uterine horn
which had previously contained the tip of the probe was
excised and separated as described above.
Preliminary testing showed that, with the probe lying
in the uterine lumen, doses of microspheres labelled with
ll+1Ce, 46Sc or 85Sr had no effect on the level of background
counts recorded by the probe.
Test for retention of 85Kr by the detector probe.
In preliminary studies on the clearance of 8 5Kr from
ovine uteri each clearance curve had a component that gave
evidence of there being a compartment of extremely slow
flow. This flow was much slower than the capillary blood
flow rate in any of the uterine tissues. The possibility
that this component was an artefact produced by temporary
retention of 85Kr by the probe [Sasaki, Wagner, Iio, Murao,
Takayanagi and Kobayashi, 1971; Takayanagi and Iio, 1974]
was investigated as follows. 8sKr was injected via an
indwelling catheter into the left uterine artery whilst
the probe was positioned either (a) in the left uterine horn
(b) in the right uterine horn, or (c) initially in the left
uterine horn but transferred into the right uterine horn
a few minutes after the injection of 85Kr.
Analysis of data.
The methods described by Thorburn, Casey and Molyneux
[1966] were used to analyse the 85Kr clearance curves.
Counts of 8-activity (corrected for background activity)
were plotted against time on log-linear paper, the curves
were analysed by graphical peeling into their various com¬
ponents and the blood flow rate (F) for each was calculated
using the equation:
F = 100k ml 100 g-1min-1
where k = 0.693/t^
th = half time of the exponential in minutes assuming
a tissue/blood coefficient for 85Kr of 1.0 and the
specific gravity of uterine tissue to be approximately
1.0.
When multiple compartments of flow were present, the
relative compartment sizes were calculated after back extra¬
polation of the exponents to time zero and the mean flow
rate (Fm) was determined using the methods of Thorburn et ai
[1966].
lol
Estimates of capillary blood flow obtained with the
two methods were compared using paired t test.
Xenon-133 experiments.
Animals.
Six mature, parous Merino ewes were used. Three were
examined at day 8-11 and three at day 15-16 of the oestrous
cycle (day of oestrus equals day 0) to broaden the range
over which comparisons of estimates of blood flow could be
made.
Surgical procedures.
On the day prior to the experiment, each ewe was
anaesthetized with halothane while polyethylene catheters
(1.0 mm i.d., 1.5 mm o.d.) filled with heparinized saline
were inserted into (a) the left ventricle via the left
carotid artery, (b) the right femoral artery via the
saphenous artery, and (c) the left recurrent tarsal vein.
On the day of the experiment, each ewe was anaesthetized
with pentobarbitone sodium (administered via the catheter
in the recurrent tarsal vein) for the duration of the exp¬
eriment (1-1% h). With the animal in a supine position,
the uterus was exposed via a mid-ventral abdominal incision
and a puncture wound was made with a 25 S.W.G. hypodermic
needle through the wall of the left uterine horn in its
middle third. The uterus was returned to the abdominal
cavity and 2 min later, a dose of microspheres was admin¬
istered into the left ventricle (see below). Five minutes
later, a dose of radioactive 133Xe (Radiochemical Centre,
Amersham) was injected into the lumen of the left uterine
horn through a 25 S.W.G. hypodermic needle inserted at the
site of the previous puncture wound. In five ewes the
procedures were repeated 45 min later using microspheres
labelled with an isotope different from that used initially.
On the conclusion of the experiment, the ewe was killed with
an overdose of pentobarbitone sodium.
Measurement of blood flow with the Xenon-133 clearance
technique.
A dose of 3.0-5.5 MBq of 133Xe in 0.2 ml of saline
(0.9% w/v) at 39° was injected into the lumen of the left
uterine horn as previously described. The uterus was
immediately returned to the abdominal cavity and the
abdomen was temporarily closed with towel clips. A
scintillator probe containing a 5 cm sodium iodide crystal
was quickly positioned over the abdomen immediately above
the uterus and the y emissions were subsequently monitored
for 30 min. The delay in positioning of the scintillator
probe was 10-20 s. The probe was connected to an amplifer,
a single channel analyser and a counter system (Ortec In¬
corporated, Oakridge, TN, U.S.A.) and the accumulated counts
for each 12 s interval appeared on a line printer controlled
by a counter-timer.
The data were analysed with a computer program as
described in Chapter 11.
RESULTS:
Krypton-85 experiments.
(a) Retention of 8sKr by the detector probe.
Following the injection of 35Kr into the left uterine
artery, a clearance curve of the type shown in Fig. 2 was
obtained when the probe was in the left uterine horn. How¬
ever, no counts were detected when the probe was in the right
uterine horn throughout the procedure. When the probe was
transferred from the left to the right horn partway through
a clearance study, it continued to register radioactivity,
the levels declining at a rate which approximated that of
the usual slow component. Over 10 clearance studies, the
contribution of this artefactual component was equivalent
to a flow rate of 1.7 ± 0.14 ml 100 g-1min-1.
Figure 2. A two component exponential curve for the clearance
of 8SKr from an ovine uterus. Only the initial 20 min of the
60 min clearance time is shown. The two components are rep¬
resented by the straight lines. (0) Totals counts of S-particle
per 10 sec interval. (x) Total counts minus corresponding
values derived from component I to define component II
{Thornburn et al., 1966 } see Analysis of data.
(b) Estimates of blood flow.
The clearance curves plotted from the original counts
(background-corrected) always had at least two components
(see Fig.2) but on three occasions, three components were
present. As the slowest component of each curve was an
artefact associated with temporary adsorption of 9 5Kr to
the probe (see section (a) above) the contribution of this
component was subtracted from the original counts. The
resultant curve was described by a single exponential
function in seven instances and by two exponential compon¬
ents in three others. The blood flow rates (F) calculated
from the former curves, together with the mean flow (Fm)
calculated from the latter curves are compared in Table 1
with estimates of capillary blood flow (Q) obtained for
the uterine tissue with the microsphere technique.
Considering only the seven clearance curves with a
single component, the estimates of blood flow obtained with
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the caruncles, the inter-caruncular endometrium or the total
endometrium (caruncles plus inter-caruncular endometrium)
(r = 0.819, r = 0.799 and r = 0.920, respectively, p<0.05)
• •
but not with Q for the myometrium. The mean Q values for
each of these tissues did not differ significantly from
each other or from the mean of the flow rates obtained with
the 85Kr method. In the three instances in which the clear¬
ance curves had two exponential components, the blood flow
in the compartment with the faster flow accounted for 20-
40% of the mean flow. However, in each instance, neither of
the two flow rates were similar to Q for either the caruncles
the inter-caruncular endometrium or the total endometrium
but the mean flow rate approximated the Q values for these
tissues. Considering all data, there was little change in
the correlation coefficient for estimates of blood flow
(F together with Fm) obtained with the 8 5Kr method and Q
for the caruncles, inter-caruncular endometrium and total
endometrium (r = 0.832, r = 0.822 and r = 0.041, respectively
p<0.005, see Fig.3).
The mean (+SEM) capillary blood flows (measured with
microspheres for the left and right kidneys were 284.8 ±
22.0 ml 100 g-1min-1 and 298.5 ± 35.9 ml 100 g~1min-1 respec¬
tively and were of the same order as previously published
values obtained in anaesthetized sheep [Bruce and Moor, 1976]
This suggests that the microspheres were distributed to the
tissues in the same proportion as was the cardiac output and
thus provided reasonable estimates of capillary blood flow
(Q) in the uterine tissues.
(c) Local influence of probe on endometrial blood flow.
Presence of the 6-detector probe in one uterine horn
produced a significant local effect on endometrial but not
myometrial blood flow (Table 2). Endometrial and caruncular
blood flows in the segment of uterine horn containing the
8-probe were significantly higher than in the equivalent
segment of the opposite horn (endometrial flow = 53.2 versus
33.7 mls/lOOg/min; paired t = 3.907, p<0.01; caruncular flow:
54.4 versus 38.7 mls/lOOg/min; paired t = 3.764, p<0.02).
TABLE2:





































































































Figure 3. Relationship between estimates of blood flow
obtained by the 8 5Kr and microsphere methods for uterine
tissue in six anaesthetized ewes. (a) caruncles, (b) inter-
caruncular endometrium, (c) total endometrium (caruncles
plus inter-caruncular endometrium), (d) myometrium.
Figure 4. A two-component exponential curve for the clear¬
ance of 133Xe from the ovine uterus. The two components
are represented by the straight lines. 0, total counts
of y particles per 12 second intervals. 0, total counts
minus corresponding values derived from component I to
define component II.
There was no significant difference in myometrial flow.
Total flow in the segment was greater but did not reach
statistical significance.
Xenon-133 experiments.
The clearance curves obtained after intra-uterine
injection of 133Xe comprised eight with two components
(see Fig.4) and three with a single component. A compar¬
ison of the blood flow rates (F) calculated from the curves
and the estimates of uterine capillary blood flow (Q)
obtained with the microsphere technique is shown in "Table
3.
With curves containing two components (curve 5172a
excepted), the fast flow (Fx) was generally of a similar
value to that of Q for the caruncles, the flow in the slow
compartment (F2) approximated Q for the inter-caruncular
endometrium and neither the F, nor the F value resembled
2
Q for the myometrium. In each of the three curves described
by a single exponential (7009b; 7009a,b), derived flow rate
F and the Q values for both the caruncles and the inter-
caruncular endometrium were of a similar order.
In the case of curve 5172a, the slow component appeared
to be an artifact because the derived compartment size (7%)
was minute compared to that of the slow compartment in all
other experiments (63.5%, SEM 6.4) and its flow rate bore
no relation to Q for any of the uterine tissues. Consequently,
it appears that the curve was more correctly represented by
a single exponential component with a flow rate approximating
Q in the caruncles and in the inter-caruncular endometrium
as in the above three instances (7008b; 7009a,b).
Taken together, the F1 values from the two-compartment
curves and the F values from single-compartment curves were
highly correlated with the corresponding Q values for
caruncles (r = 0.974, p<0.001) and the respective means (±
SEM) did not differ significantly (55.8 ± 10.3 cf. 59.9 ±
1 — 1
11.4 ml 100 g~ min ). Similarly, when considered together,
the F 2 values from two-component curves and the F value for
TABLE3:
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single-component curves were highly correlated with the
corresponding Q values for inter-caruncular endometrium
(r = 0.959, P<0.001) and the respective means (±SEM) were
not significantly different (32.3 ± 10.7 cf. 37.3 ± 9.1 ml
100 g-1min-1). There was an extremely poor relationship
between Q for the myometrium and either the Fx or the F2
values derived from the 133Xe clearance curves (r = 0.274
and r = 0.156, respectively, p>0.3).
DISCUSSION:
Krypton-85 experiments.
Since the average range of penetration of 6-particles in
tissue is less than 1 mm [Casey and Thorburn, 1965; Thorburn
et al. , 1966; Einer-Jensen, 1977] and the thickness of the
endometrium in sections of uteri taken from the experimental
ewes varied from 1.7 to 2.2 mm, it would be expected that the
majority of the 8-emissions detected by a probe lying within
the lumen of the uterus would arise from the endometrium only.
The extremely good correlation between the blood flow rates
obtained with the 8 5Kr method and Q values for the endomet¬
rial tissues as well as the general similarity of the estimates
of flow obtained with the two methods are in accord with this
expectation.
In an earlier and very preliminary study [Brown, Fraser
and Mattner, 1977] in which the efficiency of {^-detection
by the probe used was only 20-25% of that for the probe in
the present study, the F values though highly correlated with
Q for the endometrium (r = 0.985, p<0.005), were many times
smaller than Q. Thus, it appears that the sensitivity of
the probe used is an important factor in determining whether
the F value obtained is merely an index or a reasonable
estimate of the endometrial capillary flow. Nevertheless,
differences between individual Q and F values could be
expected to occur. Estimates obtained with microspheres
relate to flow during lodgement of the microspheres (approx¬
imately 30 sec; Hales and Cliff [1977] while those provided
by the 8 5Kr method represent mean values over the initial
10-15 min of the clearance time.
On the three occasions when the 8 5Kr clearance curve
was composed of two single exponential components, neither
compartment of flow could be related to any region or
tissue within the endometrium. Nor could the occurrence
of two compartments be attributed to effects associated
with stage of oestrous cycle. Additionally, with sheep
No. 700, two components were evident in only the first
of the two clearance curves obtained (see Table 1). When
two components were present, the mean flow rate approximated
Q for the endometrial tissue. It is possible that factors
such as handling of the uterus or contact of the probe with
the endometrium may have at times caused local changes in
blood flow within the endometrium without the total blood
flow to the areas involved being altered. An increase in
flow rate in some capillary beds and an associated decrease
in flow rate through adjacent beds could result in hetero¬
geneity of blood flow being recorded. Q being a mean value
would not reflect such changes.
This study clearly shows that there is a local effect
of the B-probe on endometrial blood flow in the region
in contact with the probe. This effect was seen as an
increase in endometrial blood flow with no effect on
myometrial flow. This study was unable to assess whether
the effect persisted with time, but does raise major
concerns about the advisability of using a probe technique
to measure absolute blood flow changes in endometrium
under different circumstances. It was encouraging to
find that a similar local effect was not seen in the
experiments where Xe-133 was injected into one horn. The
mechanism of this local disturbance of flow could involve
changes in prostaglandin secretion (or other locally
released vasoactive substances) of a degree which is
insufficient to influence the myometrium.
Xenon-133 experiments.
The data from the present study in ewes indicates
that when 13 3Xe diffuses from the uterine lumen into the
endometrium, it is cleared by the vasculature before it
reaches the underlying myometrium. Thus, whether the
clearance curves contained one or two components, the
derived blood flow rates were related to Q in the caruncular
and intercaruncular portions of the endometrium and not to
Q in the myometrium. The introduction of even a minute amount
of air into the uterus during deposition of the 133Xe solution
would allow some of the 133Xe to occur in the gaseous phase
with a consequent delay in the rate of clearance of that frac¬
tion of the marker from the uterus. Such an occurrence may
have contributed to the apparent presence of a second very
slow compartment of flow in observation 5172a in the present
study.
On well-established theoretical grounds, a correction
factor corresponding to the tissue-blood coefficient of the
gas (0.7 for xenon in most tissues; Andersen & Ladefoged,
1967) is usually included in the calculation of tissue blood
flow rate (F) from xenon clearance curves. However, in the
present study, in which reference values for the capillary
blood flow (Q) in the uterine tissues were provided with the
microsphere method, there was general agreement between the
F values calculated when a value of 1.0 was assigned as the
tissue-blood partition coefficient and the Q values for the
relevant tissues. It appears, therefore, that when 133Xe
is introduced into the uterine lumen, the effect of the
endometrium-blood diffusion equilibrium on the rate of
clearance of the gas from the endometrium is counterbalanced
by some other factor, possibly the endometrium-luminal fluid
diffusion equilibrium, with the result that realistic
estimates of endometrial blood flow rates may be obtained
without reference to the tissue-blood coefficient. Complete
agreement between paired estimates of endometrial blood flow
rates determined with the gas clearance and the microsphere
methods would not be expected because the period over which
the flow is assessed is considerably longer with the former
than with the latter method.
Chapter 13
ENDOMETRIAL BLOOD FLOW IN WOMEN USING XENON-133
CLEARANCE:
INTRODUCTION:
In this chapter a series of measurements of endometrial
blood flow in women with normal menstrual cycles and with
dysfunctional uterine bleeding is described. After extensive
preliminary investigations described in Chapter 11 and 12
the technique of Xenon-133 clearance from the uterine cavity
was chosen to give a confident and repeatable measure of
blood flow in superficial endometrium at different stages of
the menstrual cycle.
These studies were carried out both in Oxford (Depart¬
ment of Radiation Physics, Churchill Hospital) and in
Sydney (Department of Nuclear Medicine, Royal Prince Alfred
Hospital).
CLINICAL MATERIAL AND METHODS:
Endometrial blood flow measurement was carried out using
the intrauterine Xe-133 clearance technique as described in
detail in Chapter 11.
Subjects studied included 17 women with normal menstrual
cycles (Table 1) and 20 women with dysfunctional uterine bleeding
(6 anovulatory; Table 2). These women were studied at different
stages of the menstrual cycle and 15 were studied on more than
one occasion (7 normal cycles; 8 DUB).
Almost all subjects also had plasma oestradiol and
progesterone measured at the time of blood flow studies,
and most had several samples taken at other stages in the
same cycle. All women kept an accurate note of data of each
preceding and succeeding menstrual period and a few maintained
basal body temperature and vaginal mucus charts. A combin¬
ation of these pieces of information permitted dating of
each blood flow measurement to an idealised 28 day menstrual
cycle, except in those women with a history of anovulatory
DUB.
TABLE 1:
Clinical data on 17 women with normal menstrual cycles who underwent endometrial blood
flow studies.
Subject Age Cycle Days Since Plasma Steroid Levels Endometrial Ideali:
Number Length L.M.P. Oestradiol Progesterone Histology Cycle 1
(pg/ml) (ng/ml)
CI 41 25-28 7 555 < 1 P 10
C2 39 30-35 7 115 < 1 P 5
C3 28 26-33 12 620 < 1 LP 12
C4 37 28-31 4 - - P 4
C5 25 28-35 23 160 14.7 MS 22
C6 36 30-35 20 185 9.8 ES 18
C7 32 24-28 8 285 < 1 P 10
C8 37 28-35 10 255 < 1 P 9
C9 39 29-32 26 410 15.2 - 24
24 365 12.6 MS 21
CIO 30 27-32 25 290 8.5 - 23
5 115 < 1 - 5
11 345 < 1 - 11
Cll 32 28-34 14 490 < 1 - 12
C12 28 27-30 26 290 6.1 - 26
18 360 10.9 - 19
C13 31 24-29 5 385 < 1 - 8
1 135 1.1 - 1
3 150 < 1 - 3
C14 35 27-29 14 335 < 1 - 14
9 220 < 1 - 8
28 105 1.3 - 27
C15 30 30-34 15 200 1.8 - 15
29 265 5.3 - 27
7 155 < 1 - 6
C16 21 27-32 17 330 2.1 - 15
C17 28 26-30 25 265 12.0 - 25
16 290 4.6 - 16
P = Proliferative; LP = late proliferative; ES = early secretory; MS = midsecretory
TABLE 2;
Clinical data on 20 women with dysfunctional uterine bleeding
















AD1 46 14-50 22 600 < 1 LP ANOV (22)
AD2 43 20-60 16 380 < 1 LP ANOV (16)
AD 3 45 28-50 20 555 < 1 CGH ANOV (20)
AD4 41 25-60 2 - - - ANOV (2)
9 540 < 1 - (9)
AD 5 29 25-35 23 490 < 1 - ANOV (23)
9 720 < 1 (9)
AD6 31 18-40 26 205 < 1 - ANOV (26)
OD1 39 28-35 31 335 4.6 LS OV 27
OD2 42 21-30 13 - - ES OV 17
OD3 36 24-30 1 - - M OV 1
OD4 35 27-40 28 340 24.7 MS OV 21
OD5 31 28-35 12 195 < 1 P OV 8
OD6 36 29-35 9 135 < 1
-
OV 5
12 200 < 1 - 9
28 225 10.8 - 23
OD7 34 25-28 8 670 < 1 - OV 10
21 180 7.6 - 25
24 145 4.9 . - 26
OD8 31 26-35 12 420 < 1 - OV 12
14 135 6.3 - 16
35 105 2.1 - 27
OD9 40 27-30 11 455 < 1 - OV 11
9 390 < 1 - 9
ODlO 38 29-35 6 90 < 1 - OV 4
ODll 29 28-31 26 145 8.3 OV 25
OD12 34 27-32 15 430 < 1 - OV 11
14 275 10 . 4 - 15
24 280 14 .5 - 24
OD13 41 26-31 10 645 < 1 - OV 11
19 295 11. 8 - 19
OD14 37 21-25 5 585 < 1 - OV 10
ANOV = Anovulatory; OV = Ovulatory; P = Proliferative; LP = Late Proliferative;
ES = Early Secretory; MS = Mid Secretory; LS = Late Secretory; M = Menstrual;
CGH = Cystic Glandular Hyperplasia.
li 7
TABLE 3:































CI 10 36.6 1.9 4 1.2 55.7 96 - 53.5
C2 5 >100 < 1 < 1 4.5 15.5 100 - 15.5
C3 12 17. 9 3.9 2.5 1.4 49.1 97.5 - 48.0
C4 4 84. 4 < 1 1.2 6.1 11. 4 98.8 - 11.3
C5 22 28.3 2.4 5 1.8 37.5 95 - 35.8
C6 18 15.7 4.4 14 3.6 19.2 86 - 17.1
C7 10 21.2 3.3 3 3.3 21.0 40 1.4 49.5 57 36. 8
C8 9 40.4 1.7 6 2.2 31.4 94 - 29.6
C9 24 >100 < 1 < 1 1. 7 40.2 100 - 40.2
21 29.9 2.3 12 1.8 38.6 88 - 34. 3
CIO 23 >100 < 1 < 1 2.3 29.9 100 - 29.9
5 >100 < 1 < 1 2.6 27.0 100 - 27.0
11 16. 4 4.2 5 2.7 25.7 95 - 24 .6
Cll 12 >100 < 1 < 1 6.7 10.3 39 0.66 105.0 61 68.1
C12 26 26.1 2.6 < 1 1.9 34.9 99+ - 34.7
19 12. 6 5.5 2.6 3.5 19.6 97.4 - 19.2
C13 3 11-. 6 6.0 17 2.0 34 .0 83 - 29.2
1 14.9 4.7 1.9 2.5 27.9 98.1 - 27.5
3 27.6 2.5 14 4.9 14.1 86 - 12.5
C14 14 34.9 2.0 13 4.8 14.5 87 - 12.9
8 87.2 0.8 1.5 2.5 27.1 98.5 - 26.7
27 28.9 2.4 4 2.2 31.7 96 - 30.5
C15 15 31.7 2.2 5 4 .1 17.0 95 - 16. 3
27 >100 < 1 < 1 2.8 25.1 100 - 25.1
6 >100 < 1 < 1 3.1 22.1 100 - 22. 1
C16 15 39.4 1.8 48 4.4 15.8 52 - 9.1
C17 25 18.2 3.8 6 2.6 26.7 94 - 25.3






























AD1 22 16. 3 4.3 35 1.1 63.0 65 - 42.5
AD2 16 25.6 2.7 8 3.8 18. 2 51 1.7 40.8 41 26.2
AD3 20 19.1 3.7 22 1.5 46.2 88 - - 41.5
AD4 2 13.7 5.1 29 4.8 14.3 71 - 11.6
9 14. 4 4.8 14 2.5 28. 2 86 - 24.9
AD 5 23 20.4 3.4 2.8 1.7 42.0 97.2 - 40.9
9 19.5 3.6 1.7 1.2 57. 8 98. 3 - 56.9
AD6 26 31.5 2.2 9 1.6 42.2 91. - 38.6
OD1 27 26.7 2.6 2 1.3 52.8 98 - 51.8
OD2 17 21.0 3.3 8 3.0 22.9 92 - 21.3
OD3 1 13.6 5.1 10 2.5 27.2 90 - 25.0
OD4 21 23.7 2.9 4.8 3.2 22. 0 95.2 - 21.1
OD5 8 18. 8 3.7 12 4.8 14.5 58 2.5 27.3 30 17.0
OD6 5 82.0 0.85 2.6 3.4 20.1 97. 4 - 19.6
9 20.0 3.5 11 2. 9 23.6 50 2.1 33.6 39 25.3
23 49.4 1.4 < 1 1.7 40.8 99+ - 40.6
OD7 10 14.0 5.0 6 2.2 31.5 94 - 29.9
25 > 100 < 1 < 1 1.9 35.7 100 - 35.7
26 29. 4 2.4 < 1 2.0 35. 5 99+ - 35.3
OD8 12 15. 5 4.5 5 4.6 15.1 95 - 14.6
16 15.2 4 . 6 43 5.5 12.6 57 - 9.2
27 > '; ll 0 0 < 1 < 1 2.4 29. 4 100 - 29.4
OD9 11 18. 9 3.7 7 3.1 22. 7 93 - 21.4
9 18.6 3.7 < 1 4.3 16. 3 99 + - 16.2
ODIO 4 61.5 1.1 7 7.3 9.5 93 - 8.9
OD11 25 22. 5 3.1 3 2.1 33. 5 97 - 32.3
OD12 11 14.7 4.7 6 2.8 24.8 94 - 23.5
15 > 100 < 1 < 1 3.7 19.0 100 - 19.0
24 100 1 1 3.0 23. 4 100 - i 23. 4
OD13 11 44.4 1.6 1.4 2.3 30.5 98.6 - 30.1
19 12.0 5.8 10 6.3 11.0 42 2.3 29.7 48 19.5







Xenon-133 washout half-times and supine endometrial
blood flow calculations for each subject are summarised
in Tables 3 and 4. The overall mean (± SEM) endometrial
blood flow in women with normal cycles was 27.7 ± 2.6 ml/
100 g/min when all measurements were considered together.
Control subjects and women with ovulatory and anovulatory
dysfunctional uterine bleeding have been considered separ¬
ately according to stage of cycle in Table 5.
TABLE 5:
Endometrial blood flow measurements at different stages
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n 6 8 4 3 4 3
Ovulatory DUB 17. 8 25 . 2 14.1 20. 6 33.0 38.8 —
0 3 9 2 3 4 3
37.9
Anovulatory DUB 11.6 40 . 9 — — — —
n 1 2 5
Although numbers in each group are small there does not appear
to be much difference between women with normal menstrual
cycles and those with ovulatory dysfunctional uterine bleeding
(Figure 1 & 2).However, blood flow in normal women in the mid-
follicular phase (days 8-12) is significantly higher than
the women with ovulatory dysfunctional uterine bleeding (39.6
and 25.2 ml/100 g/min; t = 2.274, p<0.05). One woman with
ovulatory DUB had a high rate of flow (51.8 ml/100 g/min) on







Figure 1. Endometrial blood flow (ml/lOOg/min) measured usir
Xe-133 clearance at different stages of the menstrual cycle
in women with normal cycles. Data have been adjusted to fit
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Figure 2. Endometrial blood flow (ml/lOOg/min) measured
using Xe-133 clearance in women with ovulatory and
anovulatory dysfunctional uterine bleeding. Data for women
with ovulatory DUB have been adjusted to fit into an
idealised 28 day menstrual cycle.
ill
same range as controls in the premenstrual period.
The numbers of women with anovulatory DUB are too
small to make any comment except that very variable blood
flows were recorded and these overlapped with normal levels.
Women with normal cycles and ovulatory DUB have an
obvious cyclical variation in endometrial blood flow with
high levels in the mid-late follicular phase which fall
substantially around ovulation. A secondary rise occurs
through the early and mid-luteal phases and is maintained
until the onset of menstruation. In 2 women (C13 and 0D3)
measurements were carried out just after the onset of pre¬
menstrual spotting and a few hours before the onset of full
flow. In both these cases endometrial flow was still main¬
tained at a fairly high level (27.5 and 25.0 ml/100 g/min).
Later in menstruation and during the early follicular phase
flow was slower.
Only 6 examples of 3 component curves were recorded,
occurring in both DUB groups as well as in normal cycles.
There did not appear to be any particular pattern to their
occurrence, and mean flows were quite variable (17.0-68.1
ml/100 g/min).
A clear correlation between plasma oestradiol levels
and endometrial blood flow was recorded for all studies
undertaken when progesterone levels were less than 1 ng/ml
(r = 0.622; n = 31; Figure 3) and for women with normal
cycles when progesterone was less than 1 ng/ml (r = 0.760;
n = 13), but not in situations where progesterone was
elevated (total: r = 0.016, n = 25). No correlation
between plasma progesterone levels and endometrial blood
flow was found for luteal phase studies (total: r = 0.073;
n = 25). This poor correlation was particularly seen when
endometrial blood flow did not fall substantially during
the premenstrual period at a time when oestradiol and
progesterone were falling rapidly.
DISCUSSION:
Most previous work on genital tract blood flow in
TABLE6:
Bloodfl wmeasurementindiff rentute ic mpa tmentssr ort dbydi finvestiga ors. BLOODF W(ml/l g/min) INVESTIGATORTECHNIQUEENDOMETRIUMMY TRIUMINTERVILLOUS(PLACENTA) SECHERTAL (1973) SECHERTAL (1973) SECHERTAL (1973) KLINGENBERG (1974) FORSSMAN (1975)Intraluminal Xe-133 (Supine) Intramyometrial Xe-133 (Supine) Intramyometrial Xe-133 (Standing) Intramyometrial hydrogen (Supine) Intramyometrial Intraarterial Xe-133 (Supine)17.8 (13.5-29 0) 18.8 (5.2-37.9) 13.5 (3.9-33.5) 13.5 (36.5-172.9) 15.3 (3.8-35.2) REKONENTAL (1976) FRASERIntravenous Xe-133 (Supine) Intraluminal Xe-133 (Supine)27.7 (9.1-68. ) normalwo en77±2.5(SEM) pregnancy
135± (77-
49 322)
women has been directed towards study of myometrium, myomata,
endometrial cancer, amenorrhoea, dysmenorrhoea and changes
in posture, and no previous systematic studies have been
carried out in normal and abnormal cycles, or in relation
to menstruation. This investigation has provided the first
assessment of changes in absolute blood flow in human endo¬
metrium through the menstrual cycle, as well as in women with
dysfunctional uterine bleeding.
Cyclical changes in endometrial blood flow have been
clearly demonstrated, with high levels in the mid to late
follicular phase, a large fall at around ovulation and a
secondary luteal phase rise which was maintained up till
menstruation. The preovulatory measurements showed a weak
correlation between circulating levels of oestradiol and
endometrial blood flow. This correlation was lost during
the luteal phase. Other factors separate from plasma
oestradiol and progesterone must influence endometrial
blood flow at least during some stages of the cycle. There
was a major fall in blood flow at around ovulation which
seemed to slightly precede the midcycle rise in progesterone.
Unfortunately, the progesterone assays used in the study were
not reported sufficiently accurately in the lower ranges to
exclude a very small rise in progesterone in two subjects
(C14 and 0D8) who had low blood flow levels at day 12 and
14.
In the latter part of the luteal phase when luteolysis
was occurring there was no evidence of any related fall in
endometrial blood flow. In fact, blood flow was still rel¬
atively high (27.5 and 25.0 ml/100 g/min) in 2 subjects who
were experiencing premenstrual spotting and who began bleeding
heavily within 3-4 hours.
Two previous studies have provided evidence of the
occurrence of cyclical changes in endometrial blood flow
during the menstrual cycle. Markee (1950) studied endomet¬
rial auto transplants in the anterior chamber of the eye of
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Figure 3:
Comparison of endometrial
blood flow with plasma levels
of oestradiol in women with
normal cycles and ovulatory
or anovulatory dysfunctional
uterine bleeding. Only foll¬
icular phase measurements
(plasma progesterone less than
1 ng/ml) have been included.
250 500 750
PLASMA OESTRADIOL (PG/ML)
technique which assessed the speed of movement of red cells
through stromal capillaries in mm/sec. Prill and Gotz
(1961) used a heat clearance probe technique to study cyclical
changes in human endometrial blood flow in 10-lfcal.cm 1.sec~1
0c-1, although this type of technique cannot be exactly rec¬
alibrated from one day to the next. It is also pertinent to
note that an intrauterine probe may cause artificial changes
in local blood flow (Chapter 12). A comparison of the
cyclical changes demonstrated by these two groups of invest¬
igators with the present Xe-133 study is shown in Figure 4.
A comparison of these studies with the Kr-85 clearance tech¬
nique has been shown in Chapter 11. All studies show a pre¬
ovulatory peak with a post ovulatory fall and a secondary
rise in the luteal phase, although clear differences are
also apparent. The inert gas clearance techniques have
demonstrated a much more marked periovulatory fall in
endometrial flow with a very slow rise in the luteal phase.
With the heat clearance technique a slow premenstrual rise
in flow is seen which continues through until day 2-3
of menstruation. In the rhesus monkey a marked premenstrual
fall in flow was seen. Much of our current understanding
of the morphology of menstruating endometrium is based on
Markee's studies (1940), especially with respect to the
occurrence of dramatic vasoconstriction in the endometrium
just before and at the onset of bleeding. The present study
and that of Prill and Gotz (1961) suggests that this may
not occur, at least to the same extent in humans. In which
case the coagulation mechanisms studied by Christiaens et
al (1982) may play a more dominant role in the maintenance
of haemostasis in the human uterus. Nevertheless, in path¬
ological conditions such as spasmodic dysmenorrhoea excessive
uterine contractions may produce substantial falls in endo¬
metrial blood flow during menstruation (Akerlund et al 1976).
There is also some histological evidence that arteriolar
vasoconstriction may sometimes occur in human luteal phase
endometrium (Salvatore 1968).
Figure 4. Comparison of endometrial blood flow at different
stages of the menstrual cycle measured by Xe-133 clearance
in normal women (ml/lOOg/min) and compared with the data
of Markee (1950) in rhesus monkeys (mm/sec; dotted line) and
Prill and Gotz (1961) using_a heat clearance technique in
women (lO-1* Cal. cm-1 . sec"1. °C~1; continuous line).
IX (o
Only one previous investigation has reported absolute
flow measurements in human endometrium (Secher et al 1973).
This study utilised a different technique of clearance anal¬
ysis which may not always be appropriate for uterine blood
flow studies (Forssman 1975). However, this does report
the first measurements of absolute flow in human endometrium
(Table 6), and although the mean level is lower than the
present study the range overlaps greatly. It is of interest
that all the Xe-133 studies of blood flow in human myometrium
are in the same range of 3.8 - 37.9 ml/100 g/min (Table 6).
This is very similar to the measurements of endometrial flow,
although it has been demonstrated that endometrial and myo-
metrial flow may show large independent variations (Chapter
12) .
It is of interest to speculate on the mechanism of
elevation of endometrial blood flow in the late luteal phase
in women. In the light of recent evidence of the importance
of vasoactive prostaglandins in endometrial function during
menstruation it seems likely that they may be involved in
these blood flow changes. However, an influence of other
vasoactive substances such as catecholeamines (Cohen et al
1964) or angiotensin (Johnson 1980) should not be discounted.
In normal endometrium most investigators have demon¬
strated a rise in both PGF2c< and PGE2 in the late luteal and
menstrual phases (Downie et al 1974; Singh et al 1975;
Lundstrom and Green 1978) but little is known about cyclical
changes in thromboxane A2 (TXA2) and prostacyclin (PGI2).
PGF20< and TXA2 are generally vasoconstrictive while PGE2
and PGI2 are vasodilatory, with TXA2 and PGI2 also having
potent and opposite effects on platelet aggregation. It seems
that a balance between these 4 compounds may be important.
Recent evidence has been presented for a decrease in
endometrial secretion of PGF2o<^ in anovulatory DUB and an
increase in secretion of PGE2 and PGI2 in ovulatory DUB
(Willman et al 1976; Smith et al 1981a; Smith et al 1981b;
Smith et al 1982). Although this study has not demonstrated
any difference in endometrial blood flow between women with
normal cycles and menorrhagia in the late luteal phase it
does not exclude differences in flow at the onset of heavy
bleeding. A significant difference in blood flow in the
mid-late follicular phase with lower rates in women with
ovulatory DUB (Table 5) could be a pointer to differences
in prostaglandin secretion even at that early stage of the
cycle.
From the results presented- in this study it can be
seen that endometrial blood flow is slowly increasing at
the. time of implantation, and it seems likely that this
change is important to aid the success of this crucial
event in the early development of the embryo. This
increase in flow may also stimulate secretion of chorionic
gonadotrophin from the early trophoblast.
Further application of endometrial blood flow studies
in normal women, and women with various gynaecological
disorders and hormonal therapies promises to help in the
understanding of menstruation, its disorders and their





This thesis describes a series of investigations along
a developing theme through various aspects of the condition
called dysfunctional uterine bleeding. It covers these
disturbances of bleeding in all reproductive age groups and
includes studies which address the problems of definition,
incidence, perception and function of pituitary, ovary and
uterus in women with this condition. All the investigations
have raised new questions which merit more detailed study in
the future.
Dysfunctional uterine bleeding is a confusing and
controversial clinical diagnosis requiring exclusion of local
pelvic disease, pregnancy and certain generalised medical
diseases. Recent evidence suggests local and hormonal mechan¬
isms may sometimes be responsible for the clinical symptoms.
In this thesis an attempt has been made to study different
types of DUB in several ways. In several studies it has
also been necessary to investigate changes in women with
normal cycles before changes seen in women with DUB could be
interpreted.
In Section 2 oestrogen dynamics have been studied in
women undergoing hysterectomy in the mid to late reproductive
years for DUB or for conditions which did not interfere with
the menstrual cycle. At the time of the investigations
there was some basic knowledge about changes in small numbers
of normal women (Baird et al 1969; Longcope et al 1968;
Hembree et al 1969). Our studies confirmed the earlier work
and were able to demonstrate that oestradiol is virtually an
exclusive secretory product of the developing follicle and
the corpus luteum. This permitted measurement of ovarian
secretion rates of oestradiol and oestrone throughout the
cycle. Both are secreted in a biphasic pattern which is
directly reflected in the circulating plasma levels, although
much oestrone also comes from other sources.
Little was known about the secretion of oestrogens
Uc
in women with DUB although urinary excretion of oestrogens
in women with anovulatory DUB had been extensively studied
by Brown and Colleagues (Brown, Kellar and Matthew 1959;
Brown and Matthew 1962). Studies described in this thesis
demonstrated that there was no qualitative difference in
the secretion and metabolism of oestradiol and oestrone in
women with DUB but that the pattern of secretion was different
in women with anovulatory DUB. A surprising number of these
older women with DUB were found to have double ovulations or
simultaneous development of more than one follicle. Great
variability in the occurrence of ovulation and the degree of
oestrogen effect on the endometrium from cycle to cycle was
seen in most of these older women with DUB.
Although numerous studies have been reported of ovarian
blood flow in various animal species the only information
on ovarian blood flow in women is described in Chapter 4.
This indicates capillary flows of 4.6 - 36.4 ml/min
(equivalent to a mean of 2.3 ml/g/min), which are of a
simular order to those recorded in animals. Since the highest
flows were recorded in the luteal phase it is probable that
human corpora lutea have a similar high rate of capillary blood
flow to that seen in animals. Ovarian blood flow was in the
same range in 4 women with anovulatory dysfunctional bleeding.
One of the first studies of oestradiol and oestrone
concentrations in follicular fluid is described in Chapter 5.
This was planned in such a way that simultaneous studies of
oestrogen levels could be carried out in blood from both
ovarian veins and a peripheral vein. The highest oestradiol
and oestrone levels were found in large follicles (>lcm) in
the preovulatory phase. Oestradiol levels were found to be
6,000 times higher in fluid from large "preovulatory" follicles
than in peripheral blood, 100 times higher than in ipsilateral
ovarian venous blood and 1,200 times higher than in contra¬
lateral ovarian venous blood (not containing a developing
follicle), indicating almost exclusive oestradiol secretion
from the preovulatory follicle. In women with dysfunctional
uterine bleeding multiple large ovarian follicles were all
found to be actively secreting oestradiol, suggesting a
disturbance of intraovarian follicle control mechanisms in
these women.
Levels of oestrone in follicular fluid were very much
lower than oestradiol and did not show such large increases
with follicle growth, confirming that oestradiol is a much
more important product of follicle secretion. Much of the
circulating oestrone arises from peripheral conversion
(Chapter 2; Baird et al 1969).
In recent years many new studies of follicle endo¬
crinology have been published (McNatty et al 1976; McNatty
et al 1979; Hodgen 1982) but there is very little new
information on follicle dysfunction in dysfunctional
uterine bleeding. Extension of these studies into the
investigation of disturbances of intraovarian follicle control
mechanisms and other aspects of follicle endocrine patho¬
physiology would be very valuable.
Adolescent DUB is commonly anovulatory, and in those
women with recurrent symptoms the prognosis is poor with a
high incidence of long term reproductive disturbance
(Southam and Richart 1966; Chapter 6). This is especially
so for those women in whom endometrial cystic glandular hyper¬
plasia (CGH) is found. However, this particular condition at
the severe end of the spectrum of adolescent anovulatory DUB
is rare with an annual incidence in the South East of Scotland
of only 1 per 14,700 adolescent girls.
In a group of 4 women with adolescent anovulatory DUB
and CGH daily plasma sampling over 3 month periods revealed
normal patterns of follicular oestrogen production but a
failure to trigger the midcycle LH surge (Chapter 7). This
even occurred when excessive follicle growth and oestradiol
production was stimulated with clomiphene. More detailed
studies with 9 young women with anovulatory DUB and 6 normal
controls using an oestrogen provocation test and a GnRH
stimulation test confirmed that the abnormality was due to
a failure of the oestrogen positive feedback mechanism
presumably at a hypothalamic level (Chapter 8). In these
women the negative feedback mechanism and pituitary GnRH
action are both intact. It is possible that the defect is
a maturational phenomenon since positive feedback normally
develops in midpuberty, later than negative feedback
(Reiter et al 1974), and a few of these adolescents do
gain normal function later. Further investigation of these
women is indicated to see whether ovulation can be reliably
induced by timed midcycle injection of hCG.
Absence of the midcycle LH peak permitted a study of
oestradiol secretion by the maturing follicle in a situation
where ovulation did not occur (Chapter 8). In these women
urinary oestrogen excretion continued to rise for a further
5-6 days and reached levels more than double those seen in
controls (62.8 ± 12.6 yg/24 hour compared with 30.7 ± 3.1),
before falling in an exponential fashion over the next 10-
14 days. Bleeding usually began 10-12 days after the oest¬
rogen peak. A study of the mechanisms of follicle atresia
under these circumstances would be most interesting.
Further studies were planned to investigate GnRH and
oestrogen feedback actions in perimenopausal women with DUB
and in women with polycystic ovarian (PCO) disease (Van Look
et al 1977; Baird et al 1974). None of the women with PCO
and only 3 out of 5 with perimenopausal anovulatory DUB had
a positive feedback defect, indicating clearly that different
mechanisms for anovulatory DUB exist. One of the women
reported in Chapter 7 experienced an episode of bleeding
which indicates the diversity of factors bearing on such
disturbances of bleeding. In a cycle showing defective
luteal function she started bleeding heavily in the mid to
late follicular phase at a time when ovarian oestrogen
secretion was rapidly increasing. The mechanism of endometrial
bleeding in this situation remains unexplained, as it does
under many other circumstances.
Recently, a high incidence of coagulation disorders
in adolescents with menorrhagia has been reported (Claessens
and Cowell 1981). Adolescents with these diagnoses were
specifically looked for and excluded from our studies.
Early on in these investigations it became obvious
that many women were experiencing difficulty in assessing
the volume of their menstrual loss and one report provided
some objective evidence for this (Hallberg et al 1966).
As a consequence later studies included objective measure¬
ments of menstrual blood loss using the alkaline haematin
technique of Hallberg and Nilsson (1964a) as modified by
Newton et al (1977). This permitted development of the
concept of "subjective" and "objective" menorrhagia
(Fraser et al 1981). In this study of 69 women with a
convincing clinical complaint of menorrhagia only 38%
satisfied the criterion (blood loss greater than 80 mis) for
objective menorrhagia (Fraser et al 1981), and as a conseq¬
uence it was decided to study perception of menstrual blood
loss and changes in loss further in these women (Chapter 10).
As a group the women were able to distinguish the difference
between "heaviest" and "lightest" periods (69.6 ± 7.3 mis;
mean ± SEM; compared with 42.7 ± 4.7 mis), but there were
many major errors in perception by individuals. This was
particularly clearly seen in the perception of daily blood
loss when on days where bleeding was perceived as excessively
heavy measured loss varied between 1.4 and 215.8 mis (mean
22.0 mis). No correlation was found between numbers of
sanitary towels used and measured blood loss. Two other
studies carried out over the same period of time encountered
similar errors in the perception of loss (Chimbira et al
1980; Gao Ji et al 1981).
This study indicates that the only reasonably accurate
means of assessing volume of menstrual blood loss for
research or clinical studies is to measure it by an objective
technique such as that described by Hallberg and Nilsson
(1964a). It is recommended that this technique should be
available to all gynaecologists.
Some of these women noticed that their menstrual
discharge was relatively dilute, and a study of 28 normally
menstruating women confirmed that only 36% of the total
menstrual fluid loss could be accounted for by blood
(Chapter 9). However, there was a wide individual range
from 1.6 to 81.7%. This is in agreement with the very
limited data from earlier studies (Ebert and Nold 1956;
De Merre et al 1967). There was a highly significant
correlation between total fluid loss and blood loss even
in the one woman with objective menorrhagia. The main
volume of menstrual fluid is probably a transudate of
endometrial tissue origin. Since this increases in parallel
with blood loss it is unlikely to be related to endometrial
surface area (Chimbira et al 1980), and may be associated
with variations in capillary permeability or rate of
endometrial blood flow in women with DUB. Some variations
in the proportional content of blood were seen with different
methods of contraception but these require confirmation.
Much further research is required to study mechanisms and
factors influencing the fluid composition of the menstrual
discharge. Prostaglandins, lysosomes and coagulation factors
clearly merit further investigation. In fact, data on the
composition of menstrual blood under most circumstances
are very limited (Hahn 1980). Detailed investigation of
factors influencing perception of blood loss should also be
a high priority.
It seemed possible that abnormalities of endometrial
blood flow might exist in women with DUB, and a major study
was initiated to test this hypothesis (Chapter 11, 12 and
13). This also necessitated an extensive study of normal
women. The only existing techniques for blood flow measure¬
ment which seemed applicable to the study of changes in
absolute blood flow in human endometrium were a Krypton-85
rebreathing and clearance technique with an intrauterine
8-probe and a Xenon-133 intrauterine clearance technique
monitored by an external gamma camera (Chapter 11). These
two methods were carefully evaluated (Chapter 11) and were
then validated by direct comparison with a radioactively
labelled microsphere technique in sheep (Chapter 12). None
of the methods previously used for the measurement of
human uterine blood flow had been validated in any such
way.
Only one study of absolute levels of human endometrial
blood flow has been reported (Secher et al 1973) and these
levels fall within the lower part of the range reported in
the present study (Chapter 13). The study of Secher et al
(1973) indicated that endometrial and myometrial blood
flow were in the same close range. However, our studies in
sheep have demonstrated that endometrial and myometrial
blood flow can vary quite independently, especially in the
presence of an intrauterine probe or with uterine artery
cannulation (Chapter 12; Brown, Fraser and Mattner 1984).
Partly for this reason the intrauterine instillation of
Xe-133 was chosen for the main human study rather than the
intraluminal g-probe with Kr-85.
This study demonstrated a clear cyclical variation in
endometrial blood flow in normal women with an early to
midfollicular phase rise, preovulatory peak, (mean 39.6 ml/
100 g/min) marked periovulatory fall and slow midluteal phase
rise which was maintained up to the onset of menstruation
and then fell during menstruation (Chapter 13). These values
may be compared with the very high rates of flow found in
the human ovary (mean 230 ml/100 g/min; Chapter 4). The
preovulatory blood flow measurements correlated fairly
closely with plasma levels of oestradiol (r = 0.760), but
this correlation was lost after ovulation because of the low
early-mid luteal and elevated late luteal phase flow rates.
A tendency to a late elevation of luteal phase flow was
also shown by Prill and Gotz (1961) and may indicate
differences between women and rhesus monkeys (Markee 1940;
1950) on which species much of our current understanding of
menstrual vascular changes is based. It is possible that
arteriolar vasoconstriction is not such an important
mechanism for limiting the volume of menstrual loss in the
human as in the monkey. However, many vasoactive substances
are present in endometrium and local changes in blood flow
136
or sudden changes after the onset of menstruation may
still occur in women. Endometrial vessels have unusual
morphological appearances which must relate to function
and probably blood flow. The spiral arterioles have been
well described (Bartelmez 1933; Fanger and Barker 1961;
Farrer-Brown et al 1970 a; Ancla and de Brux 1964) but
unusual ultrastructural features such as bizarre endothelial
protrusions in small vessels (Fraser 19-80, and unpublished
observations) have still to be clearly defined. The data
are limited for normal endometrium and are almost non¬
existent for DUB.
Women with ovulatory DUB also exhibited cyclical
changes in endometrial blood flow. These only differed
from normal women in being significantly lower in the mid-
late follicular phase. No differences were demonstrated
in the late luteal or premenstrual phases but some individuals
may show abnormalities. Women with anovulatory DUB exhibited
very variable but generally high levels of flow.
The series of investigations described in this thesis
has raised numerous questions which require further study
in almost every area addressed by the thesis. These relate
particularly to the perception and measurement of bleeding,
endometrial function and composition of the menstrual
discharge, factors influencing endometrial blood flow and
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Cnn conversion ratio of oestrone to oestradiol inBB
blood
Ci curie
{mCi: millicurie; jtCi: microcurie}
CGH: cystic glandular hyperplasia of the endometrium
cpm counts per minute
DMPA depotmedroxyprogesterone acetate
dpm disintegrations per minute




EBF endometrial blood flow
FSH follicle stimulating hormone
g gram
{mg: milligram; yg: microgram; ng: nanogram; pg: picogram}
GnRH gonadotrophin-releasing hormone
3H tritium
HCG human chorionic gonadotrophin
125I iodine-125
IRP-HMG international reference preparation of human
menopausal gonadotrophin
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MCR metabolic clearance rate




n number of observations
NEg norethisterone
P 2 blood production rate of oestradiol
D
PCO2 partial pressure of carbon dioxide
PGE prostaglandins of the E series
PGE 2 prostaglandin E2
PGF2CI prostaglandin F20S
PGI2 prostacyclin
pH hydrogen ion concentration
P02 partial pressure of oxygen
PRL prolactin
rpm revolutions per minute
3^S Sulphur-35
SD standard deviation
SEM standard error of the mean
E i
Sov ovarian secretion rate of oestrone
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